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ABSTRACT 
 
Angiogenesis, the formation of new vessels from pre-existing ones, is essential for 
primary tumour growth as well as for metastasis, and endothelial cells play a central 
role in this process: they drive blood vessel formation in response to signals from the 
local environment by a mechanism that is integrin-dependent.  
 
αvβ3-integrin seemingly poses an ideal anti-angiogenic target. Its expression is vastly 
up-regulated in neo-angiogenic vessels, while its expression in quiescent vasculature 
is minimal.  However, anti-angiogenic therapy targeting αvβ3-integrin has proven 
somewhat disappointing. In part, this may relate to the fact that αvβ3-integrin is not 
expressed solely by endothelial cells, but across a wide range of cell types that each 
contribute to angiogenesis.  
 
In this thesis, I describe my studies on understanding the role of αvβ3-integrin as 
expressed specifically by endothelial cells in tumour growth and angiogenesis using 
endothelial specific β3-integrin deficient mice. I have shown that inducible deletion of 
endothelial β3-integrin inhibits tumour growth and angiogenesis preventatively, while 
its cnstitutive deletion is ineffective; furthermore, I have found that even the inducible 
deletion does not alter angiogenesis in already established tumours.  
 
The findings described in this thesis re-establish αvβ3-integrin as good anti-
angiogenic target, but imply that timing and length of inhibition are critical factors to 
be considered when targeting endothelial β3-integrin-expression.  
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1. INTRODUCTION 
 
1.1 The vascular system 
 
During the early stages of development the embryo receives its nutrition through 
diffusion (oxygen and nutrients diffuse across a short distance of 100-150 µm), but 
while growing bigger, it requires a specialized system to function as a major 
communication system between distant organs and tissues. Indeed, the vascular 
system, also known as the circulatory system, is the first organ that forms and 
becomes functional during embryonic development. 
 
 
 
Figure 1.1 The anatomy of man: the cardiovascular system  
Leonardo da Vinci’s famous anatomy drawings explored the human body (1508). He firstly 
suggested the analogy between the vascular system and a tree speculating that blood vessels 
develop like a tree, starting from a seed (the heart) and expanding into trunk and branches 
(aorta and large vessels) as well as roots (small capillaries) (taken from Risau,1997). 
 
In the adult, the vascular system is functionally divided in cardiovascular and 
lymphatic systems. Blood, heart and blood vessels form the cardiovascular system 
(Figure 1.1), whose function is to deliver oxygen and nutrients as well as clear carbon 
dioxide and metabolic products from tissues; whereas lymph, lymph nodes and 
lymphatic vessels form the lymphatic system, which serves to drain fluids from the 
extracellular spaces and move them back to the blood circulation (Purves et al., 
2004).     
 
The cardiovascular system is a closed system composed of two functionally distinct 
but interconnected circulations: the systemic circulation in which the heart pumps 
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oxygenated blood through arteries and arterioles into capillaries whereby gases and 
metabolites are exchanged between the blood and surrounding tissues, then the 
deoxygenated blood is pumped back to the heart through venules and veins; and the 
lung circulation in which the deoxygenated blood is carried to the lungs to be 
reoxygenated and then back to the heart to be delivered systemically (Purves et al., 
2004). 
 
1.2 Blood vessel morphology 
 
The cardiovascular tree includes arteries, veins and capillaries. Cardiac contraction 
pumps high-pressure oxygenated blood flow through the arteries, which are 
characterized by the mechanical support of smooth muscle cells; while blood from 
the periphery returns under lower pressure to the heart through veins, which are 
characterized by specialized valve structures to maintain proper directional flow. 
Small caliber vessels (capillaries, arterioles and venules) enable the actual exchange 
of water and molecules between blood and the tissues. 
 
Arterial-venous specification is genetically programmed, even before the first 
embryonic heart beat and results from the combination of hemodynamic and 
transcription factors, as well as, signaling molecules; all of which define the 
specification of blood vessel type during development (Swift and Weinstein, 2009). 
However, the maintenance of arterial-venous phenotype is susceptible to some 
degree of plasticity. In response to microenviromental cues, vessels can undergo 
morphological and functional changes, which allows adaptation to the diverse needs 
of the various tissues/organs and also to account for inter-organ and intra-organ 
vessel heterogeneity. 
 
Larger vessels consists of a three-layered structure: tunica intima, the inner layer, 
composed of an endothelial cell monolayer and basement membrane; tunica media,  
the middle layer, composed of vascular smooth muscle cells, collagen and elastic 
fibres, and tunica adventitia, the outer layer, composed of fibroblasts, collagen and 
elastic fibres (Figure 1.2). The tunica adventitia is also innervated and has its own 
blood supply, called vasa vasorum. These three layers are separated from each other 
by two thin sheets of elastic fibers: the internal elastic lamina between the tunica 
intima and media and the external elastic lamina between the tunica media and 
adventitia. These elastic laminae, together with the smooth muscle cells, regulate 
vessel tone and contraction acting on vessel diameter and blood flow. The wall of 
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smaller blood vessels is composed of vascular endothelial cells and mural cells 
(pericytes and vascular smooth muscle cells) surrounded by extracellular matrix. 
 
 
 
Figure 1.2 Microscopic anatomy of vessel structure  
Cross-sections of blood vessels displaying their characteristic 3-layered-structure of tunica 
intima, tunica media and tunica adventitia. While arteries have a thick elastic muscle layer 
which can handle the high pressure of the flowing blood, veins have a thin elastic muscle layer 
with semilunar valves which prevent the blood from flowing in the opposite direction. Nerves 
can be distinguished by the absence of lumen (taken from http://wurstwisdom.com/).  
 
1.2.1 Endothelial cells 
 
Initially described as a “layer of nucleated cellophane” (Florey, 1966) endothelial cells 
(ECs) form a monolayer that lines the vessel lumen of the entire vascular system 
(Claever and Melton, 2003). In adults, approximately ten trillion cells form an almost 
1 kg `organ' which is far from being inert. As a barrier, the endothelium is 
semipermeable and regulates the transfer of small and large molecules through 
specific transport mechanisms and cellular junctional structures.  
 
Endothelial cells also have metabolic and synthetic functions through the secretion 
of a large variety of mediators which control blood flow and vascular tone, hemostasis 
and coagulation, angiogenesis and tissue repair, inflammation and lipid catabolism. 
They act in autocrine, paracrine and endocrine manners affecting smooth muscle 
cells, platelets and immune cells. They display a remarkable phenotypic 
heterogeneity in different parts of the vascular system, such as to specifically meet 
the metabolic need of each organ and tissue. 
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1.2.2 Mural cells 
 
Mural cells reside at the interface between the endothelium and the surrounding 
tissue (Gerhardt and Betsholtz, 2003). They are commonly subdivided in vascular 
smooth muscle cells (vSMCs) and pericytes. Vascular smooth muscle cells are 
associated with arteries and veins whereas pericytes are associated with the smallest 
diameter blood vessels (arterioles, capillaries, and venules), (Gaengel et al., 2009). 
Pericytes were once known as “Rouget cells” after the first description by Rouget 
(Rouget, 1873) of perivascular cells adjacent to capillaries.  Only in 1923, Zimmerman 
introduced the term “pericyte” to identify cells lying in close proximity of endothelial 
cells (Zimmerman, 1923).  
 
Pericytes physically “sit” on top of endothelial cells in small caliber vessels 
(capillaries, arterioles and venules). They express a number of markers of 
differentiation such as α Smooth Muscle Actin (αSMA), desmin, chondroitin sulfate 
proteoglycan marker NG-2 and platelet-derived growth factor receptor β (PDGFRβ). 
Nevertheless, there is no single molecular marker able to unequivocally identify 
pericytes. Moreover, the multiple markers which are commonly used are neither 
entirely specific, nor stable in their expression (Armulik et al., 2011). Pericytes provide 
structural support and stability to the vascular endothelium: pericytes and endothelial 
cells act as a functional and physical unit through the establishment of cell-cell 
heterotypic contacts, synthesis and secretion of growth factors and common 
basement membrane that promote their mutual survival. 
 
1.2.3 Endothelial basement membrane 
 
Endothelial cells and pericytes are embedded in a specialized extracellular matrix 
(ECM), known as endothelial basement membrane (EBM). The endothelial basement 
membrane was first described in muscle by Bowman in 1840 and later observed in 
nearly all tissues (Davies and Sanger, 2005). It is a layered cell-adherent extracellular 
matrix that forms part of tissue architecture. In close proximity to the plasma 
membrane, it protects tissues from physical stresses and provides an interactive 
interface between the cellular and extracellular compartments. The endothelial 
basement membrane is rich in collagen type IV, laminin, entactin/nidogen, fibronectin 
and perlecan; but its composition and integrity are modified according to blood vessel 
type, tissue, developmental and/or physiological stage (Yurchenko, 2011). 
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The EBM primarily provides a scaffold for maintaining the organization of vascular 
endothelial cells into blood vessels; but it also exerts essential functions in supporting 
signalling events such as proliferation, migration, survival; all of which are critical for 
endothelial cells functions, in association with integrins and growth factors. 
 
1.3 Blood vessel development and physiology 
 
During development, two processes of blood vessel formation can be distinguished, 
namely vasculogenesis and angiogenesis. By definition, vasculogenesis is the de 
novo formation of blood vessels and it primarily takes place during embryonic 
development; whereas angiogenesis is defined as the formation of new vessel from 
pre-existing ones. 
 
1.3.1 Vasculogenesis 
 
Early in development within the mesoderm, hemangioblasts which are mesoderm-
derived precursor cells, connect with each other forming blood islands, whereby cells 
at the periphery flatten and differentiate into angioblasts (endothelial cell precursors), 
while the cells located in the central islands differentiate into haematopoietic stem 
cells (HSCs) (Risau and Flamme, 1995).  
 
Angioblasts further differentiate into endothelial cells, which eventually fuse with each 
other, consequently forming lumenized vessels (Downs, 2003). The first vessels arise 
in the yolk sac and, then, the dorsal aorta and cardinal veins form in the embryo itself. 
After vasculogenesis has occurred, the primary vascular tree is subsequently 
remodelled through the process of angiogenesis. This leads to the formation of a 
mature vascular system in which vessels are morphologically and functionally 
distinguished into arteries and veins (Risau and Flamme, 1995).   
 
1.3.2 Angiogenesis 
 
The formation of new vessels can take place either by sprouting or non-sprouting 
angiogenesis, depending on whether endothelial cells proliferate (the former) or not 
(the latter). In sprouting angiogenesis, the extracellular matrix is proteolytically 
degraded by specific proteases, endothelial cells start to migrate and proliferate, 
forming a monolayer characterized by a tube like structure. Thereafter, the basal 
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lamina is remodelled and mural cells are recruited to stabilize the vascular wall and 
the blood flow is re-established (Carmeliet, 2000).  
 
In contrast, non-sprouting angiogenesis (or intussusception) is a process by which 
single vessels split in two by extending the vessel wall into the lumen. This separation 
depends on the reorganisation of existing cells, without involving endothelial cell 
proliferation (Carmeliet, 2000). Irrespective of the way they are formed, new vessels 
undergo further remodelling processes, referred to as vessel maturation, which 
include stabilization of vessel structure by cell-cell, cell-ECM interactions and mural 
cell recruitment. Ultimately, excess endothelial cells or vascular segments are 
eliminated by vascular regression or pruning in order to construct and preserve a 
functionally efficient network (Risau, 1997). 
 
1.3.3 Mechanism of sprouting angiogenesis 
 
For new blood vessel sprouts to form, pre-existing vessels dilate and become leaky 
in response to vascular endothelial growth factor (VEGF) which is up-regulated in 
hypoxic tissues (Giordano and Johnson, 2001). Endothelial cells lose inter-
endothelial cell contacts and detach from surrounding vSMCs (Dvorak et al., 1999).  
 
This effect is further sustained by Angiopoietin2 (Ang2) binding to the endothelial cell 
tyrosine kinase receptor Tie2 (Tyrosine kinase with immunoglobulin-like and EGF-
like domains-2), which has been implicated in the detachment of ECs from vSMCs, 
thereby destabilizing the endothelium (Scharpfenecker et al., 2005). Secretion of 
proteinases of the matrix metalloproteinases (MMPs) or heparanase families by 
endothelial cells leads to ECM degradation (creating room for the endothelial cell to 
migrate) and the release of growth factors sequestered within it such as VEGF and 
basic fibroblast growth factor (bFGF) (Jakobsson et al., 2006). These growth factors 
induce endothelial cell migration, proliferation and differentiation.  
 
Sprouting angiogenesis involves the specification of endothelial cell populations: tip 
cells which migrate towards a VEGF gradient by extending filipodia at the leading 
edge of the new-forming vessel, followed by stalk cells which actively proliferate to 
elongate the sprout (Gerhardt et al., 2003). The process of tip/stalk differentiation is 
under the control of VEGF and Notch signalling. VEGF promotes tip cell induction 
and induces the expression of the Notch ligand Delta-like 4 (DLL4), which activates 
Notch signalling in neighbouring cells via Notch Intracellular domain (NCID),  thereby 
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suppressing VEGF receptor 2 (VEGFR2) expression and tip cell behaviour (Williams 
et al., 2006).   
 
Notch activity is required for stalk cell specification: they proliferate, form tubes and 
branches to elongate the vessel sprout. Tip and stalk cell are transient phenotypes, 
not fixed cell fates, and competition for tip cell position ensure the maximal efficient 
of vascular sprouting (Geudens and Gerhardt, 2011). Importantly, adhesion 
molecules, such as integrins, are essential to promote endothelial cell proliferation 
and migration, followed by their assembly into cords and lumen formation (Eliceiri 
and Cheresh, 2001). 
 
1.3.4 Vessel maturation 
 
In order to become functional, newly formed blood vessels have to mature. This 
involves the recruitment of vascular smooth muscle cells and the deposition of new 
basement membrane. The recruitment of pericytes is mediated by Platelet-derived 
growth factor type-b (Pdgfb) and its receptor PDGFRB (von Tell et al., 2006).  
 
Pdgfb is expressed by endothelial cells and acts on pericytes which express its 
receptor. vSMCs express a number of molecules which have a paracrine effect on 
the endothelium such as Angiopoietins which includes Angiopoietin1 (Ang1) and 
Angiopoietin2 (Ang2). Ang1 is expressed by vSMCs, whereas Ang2 is primarily 
expressed by ECs. Binding of Ang1 to its Tie2 receptor on endothelial cells results in 
the activation of Akt (Protein kinase B, PKB), which in turn promotes endothelial cell 
quiescence and survival; whereas EC-Ang2 antagonizes Ang1 activity, thus 
destabilizing vessels and sensitizing them to pro-angiogenic signals. (Fiedler and 
Augustin, 2006). 
 
vSMCs make focal contacts with endothelial cells and stabilize the vessel wall by 
inhibiting proliferation and migration of endothelial cells (Bergers and Song, 2005). 
Pericytes also express sphingosine-1-phosphate (S1P) which binds to S1P receptor 
on endothelial cells and regulates EC barrier properties by stabilizing VE-cadherin 
(VEC) junctions and increasing N-cadherin (N-CAD) expression (von Tell et al., 
2006). Additionally, the onset of blood flow remodels endothelial cell shape and 
patency and stabilizes vessel connections (vascular remodelling), while hypo-
perfused vessels regress and endothelial cells undergo apoptosis (vascular 
regression) (Potente et al., 2011). 
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1.3.5 Vessel quiescence and permeability 
 
Quiescent endothelial cells named phalanx cells, as resembling the ancient Greek 
military formation (Mazzone et al., 2009), adhere tightly by cell-cell junctions and form 
barriers which control the exchange of molecules and fluids between blood and 
tissues as well as extravasation of immune cells (Potente et al., 2011). In the 
quiescent state, endothelial cell proliferation diminishes and it is contact-inhibited: 
only one in every 10,000 endothelial cells divides (Lampugnani et al., 1997). 
Moreover, endothelial cells become less sensitive to growth factor stimulation, 
protected from apoptosis and in full control of permeability (Lampugnani et al., 2003). 
Barrier function and endothelial cell permeability rely on junctional complexes 
including tight junctions (TJs) and adherens junctions (AJs), both of which contain 
proteins that mediate homophilic adhesion at the cell surface (Figure 1.3). TJs 
regulate paracellular permeability, whereas AJs are involved in cell-cell adhesion, 
cytoskeletal dynamics and intracellular signalling (Lampugnani and Dejana, 2007).  
 
The main component of AJ is Vascular endothelial-cadherin (VEC) which is part of a 
protein complex comprising p120-catenin, α-and β-catenin at site of cell-cell contacts 
(Dejana, 2004). Binding of VEGF to its receptor VEGFR2 leads to an activation of the 
kinase c-Src (cellular Src kinase), which in turn phosphorylates VEC. Phosphorylation 
of VEC results in the disruption of the complex thereby enhancing vascular 
permeability and leukocyte transmigration (Wallez et al., 2007).  
 
Conversely, VE-cadherin regulates VEGFR2 signalling through phosphatase Dep1 
(CD148) which associates with VE-cadherin and attenuates tyrosine phosphorylation 
of VEGFR2 thereby suppressing receptor activity (Lampugnani et al., 2003).VEC also 
controls endothelial cell survival: it is required for the VEGF-dependent survival 
signals through formation of a VEC/β-catenin/PI3K/VEGFR2 complex which leads to 
Akt survival signalling pathway and increased levels of the anti-apoptotic mediator 
Bcl2 (Carmeliet et al., 1999). 
 
1.4 Molecular mechanisms of angiogenesis 
 
1.4.1 VEGF/VEGFR  
 
Initially, Vascular Endothelial Growth Factors were identified as vascular permeability 
factor (VPF) (Senger et al., 1983) because of their effect on permeability by promoting 
26 
 
intercellular adhesion molecule rearrangements, such as platelet endothelial cell 
adhesion molecule (PECAM-1) and VE-cadherin (Bates and Harper, 2002) and on 
vessel dilatation, by stimulating endothelial nitric oxide synthase (eNOS) (Kroll and 
Waltenberger, 1999). Currently, VEGFs are acknowledged primarily for their role as 
master regulators of angiogenesis (Ferrara et al., 2003). They are dimeric cystein-
linked secreted glycoproteins produced in response to hypoxia and upon stimulation 
with other growth factors. In mammals, the VEGF family includes VEGF-A, VEGF-B, 
VEGF-C, VEGF-D and PlGF (Placental Growth Factor).  Furthermore, highly related 
proteins called VEGF-E and VEGF-F are found in orf virus and snake venom, 
respectively (Figure 1.3). 
 
 
Figure 1.3 Schematic diagram of VEGFA isoforms 
There are six isoforms of VEGF-A. Exons are indicated by numbers. Exon 3 (blue) is primarily 
involved in VEGF homodimerization and interactions with VEGFR-1. Interactions with 
VEGFR-2 are mainly mediated by exon 4 (green). Binding to heparin is mediated by exon 7 
(red) and to neuropilins by exons 8 and 9 (red and yellow). Exon 9 (dark green) is expressed 
in the inhibitory VEGF165b variant. 
 
The biological functions of VEGFs are mediated upon binding to type III receptor 
tyrosine kinase (RTK) Vascular Endothelial Growth Factor Receptors, namely 
VEGFR-1, VEGFR-2 and VEGFR-3 (Cebe-Suarez et al., 2006). The receptors 
consist of seven extracellular immunoglobulin-like domains, a transmembrane 
domain, a regulatory juxtamembrane domain, an intracellular tyrosine kinase domain 
interrupted by a short peptide and the kinase insert domain, followed by a sequence 
carrying several tyrosine residues involved in recruiting downstream signalling 
molecules (Figure 1.4).  
 
Each VEGF isoform binds specifically to a particular subset of VEGFRs with some 
degree of promiscuity though (Figure 1.5). Ligand-binding induces receptor 
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dimerisation, activation of the kinase domain and finally specific activation of distinct 
downstream pathways (Cebe-Suarez et al., 2006). VEGFR signalling is further 
modulated upon recruitment of co-receptors (such as neuropilins and integrins) that 
additionally regulate signal strength, and timing and specificity of responses, thereby 
accounting for the complexity of VEGF-induced signals (Staton et al., 2007). For 
instance, neuropilin1 (NRP1) has been shown to increase the binding affinity of 
VEGFA for VEGFR2 (Soker et al., 1998). The best characterized variant of VEGFs 
is VEGFA (commonly reffered as to as VEGF) which signals through both VEGFR1 
and VEGFR2, the latter being the most important receptor in angiogenic signalling.  
 
 
 
Figure 1.4 Overview of VEGF/VEGFR binding 
Vascular Endothelial Growth Factor (VEGF) -A, -B and Placenta growth factor (PLGF) bind to 
VEGFR1, VEGFA to VEGFR2 and VEGFC and -D to VEGFR3. Proteolytic processing of 
VEGFC and -D enables them to bind VEGFR2 (taken from Staton et al., 2007). 
 
 
VEGFA is produced by several cell types including macrophages, keratinocytes, 
pancreatic cells, hepatocytes, vSMCs, embryonic fibroblasts and tumour cells 
(Ferrara et al., 2003). Its expression is regulated by a plethora of stimuli such as other 
growth factors, inflammatory cytokines, hormones and hypoxia. Indeed, low 
concentration of oxygen activates the hypoxia inducible transcription factor-1 (HIF1) 
which in turn up-regulates VEGFA expression (Takahashi and Shibuya, 2005). 
VEGFA gene consists of nine exons separated by seven introns and alternative 
splicing gives rise to a number of functionally distinct isoforms (at least six isoforms 
in humans VEGFA 121, 145, 165, 183, 189 and 206) which differ in their ability to 
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bind heparin/heparan sulphate in the extracellular space and to neuropilin receptors 
and therefore have different signalling properties (Roy et al., 2006).  
 
VEGFR2 (Flk-1, in mouse) is produced as a 150-kDa protein, which is processed 
within the cell to a 200-kDa form and further glycosylated and expressed at the cell 
surface as a 230-kDa protein. During early embryogenesis, VEGFR2 is highly 
expressed in haematopoietic and endothelial cell precursors, haemangioblasts. At 
later developmental stages, the blood vascular expression of VEGFR2 decreases 
and, in adults, is upregulated under pathological conditions such as tumour 
angiogenesis (Shibuya and Claesson-Welsh, 2006). Non-endothelial cells, including 
neuronal cells, retinal cells, osteoclasts and megakaryocytes, can also express 
VEGFR2 (Otrock et al., 2007). 
 
The central role of VEGF/VEGFR axis in regulating angiogenesis is confirmed by a 
number of genetic studies. Both VEGFA and VEGFR2 knockout mice are embryonic 
lethal. Homozygous VEGFA knockouts die earlier, at E9, due to severe defects in the 
formation of blood islands, development of endothelial cells and reduced angiogenic 
sprouting (Carmeliet et al., 1996). Whereas the deletion of a single allele of VEGFA 
in mice results in early vascular defects and embryonic lethality at E11-E12 
(Carmeliet et al., 1996; Ferrara et al., 1996). Deletion of VEGFR2 in mice leads to 
embryonic lethality between E8.5 and E9.5 due to a lack of blood island formation in 
the yolk sac, an absence of vasculogenesis and severe defects in the development 
of endothelial and haematopoietic cells (Shalaby et al., 1995).  
 
1.4.2 Regulation of  VEGFR2  activity 
 
VEGFR2 is the main receptor in angiogenesis by transducing proliferation, migration 
and survival signals to endothelial cells (Figure 1.5). Like other RTKs, VEGFR2 
activates upon VEGF-mediated receptor dimerization, whereas its activity is 
downregulated by receptor dephosphorylation via phosphatases such as SHP-1 and 
SHP-2 (Dougher et al., 1999). Activated VEGFR2 is subsequently internalized into 
endocytic vesicles whereby it can be trafficked to the cell membrane through 
recycling (through early, late, and recycling endosomes) or degraded in lysosomes 
or proteasomes (Duval et al., 2003).  However, contrary to other RTKs, unstimulated 
VEGFR2 is only partially localised at the plasma membrane with a pool of receptor 
(40%) costantlly internalized and recycled back to the surface (Berger and Ballmer-
Hofer, 2011). 
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Ligand-induced dimerization leads to structural changes to the intracellular kinase 
domain following conformational rearrangement of the transmembrane and 
juxtamembrane domains. Both the juxtamembrane and intracellular domains have 
tyrosine phosphorylation sites which have an either regulatory or signalling function. 
Among the 19 tyrosine residues present in the intracellular domain of VEGFR-2, 5 of 
them (Y951, 1054, 1059, 1175 and 1214) have been identified as the most prominent 
phosphorylation sites (Shibuya and Claesson-Welsh, 2006).  
 
 
 
 
Figure 1.5 Schematic overview of VEGF signalling pathways 
VEGF signalling is mediated via tyrosine kinase receptor whose activation occurs through 
ligand-induced dimerization and receptor autophosphorylation at multiple tyrosine residues in 
the intracellular domain (taken from Zachary, 2003). 
 
1.4.2.1 VEGFR2 promotes EC proliferation 
 
Y1175 is clearly one of the most important VEGFR2 phosphorylation sites: it is 
implicated in the activation of many signalling pathways through phospholipase Cγ 
(PLCγ) (Takahashi et al., 2001). In detail, PLCγ promotes phosphatidylinositol 4,5-
bisphosphate (PIP2) hydrolysis resulting in to 1,2-diacylglycerol (DAG) and inositol 
1,4,5-trisphosphate (IP3). DAG activates Protein kinase C (PKC), whereas IP3 acts 
on endoplasmic reticulum, resulting in the release of intracellular stored Ca2+ in the 
cell cytoplasm. PKC leads to Ras-independent Raf activation which in turn, induces 
ERK 1/2 (Extracellular-signal Regulated protein Kinase 1/2) activity.  
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Activated ERK1/2 activates c-Jun by phosphorylation, which then translocates to the 
nucleus whereby it forms a transcriptional complex with c-Fos leading to DNA 
synthesis and cell proliferation   (Zachary and Gliki, 2001).  Y1175 importance has 
been further confirmed in knockin mice expressing a Y1175 mutant which dies in 
utero due to vascular defects, similar to those observed in VEGFR2 null mice 
(Sakurai et al., 2005).  
 
Y1054 and 1059 are homologous to regulatory residues conserved in all protein 
kinases and are autophosphorylation sites important for receptor activation (Cebe-
Suarez et al., 2006).  
 
Y951 has been shown to mediate the binding to T-cell specific adapter (TSAD) which, 
then leads to c-Src  activation thereby regulating actin stress fiber organization and 
migratory responses of endothelial cells (Matsumoto et al., 2005).  c-Src proto-
oncogene is a non-receptor protein tyrosine kinase protein, it has an SH2 domain, an 
SH3 domain, and a tyrosine kinase domain and it is implicated in a wide variety of 
pathways, including cell proliferation.  
 
VEGFR2 can promotes proliferation upon the activation of the Ras-dependent 
signaling pathway impinging on MAP kinases such as ERK1/2 (Meadows et al., 2001) 
or alternatively through PI3K/S6kinase/Akt signalling pathway, although conflicting 
data suggest that PI 3-kinase is not required. Moreover, c-Src and NO have also been 
identified as intracellular mediators of VEGFR2 mitogenic signaling (Cebe-Suarez et 
al.,, 2006). 
 
1.4.2.2 VEGFR2 regulates EC migration 
 
With respect to migration, VEGFR2 signalling is mainly mediated by focal adhesion 
kinase (FAK), which regulates focal adhesion assembly and disassembly and the 
organization of the actin cytoskeleton (Abedi et al., 1997). Focal adhesions are 
dynamic macromolecular structures required for cell adhesion and migration: they 
assemble, mature, and disassemble upon different cues transmitting both cellular 
signalling and mechanical signalling. (Petit and Thiery, 2000). The turnover of focal 
adhesions is essential for cell motility and the formation of the actin stress fibres 
occurs at the leading edge of the cell, whereby lamellipodia (flat extensions of plasma 
membrane) generate mechanical forces that alter local cytoskeletal dynamics.  
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Integrin transduce extracellular cues to the cytoskeleton via the activation of the 
tyrosine kinases Src and FAK.  
 
FAK is a non-receptor tyrosine kinase which interacts with integrin via its FERM 
domain and gets activated upon integrin binding to autophosphorylate Y397, this 
induces subsequent binding of Src by the SH2 domain, leading to stable and 
increased activation of Src–FAK complex (Schaller et al., 1994). FAK also binds to 
with adaptor protein such paxillin and talin via its focal adhesion targeting (FAT) 
domain. VEGF/VEGFR2 via integrin cooperation induces FAK phosphorylation by 
recruiting this kinase to focal adhesions thereby promoting cell migration (Abedi et 
al., 1997).   
 
VEGF-induced endothelial cell migration is also mediated by stress activated protein 
kinase 2, SAPK/p38 which induces phosphorylation of heat shock protein HSP27 
(Rosseau et al, 2000). This then leads to actin reorganization and formation of stress 
fibers and lamellipodia thus promoting cell migration. Furthermore VEGFR2 can 
regulate the small GTPases Rho and Rac, which in turn modulate actin dynamics 
and cell contraction leading to endothelial cell migration (Zeng et al., 2002). 
 
1.4.2.3 VEGFR2 controls EC survival and vessel permeability 
 
VEGFR2 is also essential for cell survival: it protects endothelial cells against 
apoptosis via the activation of the PI3-kinase/Akt pathway and by promoting the 
expression of anti-apoptotic molecules including the caspase inhibitor Bcl-2 (Gerber 
et al., 1998). Moreover, VEGFR-2 provides survival signals through the formation of 
the tetrameric complex of VEGFR-2, PI3-kinase, VE-cadherin and β-catenin whose 
disruption inhibits the PI3-kinase/Akt pathway and induces endothelial cell apoptosis 
(Carmeliet et al., 1999). 
 
VEGF also regulates vascular permeability by loosening the junctions between 
endothelial cells, giving rise to the formation of transcellular gaps; indeed 
phosphorylation of major components of junctional complexes such as VE-cadherin, 
β-catenin, occludin has been described in response to VEGF (Dejana et al.,1999; 
Esser et al., 1998). Moreover, vessel dilation is controlled by NO which in turn is 
upregulated by Akt upon induction of endothelial NO synthase (eNOS) expression 
(Fulton et al., 1999). 
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1.5 Pathological angiogenesis 
 
Physiological angiogenesis is required to ensure adequate function and dynamic 
plasticity of the vascular system for tissue growth and homeostasis. As such, its 
dysregulation causes pathological conditions due either to insufficient angiogenesis 
(heart and brain ischemia, hypertension, osteoporosis and pre-eclampsia) or 
excessive and uncontrolled angiogenesis (cancer, eye diseases, arthritis, psoriasis, 
atherosclerosis) (Carmeliet and Jain, 2000). 
 
1.5.1 Tumour angiogenesis 
 
With respect to cancer, it is well established that the acquisition of an angiogenic 
phenotype (the so-called “angiogenic switch”) by cancer cells is required very early 
in the transformation process and it is considered a marker of malignant 
transformation as proposed in the fundamental review “The hallmarks of cancer: the 
next generation” by Hannah and Weinberg (2010). In 1939, Ide et al. first observed 
that tumour growth was accompanied by infiltration of newly formed blood vessels in 
a rabbit tumour model (Ide et al., 1939). Less than 10 years later, in 1945, Algire and 
Chalkeley reported that transplanted tumour cells could induce vessel formation 
before tumour growth occurred and suggested that tumour explants require the 
development of a new vascular supply to grow (Algire et al., 1945). Their work 
represented the first demonstration that tumours actively attract new blood vessels, 
the process that, 30 years later, would become known as “tumour angiogenesis”.   
 
Tumours cannot grow bigger than a few millimeters in size until they acquire the ability 
to recruit their own blood supply. Avascular tumour masses, named dormant tumours 
were firstly identified in human autopsies, they can persist in situ or progress to an 
active vascular state which allows exponential cell growth and expansion, eventually 
leading to invasion and metastasis (Black and Welsh, 1993). Initially, tumour cells 
grow around existing vessels, hence, they do not need to induce angiogenesis; but 
when they do, they have been shown to exploit different strategies, aside from 
sprouting angiogenesis, to ensure their own blood supply. Tumour cells can release 
soluble factors, including VEGF, to recruit bone marrow derived cells (BMDCs, 
broadly defined as CD45+) at the site of primary tumours and metatastic lesions, 
which in turn produce angiogenic factors and sustain tumour angiogenesis  (Wilson 
and Trumpp, 2006; Grunewald et al., 2006).  
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Less defined and still debated, it is the role of endothelial precursor cells (EPCs, 
defined as CD34+/VEGFR2+) which have been firstly described as able to 
differentiate in Von Willebrand Factor (vWF)+ cells and form new vessels through 
vasculogenesis (Asahara et al., 1997; Lyden et al., 2001). Even though the number 
of EPCs in tumour vasculature is very low (<10%) and the lack of definitive and 
specific EPC markers has contributed to a wide variability of results (De Palma et al., 
2003), there is evidence supporting a correlation between the number of blood 
circulating EPCs and tumour recurrence and metastasis, thus suggesting their 
involvement in tumor progression (Naik et al., 2008; Igreja et al., 2007). 
 
Tumours can induce the remodelling of pre-existing vessels in order to split and as a 
consequence increase them by intussusception. Intussusceptive angiogenenesis has 
been observed both in mouse and human tumour models and reported to be 
happening on a time scale of minutes due to low energy requirements (Patan et al., 
2001). In highly vascularized stromal tissues, such as lung and brain, tumour cells 
can collectively migrate along the vessels and invade the surrounding tissue in a 
perivascular fashion through a mechanism known as vessel co-option (Holash et al., 
1999).  Interestingly, tumour cells can re-program their gene expression to display an 
endothelial cell-like phenotype, therefore acquiring the capability of line vessel 
themselves (Maniotis et al., 1999). This process defined as vascular mimicry seems 
to be independent of the canonical angiogenic factors such as VEGF and bFGF, while 
VE-cadherin and EphrinA2 have been shown to play a significant role: however the 
molecular mechanisms have not been thoroughly identified yet (Hendrix et al., 2001).  
 
Regardless of the mode, tumour vessels are abnormal in their structure and function 
(Jain, 2005). They are tortuous and dilated, they branch irregularly and they are leaky. 
Moreover, pericyte and basement membrane coverage are reduced and 
discontinuous. This structural disorganization creates a constitutive hypoxic 
environment which leads to a further enhanced production of pro-angiogenic factors 
by tumour cells thereby establishing a vicious cycle (Jain, 2005). From a clinical point 
of view, dysfunctional tumour vasculature causes reduced drug delivery and high fluid 
pressure due to vessel leakiness (Bergers and Hanahan, 2008). Taken together, 
these conditions significantly impair the efficacy of chemotherapy and radiotherapy 
which rely on the formation of oxygen radicals to exert their cytotoxic functions. 
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1.5.2 Metastatic disease: vessels required 
 
Metastasis is the primary cause of tumour related death, lung and bone being the 
most common site for metastasis in breast and prostate cancers. Most metastatic 
lesions are not treated by surgery, as the presence of a single metastatic lesion 
frequently indicates wider systemic metastatic dissemination (Christofori, 2011; 
Yachida et al., 2010). Metastatic dissemination is a multi-step process whereby 
vessels are used as a route by invasive cells to spread from the primary tumour by 
extravasating and entering the circulation (either blood or lymphatic), to then 
intravasate and colonize distant tissues and organs. 
 
According to the Paget theory of  “seed and soil” (Paget, 1989), tumour cells can only 
survive and grow if they encounter the right host environment, their appropriate ‘‘soil” 
and the vasculature plays a central role in contributing to the “seeding” of tumour cells 
during the process of metastasis. Indeed metastatic primary tumours can set pre-
metastatic niche by providing the required growth factors, chemoattractants, 
adhesive molecules and proteinases to create a conducive microenvironment for 
tumour cells to engraft at distant sites and expand as metastatic outgrowths 
(Hiratsuka et al., 2006; Kaplan et al., 2005).  
 
Tumours can directly pre-condition the vasculature releasing angiogenic factors 
which can facilitate extravasion of tumour cells as well as their intravasation at distant 
sites. As an example, high VEGF tumour levels promote the loosening of endothelial 
tight junctions, thus allowing extravasation of tumour cells into the circulation 
(Hanahan and Coussens, 2012). Enhanced FAK activity by tumour cells has been 
shown to reduce blood vessel barrier integrity through a VEGF/cSrc/VEC dependent 
mechanism, thereby increasing the passage of tumour cells through the endothelium 
(Jean et al., 2014). In addition, the hypoxic milieu surrounding tumour vessels 
induces hypoxia inducible related genes including inducible nitric oxide synthase 
(iNOS) whose altered function impairs pericyte recruitment and, as a consequence, 
destabilizes the endothelium (Kashiwagi et al., 2005). Significantly, endothelial HIF 
expression controls metastatic success: depending on which HIF isoform is 
expressed, it can act to both promote and inhibit metastasis through the regulation of 
NO homeostasis (Branco-Price et al., 2012). 
 
Tumours can also indirectly dictate changes which render the secondary 
microenviroment receptive to tumour cell colonization. As examples, tumours can 
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induce the mobilization of VEGFR1+ hematopoietic precursor cells from the bone 
marrow to home at pre-metastatic sites. Further, tumour secreted inflammatory 
chemoattractants (such as S100A8 and S100A9) can recruit myeloid cells at pre-
metastatic sites (Hiratsuka et al., 2006). BMDCs are the main source of MMP9 which 
in turn releases matrix-bound VEGF thereby prompting angiogenesis within 
metastatic tissues (Hiratsuka et al., 2002).  
 
1.5.3 The role of immune cells in tumour angiogenesis 
 
Over the last decades, a growing body of literature has highlighted the importance of 
the microenvironment for tumour growth and metastatic spread. The concept of 
tumour microenvironment has been broadened to include the influx of cells from the 
periphery in addition to the canonical cellular architecture of the tissue. Infiltration of 
immune cells in tumours was firstly observed by Virchow as early as the mid-
nineteenth century (Balkwill and Mantovani, 2001). For a long time, it was believed 
that immune cells could recognize tumour cells as being foreign and efficiently 
eradicate them. This view was not only challenged by the evidence that tumour cells 
can escape host immune surveillance (Kim et al., 2007), but also reversed by the 
findings that they can play a dual role in tumour progression: either induce anti-
tumour immune responses or sustain tumour growth and metastasis (Mantovani et 
al., 2008).  
 
Tumour immune infiltrate consists of many cell subsets, including macrophages and 
neutrophils.  Macrophages are key orchestrators of chronic inflammation and are 
functionally distinguished as M1 and M2 populations, M1 being potent effector cells 
that kill pathogens and tumours, while M2 tune inflammation and adaptive immunity 
(Galdiero et al., 2013). Tumour-Associated Macrophages (TAMs) are recruited into 
the tumour-associated stroma and polarized toward a pro-tumoural M2 phenotype, 
thereby contributing to the establishment and maintenance of a chronic inflammation 
state which favours tumour growth and progression (Figure 1.6) (Sica and Mantovani, 
2012). TAMs can sustain tumour growth through the production of growth factors, 
and they can promote tissue invasion and angiogenesis through the release of 
proteases and angiogenic molecules respectively. They can also inhibit antitumoural 
responses through the production of immunosuppressive cytokines (Sica and 
Mantovani, 2012). Macrophages are also associated with increased metastatic 
potential as demonstrated by studies in which their transfer or depletion significantly 
affects the frequency of metastatic nodules (enhanced or reduced respectively) (De 
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Nardo et al., 2009; Joyce and Pollack, 2009). Studies have suggested that 
macrophages are recruited to the sites of tumour cell colonization while in their 
absence, tumour cell extravasation and survival is reduced thereby diminishing 
metastatic cell seeding efficiency. Furthermore, poor recruitment of macrophages 
within neoplastic lesions limits metastatic growth, even if metastatic lesions have 
already been established (Talmadge, 2013).  
 
 
 
Figure 1.6 The role of Tumour-Associated Macrophages (TAM) in cancer 
M2 polarized TAMs are recruited into the tumour microenviroment where they release of a 
plethora of growth factors, proteolytic enzymes and cytokine which contribute to sustain 
tumour growth and invasion as well as block antitumoural immune responses (taken from 
Galdiero et al., 2013). 
 
Neutrophils are the most abundant leukocyte subset in the peripheral blood and they 
set the first line of defence against microbial organisms. Due to their very short life-
span their role in tumour growth has been long disregarded; while only recently 
acknowledged as tumour infiltrating cells, playing an important role in tumour growth 
and progression (Mantovani et al., 2011). Similarly to macrophages, they have both 
pro-tumoural and anti-tumoural functions, mirroring the same dualistic profile of N1 
and N2. Tumour-Associated Neutrophils (TANs) can favour genetic instability of 
tumour cells through the release of Reactive Oxygens Species (ROS) and the 
activation of proteolytic enzymes through the release by nitric oxide derivates 
(Sandhu et al., 2000).  The liberation of Neutrophil Elastase (NE) from their azurophil 
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granules has been shown to promote tumour cell proliferation and epithelial-to-
mesenchymal-transition (EMT) in epithelial lung cancer cells (Houghton et al, 2010).   
Neutrophil infiltration can also enhance the metastatic potential via expression of pro-
migratory and pro-invasive factors and can enhance angiogenesis by inducing the 
release of VEGF from the ECM, (Galdiero et al., 2013). Furthermore, neutrophils can 
suppress anti-tumoural T CD8+ responses by Transforming Growth Factor- β (TFG-
β) production (Fridlender et al., 2009). 
 
In addition to TAMs and TANs, tumour growth has been found to be further sustained 
by the presence of a population of immunosuppressive cells referred to as myeloid 
derived suppressive cells (MDSCs) (Sica and Bronte, 2007). Morphologically, these 
populations consist of monocytes, granulocytes, and immature myeloid cells and are 
functionally identified by their capacity to suppress cytotoxic T-cell responses. 
MDSCs in mice are divided in monocytic MDSCs (CD11b+/Ly6C+) and granulocytic 
MDSCs (CD11b+/Ly6G+) (Galdiero et al., 2013). Several mechanisms have been 
proposed for their immunosuppressive effects such as up-regulation of ROS and NO 
production, as well as the secretion of immunosuppressive cytokines, all of which 
contribute to suppress T cell proliferation and activation   
 
1.6 Integrins 
 
1.6.1 Integrin structure  
 
Integrins are a family of cell adhesion receptors as well as signalling molecules which 
transduce signals bidirectionally across the plasma membrane and regulate essential 
functions such as cell proliferation, survival and migration (Avramides et al., 2008).  
They are expressed by almost all cell types, including tumour cells. Together with 
immunoglobin superfamily, cadherins and selectins, they constitute the four families 
of cell adhesion molecules that have been detected in angiogenic blood vessels 
(Enenstein and Kramer, 1994).  
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Figure 1.7 Integrin receptor family 
The diagrams shows the mammalian subunits and their α-β associations: 8 β 
subunits heterodimeryze with 18 α subunits to form 24 distinct integrins. These are 
classified in subfamilies based on evolutionary relationships (displayed in different 
colours) and ligand specificity (taken from Hynes, 2002).   
 
 
They are heterodimeric transmembrane glycoprotein composed of non-covalently 
bound α and β subunits. There are 18 types of α subunit and 8 different types of β 
subunit that have been identified in mammals and which can assemble into at least 
24 distinct integrins (Hynes, 2002; Hodivala-Dilke et al., 2003).  
 
Each subunit consists of an extracellular domain, a single transmembrane region and 
a short cytoplasmic tail. The extracellular domains of both subunits form the ligand-
binding site and the combination of α and β subunits confers integrin ligand specificity 
(Humphries, 1990). The short cytoplasmatic tail (fewer than 60 amino acids long) is 
present in all integrin subunits except for β4 and β8; it is not catalytic active and it 
associates with a set of proteins to mediate intracellular signalling. Integrins bind to 
components present in the ECM, such as laminin, collagen, fibronectin, vitronectin 
and different cell types have different integrin profiles (van der Flier and Sonnenberg, 
2001).  
 
Some integrins bind to a single ligand, others bind to multiple lingands, typically 
recognizing short peptide sequences in their ligands (such as the tripeptide Arg-Gly-
Asp or RGD). In fact, they can be broadly divided into four main groups: collagen 
receptors, laminin receptors, RGD-ligand receptors and those with expression 
restricted to leukocytes (Figure 1.7). 
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1.6.2 Integrin activation and signalling 
 
Integrins provide a physical connection between the extracellular compartment and 
the actin cytoskeleton (Hynes, 2002). They exert adhesive functions and have signal 
transduction capabilities, but they do not have any intrinsic enzymatic activity by 
themselves. They signal bidirectionally according to their activation states throught 
“outside-in signalling” which mediates signals that are transduced intracellularly upon 
the binding to ECM ligands and the “inside-out signalling” which regulates the 
extracellular binding activity of integrins from inside of the cell through the induction 
of conformational changes in their structure (Giancotti and Ruoslahti, 1999; Ginsberg 
et al., 2005). The adhesive properties of integrins rely on their activation, the process 
by which they switch from low to high binding affinity to ECM components, followed 
by their clustering at the plasma membrane, resulting in an increased avidity for their 
ligands. In fact, integrin subunits can bend to generate a conformational form in which 
the N-terminal domain is in close proximity to the cell membrane, forming a V-shape, 
and stabilised by inter-subunit clasps. This bent conformation represents a low affinity 
state for ligand binding (Takagi et al., 2002)  
 
Integrin activation is regulated both by intracellular activators (such as talin and 
kindlins) or suppressors (such filamin) which bind to the short cytoplasmic tails of 
integrin subunits. The binding of an activator disrupts the inter-subunit clasps 
between the α and β subunits by altering the angle of the transmembrane domain 
and causing their separation. This then transmits a conformational change to the 
extracellular domain which induces the transition to a conformation with a high affinity 
for ligand binding (Mould and Humpries, 2004). In their active state integrins form 
oligomeric complexes (process referred to as clustering) and this has been shown to 
occur following both inside-out and outside-in stimulation. Further integrin activity can 
be modulated by controlling integrin availability at the cells surface and within 
adhesive structures via their internalization and trafficking (Hynes, 2002). 
 
The interaction of integrins with the actin cytoskeleton is important for their signalling 
functions (Figure 1.8). Integrins assemble at focal contact sites, where they associate 
with adaptor proteins and signalling molecules, thereby integrating adhesion to ECM 
with intracellular signalling pathways that control processes such as proliferation, 
migration, and survival. (Eleiceri, 2001). Examples of adaptor proteins are talin, 
paxillin, vinculin.  Signalling molecules include, FAK, members of the c-Src family of 
non-receptor tyrosine kinases, ERK1/2, c-Jun kinase/mitogen-activated protein 
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kinase (JNK/MAPK) and members of the Rho family of small GTPases (van der Flier 
and Sonnenberg, 2001). In endothelial cells, integrins play a central role in 
VEGF/VEGFR signalling. For instance, β3 integrins specifically bind to the 
extracellular domain of VEGFR2 resulting in increased receptor activation upon 
VEGF stimulation (Soldi et al., 2000).  
 
 
       
 
Figure 1.8 Integrin intracellular signalling 
Signal transduction proteins associated with, or activated by integrins. Signalling molecules, 
such as FAK, c-Src, bind to and recruit additional signalling molecules, creating a complex 
signalling network that is intimately connected to the cytoskeleton network and regulate cell 
proliferation, survival and migration (adapted from Hynes, 2002).    
 
1.6.3 Integrin in cancer 
 
Integrin expression in cancer cells has been found to contribute to tumour 
progression and metastasis. Even if integrins are not oncogenic by themselves, they 
have been found to be involved in the tumour initiation process activated by some 
oncogenes (Bendas and Borsig, 2012; Koistinen and Heino, 2000). As such integrins 
have been investigated and developed as therapeutic targets (Desgrosselier and 
Cheresh, 2010) Increased expression of α5, β1 and β3 integrin subunits has been 
shown to correlate with poor prognoses in patients with non-small lung cell carcinoma 
(Dingemans et al., 2010). Constitutively active β1 integrin has been shown to drive 
metastasis in vivo (Kato et al., 2012); whereas its ablation in pancreatic β-cells was 
found to decrease tumour growth, but to mediate metastatic dissemination in the 
mouse Rip-Tag model (Kren et al., 2007). Integrins α5, β1 αv and β3 have been 
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shown to be overexpressed in glioma, with αvβ3 integrin abundantly expressed at the 
tumour periphery of high grade gliomas and in the tumour vasculature (Gladson et 
al., 1996).   
 
αvβ3-integrin has been shown to cooperate with PDGFRB in glioma cells implicating 
αvβ3-integrin in tumour invasion in gliomas which secrete high levels of PDGF (Ding 
et al., 2003). Furthermore, αvβ3-integrin has been shown to be overexpressed in 
breast and prostate cancers and to correlate with bone metastasis (Sheldrake and 
Patterson, 2009); whereas in pancreatic tumour, its increased expression is 
associated with increased MMP-2 activation of and lymph node metastasis (Hosotani 
et al., 2002). Therefore, the critical role of integrins in cell adhesion and migration 
coupled with their dysregulated expression in different cancers have made integrins 
a focus of targeted drug design. 
 
1.6.4 Vascular integrins 
 
The first evidence that integrins were involved in angiogenesis was supported by their 
expression patterns in newly formed blood vessels. In particular, attention has been 
given to αvβ3=integrin as although it is barely detectable in quiescent vessels, its 
expression is elevated greatly in angiogenic sprouts (Brooks et al., 1994).  
 
Vascular endothelial cells express several integrins including: the collagen receptors 
α1β1 and α2β1; the laminin receptors α3β1, α6β1 and α6β4; the fibronectin receptors 
α4β1 and α5β1; the ostepontin receptor, α9β1 and the vitronectin receptors αvβ3 and 
αvβ5. Even though αvβ3 is referred to as the vitronectin receptor, on endothelium it 
can also bind to von Willebrand factor, fibronectin, osteopontin, thrombospondin, 
tumstatin as well as other ECM proteins, all of which contain a arginine-glycine-
aspartic acid (RGD) peptide motif (Hodivala-Dilke et al., 2003).  
 
1.6.5 αvβ3-integrin 
 
αvβ3-integrin has gathered much attention since it is expressed only by neo-
angiogenic tumour vessels and not by normal ones thereby reducing the potential for 
side-effects from its blockade (Brooks et al., 1994). αvβ3-integrin is expressed in the 
endothelium of newly formed blood vessels: it is dramatically upregulated in tumour 
endothelium and in the vasculature at sites of inflammation and tissue repair (Brooks 
et al., 1995).  
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Moreover its expression on tumour cells has been correlated with poor patient 
survival. However, in some human tumours (such as angiosarcomas) endothelial cell 
αvβ3 levels decrease as malignant transformation progresses and vascular αvβ3 
levels have been found to be significantly lower in lung metastases from colorectal 
carcinomas compared to those in primary tumours (Robinson and Hodivala-Dilke, 
2011) implying it might also exert an antiangiogenic role. 
 
1.6.5.1 αvβ3-integrin signalling in angiogenesis 
 
At a molecular level, ligation of αvβ3-integrin induces the activation of MAPK 
(mitogen-activated protein kinase), FAK and  c-Src, resulting in cell proliferation, 
survival and migration which are all steps endothelial cells undergo during the 
angiogenic process (Miranti and Brugge, 2002). Whereas unligated αvβ3-integrin 
negatively regulates cell survival and promotes apoptosis by recruiting caspase-8 to 
the plasma membrane in a process defined as Integrin-Mediated death (IMD) 
(Stupack et al., 2001). The disruption of αvβ3 ligation, either by neutralizing 
antibodies or by small RGD inhibitors, results in prevention of vessel formation in vitro 
and inhibition of tumour growth and angiogenesis in vivo in some models (Brooks et 
al., 1995; Drake et al., 1995; Hammes et al., 1996; Kumar et al., 2001). 
 
Importantly, αvβ3-integrin and VEGFR2 have been shown to interact synergistically 
(Mahabeleshwar et al., 2006). VEGFR2 activation induces αvβ3-integrin tyrosine 
phosphorylation that, in turn, is crucial for VEGF-induced VEGFR2 phosphorylation 
in a c-Src dependent mechanism. Indeed, knockin mice, expressing a mutant form of 
αvβ3-integrin unable to undergo cytoplasmic tyrosine phosphorylation (DiYF) display 
impaired pathological angiogenesis whereby tumour growth and associated 
neovascularisation were reduced significantly (Mahabeleshwar et al., 2006).  
 
Taken together these results suggest that αvβ3-integrin is required for pathological 
angiogenesis. In addition, αvβ3-integrin has been shown to associate with Neuropilin-
1, a VEGF co-receptor that augments signalling through VEGFR2 (Robinson et al., 
2009) and with a number of pro-angiogenic growth factor receptors, substantiating 
the role of αvβ3-integrin as a positive regulator of angiogenesis (Miranti and Brugge, 
2002). 
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1.6.5.2 ECM ligands for αvβ3-integrin 
 
The interactions of αvβ3-integrin with the extracellular environment determines 
endothelial cell behaviour and thus angiogenesis. Despite defined as “vitronectin 
receptor”, αvβ3-integrin can bind to other RGD-containining-ECM ligands such as 
fibronectin, fibrinogen, von Willebrand Factor (vWF), Osteopontin (OPN) and 
thrombospondin.   Brooks et al. (1995) showed that αvβ3-integrin antagonists (RGD 
mimetics) induce endothelial cell death, implying that this integrin is pro-angiogenic 
and required for angiogenesis. In contrast Alghisi et al. (2009) reported that the RGD 
mimetic treatment of HUVECs (human umbilical endothelial cells) cultured on ß1-
integrin ligands (such as laminins, collagens and fibronectin) led to αvβ3-integrin 
activation and associated with an increase in endothelial monolayer permeability; 
thereby suggesting αvβ3-integrin functions are dependent on ECM ligation. Further, 
αvβ3-integrin on HUVECs binds to acutely secreted von Willebrand factor (vWF) and 
sustains platelet adhesion (Huang et al., 2009). 
 
αvβ3-integrin as expressed by other cell types is also affected by interaction with the 
extracellular matrix.  For istance, in osteoclasts αvβ3-integrin binding to Osteopontin 
in osteoclasts results in a reduction in cytosolic Ca2+ which in turns regulates 
osteoclast function (Miyauchi et al., 1993); whereas it promotes migration in smooth 
muscle cells (Liaw et al., 1995). Furthermore in melanoma cells, αvβ3-integrin 
function has been shown to be modulated by thrombospondin acts via CD47 (Integrin 
associated Protein-IAP) and to affect cell spreading and focal adehesion turnover 
(Gao et al., 19960. In addition, αvβ3-integrin can also act together with α5β1-integrin 
in promoting adhesion and spreading on fibronectin in M21 melanoma cells (Charo 
et al., 1990). 
 
1.6.5.3 β3-integrin knockout and knock-in mouse models 
 
Unexpectedly, the genetic ablation of β3-integrin not only supports tumour growth 
and tumour angiogenesis, it enhances these processes (Reynolds et al., 2002; 
Taverna et al., 2004), implying that, in contrast to what originally was thought, β3-
integrin is not required absolutely for tumour angiogenesis and indicating that it can 
also negatively regulate angiogenesis. β3-integrin knock-out (KO) mice also display 
a bleeding phenotype due to the loss of αIIbβ3 integrin in platelets, which is required 
for platelet clotting (Hodivala-Dilke et al. 1999). Furthermore, the enhanced 
pathological angiogenesis displayed by β3 KO mice has been shown to be associated 
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with increased VEGFR2 expression and function (Reynolds et al., 2004). This 
phenotype can be normalized by administering VEGFR-2 inhibitors, suggesting that 
a VEGFR2 compensatory mechanism may be involved in tumour angiogenesis when 
αvβ3 integrin is absent (Reynolds et al., 2002). 
 
DiYF knock-in mice (expressing a mutant β3-integrin unable to undergo tyrosine 
phosphorylation) undergo normal embryonic development and organogenesis, but 
they show impaired normal and pathological angiogenesis (Mahabeleshwar et al., 
2006). Importantly, they do not show any compensatory changes in VEGFR2 
signalling (Mahabeleshwar et al., 2006) as reported for by β3 KO mice (Reynolds et 
al., 2004).  
 
Floxed mice with cell-specific conditional deletion of β3-integrin in platelets and 
myeloid cells have also been generated (Morgan et al., 2010). Consistently, β3 KO 
in platelets leads to a bleeding phenotype, but has no effect on tumor growth and 
angiogenesis.  Interestingly, tumour growh is enhanced in myeloid β3 KO mice but 
without an increase in tumour angiogenesis. Moreover, β3-integrin deletion in 
myeloid cells induced osteopetrosis (similar to that observed in the global β3 
knockout mice) due to impaired osteoclast activitity (Morgan et al., 2010).  
 
αvβ3-integrin is expressed by different cell types (pericytes, platelets, macrophages, 
bone marrow derived cells, fibroblasts, osteoclasts) each contributing in their own 
way to angiogenesis (Robinson and Hodivala-Dilke, 2011) and in fact both KO and 
DiYF angiogenic phenotype can be rescued by restoring wild-type expression of β3-
integrin in bone marrow derived cells, through bone marrow transplant (Reynolds et 
al., 2002; Feng et al., 2008). In line with this finding, the disruption of β3 expression 
in BMDCs has been shown to give rise to similar angiogenic phenotypes as the ones 
observed in β3 KO mice (Morgan et al., 2010). This suggests that ablation of β3-
integrin in non-ECs may be responsible for the phenotypes seen in KO studies.  
 
Collectively, the studies illustrate that αvβ3-integrin can play both pro- and anti-
angiogenic roles in tumour development depending on its level of  expression, on the 
molecules with which it is interacting and on the cell type expressing it in complex 
ways we do not fully understand yet and as such we can not exploit them effectively 
in clinical settings (Robinson and Hodivala-Dilke, 2011). However, a major limitation 
of these genetic and pharmacological studies is the global nature of the imposed 
inhibition (e.g. multiple cell types are affected by both manipulations). Moreover a 
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systemically administered drug directed against αvβ3-integrin is acting differently 
than a genetic alteration that abrogates the expression of the β3-integrin subunit.  In 
reality, both are blunt tools to dissect the complex cellular and molecular pathways 
regulated by this molecule (Atkinson et al., 2014). More refined work is needed in 
order to clarify how αvβ3-integrin regulates pathological angiogenesis. 
 
1.6.5.4 αvβ3-integrin inhibitors 
 
Preclinical in vitro studies have provided the rationale for the development of αvβ3-
integrin antagonists as anti-angiogenic agents (Brooks et al., 1994). LM609 (mouse 
anti-αvβ3 antibody) was fully humanized and known as Vitaxin, then MEDI-522. It 
has been developed by Astra-Zeneca as etaracizumab (Abegrin). Despite being well 
tolerated in Phase I trials (Delbaldo et al., 2008), Abegrin did not show objective 
response in a Phase II trial for melanoma (Hersey et al., 2010). It Abegrin is currently 
being tested in other clinical trials for solid tumors (metastatic melanoma (prostate 
and ovarian cancer) and auto-immune diseases (psoriasis, and rheumatoid arthritis. 
Furthermore, Abegrin has proven successful as a targeting ligand for molecular 
imaging agents (Liu et al., 2010). 
 
The most promising αvβ3 candidate was Cilengitide (RGD-peptide), which was first 
synthesized by Kessler and colleagues (Aumailley et al., 1991) and subsequently 
identified using a cell-free receptor assay for the inhibition of integrins αvβ3 and αvβ5 
but not αIIbβ3 (Smith et al., 1990). Since αvβ3 is highly expressed in glioblastoma 
multiforme (on both tumour astrocytes and endothelial cells; Gladson and Cheresh, 
1991), Cilengitide has been tested in patients with newly diagnosed glioblastoma.  
 
Despite initial clinical trials have shown encouraging results: antitumor activity, 
including durable remissions, and increased survival for a subset of patients; the 
latest Phase III study (CENTRIC) aimed to test standard treatment in combination 
with Cilengitide have recently failed (see paragraph 1.7.2).  
 
1.7 Anti-angiogenic therapy 
 
The concept that tumour angiogenesis may have therapeutic implications in the 
control of tumour growth was introduced by Folkman in 1971 (Folkman, 1971). Given 
the premise that tumours depend on angiogenesis for their growth, progression and 
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spread, targeting of tumour blood vessels has been considered a logical approach to 
target different tumours over the past decades (Carmeliet and Jain, 2000). 
 
1.7.1 Clinically approved anti-angiogenic therapies 
 
Ever since 1971, research in angiogenesis inhibition as a therapeutic strategy has 
led to the discovery of the molecular mechanisms of angiogenesis: pro- and anti-
angiogenic molecules, their ligands and receptors, as well as their downstream 
signalling pathways have been identified and investigated as potential targets (listed 
in Figure 1.9).   
 
Figure 1.9 Overview of anti-angiogenic drugs in cancer 
List of main anti-angiogenic drugs with their specificity, target and approved 
indications. Since 2004, a huge panel of antiangiogenic inhibitors, either alone or in 
combination with cytotoxic and chemotherapy drugs, have been tested in clinical 
trials, and approved (adapted from Limaverde-Sousa et al., 2014). 
 
 
Due to its main role in angiogenesis, vascular endothelial growth factor (VEGF) and 
its receptors (VEGFR) have been the most widely studied targets (Hicklin and Ellis, 
2005). This has resulted in the development of VEGF inhibitors, amongst which 
BEVACIZUMAB (a monoclonal anti-VEGF antibody-Avastin®) was the first 
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angiogenesis inhibitor that was shown to have a significant and clinically relevant 
survival benefit in phase III trial for advanced colorectal cancer (CC) and the first to 
be approved by the Food and Drug Administration (FDA) in 2004. In detail, 
BEVACIZUMAB was shown to extend both overall survival (OS) and progression free 
survival when combined with standard chemotherapy agents (irinotecan, 5-fluoro-
uracil, leucoverin- IFL scheme) (Hurwitz et al., 2004).  
 
Shortly after that, the use of Bevacizumab was additionally approved for the treatment 
of metastatic breast cancer (MBB), hepatocellular carcinoma (HC), renal cell 
carcinoma (RCC), non small lung cell cancer (NSCLC), gastrointestinal stroma 
tumours (GIST) and glioblastoma (GBM). Besides Bevacizumab, other monoclonal 
antibodies designed to block epithelial growth factor (EGF/HER) receptors, such as 
cetuximab (Erbitux), trastuzumab (Herceptin) and panitumumab (Vectibix) have been 
found to exhibit antiangiogenic functions due to crosstalk between the signalling 
pathways that involve VEGF (Welti et al., 2013).   
 
Moving from single target therapy to the second generation of anti-angiogenic drugs, 
broad-spectrum receptor tyrosine kinase inhibitors (TKIs) were subsequently 
approved for clinical use: SUNITINIB (Sutent®) for metastatic RCC and advanced 
pancreatic neuroendocrine tumours, PAZOPANIB (Votrient®) for metastatic RCC,  
SORAFENIB (Nexavar®) for unresectable HC and metastatic RCC and 
VANDETANIB (Zactima®) for medullary thyroid cancer (Welti et al., 2013). These 
VEGFR inhibitors are also able to block other receptor targets such as Platelet 
derived growth factor receptor (PDGFR), Epidermal growth factor receptor (EGFR), 
c-Kit or RET, thereby preventing the establishment of resistance mechanisms 
associated with long-term monotherapy. Unlike antibodies, TKIs cross the cell 
membrane due to their small size and hydrophobicity, interacting directly with the 
intracellular domain of receptors and/or other signalling molecules. Several multi-
target TKIs display activity as single agents, but they have also been investigated in 
combination as described for single-target anti-angiogenic treatments (Limaverde-
Sousa et al., 2014).  
 
In addition to the above-mentioned drugs, several other molecules with anti-
angiogenic activities have been developed and studied extensively both in vivo and 
in vitro. Integrins are a family of cell adhesion molecules that have been 
demonstrated to play a key role in tumour angiogenesis and metastasis and, as such, 
they have been exploited as therapeutic targets (Desgrosseliers and Cheresh, 2011). 
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Inhibitors of integrin activity include monoclonal antibodies such as VITAXIN (a 
humanized anti-integrin αvβ3 monoclonal antibody) and peptides such as 
CILENGITIDE (a cyclic pentapeptide inhibitor mimicking the RGD motif recognized 
by αvβ3- and αvβ5-integrins) and ATN-161(a fibronectin derived peptide recognized 
by α5β1 and αvβ3)  (Cai et al., 2006; Reardon et al., 2008; Khalili et al., 2007). 
Peptides, compared to full size recombinant monoclonal antibodies, retain the activity 
of the parent molecule and have significant advantages such as low toxicity, high 
specificity and good tissue penetration due to their small size. 
 
1.7.2 Concern and challenges of anti-angiogenic therapies 
 
Although there is general consensus on the notion that targeting angiogenesis 
represents a clinically effective therapeutic strategy in oncology, in reality the multiple 
anti-angiogenic strategies which have been pursued, have proved largely 
disappointing. Despite initial encouraging results, BEVACIZUMAB, along with other 
anti-angiogenic drugs, failed to prove significant clinical efficacy, whereas showing a 
modest success represented by an increase in overall survival measured in the order 
of months (Bergers and Hanahan, 2008). Indeed, the FDA has revoked 
BEVACIZUMAB indication for the treatment of metastatic breast carcinoma in 2012 
(Mackey et al., 2012). In February 2013, Merck announced that  CILENGITIDE had 
not passed a phase III clinical trial aimed at evaluating OS in glioblastoma patients 
when added to the current standard chemo-radiotherapy treatment (temozolomide 
and radiotherapy) (Soffietti et al., 2014). In addition to that, VEGF blockade has been 
associated with an increase in tumour invasion and metastasis giving raise to safety 
concerns in clinical settings (Kerbel et al., 2008), while the concept of normalization 
of the tumour vasculature (therefore improving the delivery of drugs and oxygen to 
tumours) has emerged as potentially beneficial in reducing tumour growth and 
metastatic dissemination (Jain, 2001). 
 
Taken together this evidence calls into question the simple concept of the causal link 
between tumour growth and angiogenesis which needs to be further evaluated 
(Atkinson et al., 2014). First of all, the molecular pathways regulating developmental 
and physiological angiogenesis might not necessarily recapitulate the mechanisms 
underlying tumour angiogenesis; second of all, in vitro and in vivo models used to 
test anti-angiogenic drugs do not completely reflect the heterogeneity of human 
cancers; finally, and partially related to this, the mode of action of these targets in 
patients is not fully understood yet,  as well as the duration and dose of treatment 
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remain to be effectively determined since rebound tumour growth effect may happen 
after stopping anti-angiogenic drugs (Welti et al., 2013).  
 
Rather relevant, these drugs are employed for the treatment of patients with highly 
metastatic disease and, as such, displaying an already aggressive tumour 
phenotype, thereby possibly accounting for intrinsic refractoriness or subsequent 
acquired resistance to anti-angiogenic drugs (Leite de Oliveira et al., 2011).  Because 
angiogenesis is regulated by different factors, often displaying redundant functions, 
the inhibition of a single target is likely to increase the dependency on alternative 
pathways or to induce the selection of cells in which angiogenesis is driven by other 
factors.  
 
Furthermore, the reasons for limited efficacy of anti-angiogenic approaches are likely 
the result of multiple factors relying both on tumour cells and the tumour 
microenvironment (Hanahan and Coussens, 2012). Tumour cells can produce pro-
angiogenic molecules other than VEGF (VEGF-independence), they can switch 
between different modes of vascularization (angiogenesis independence), become 
tolerant to hypoxic conditions or metastatise via lymphatic vessels (vascular 
independence) thereby escaping VEGF (receptor) blockade. In addition, cancer stem 
cells can give rise to an alternative source of vascular cells with reduced sensitivity 
to VEGF inhibition (Welti et al., 2013). 
 
The unforeseen plasticity of tumour cells along with the dynamic characteristics of 
the tumour microenviroment still pose unresolved challenges which will require new 
anti-angiogenic strategies both in the form of alternative molecules and target cells 
such as the more genetically stable endothelial cells or pericytes and alternative 
therapeutic schemes, such as neoadjuvant or metronomic therapies (Welti et al., 
2013). Importantly, there is a need for more suitable preclinical models to investigate 
resistance mechanisms and how they can be effectively overcome; and, equally 
important, the need for clinically predictive biomarkers tailored for tumour type, stage 
and treatment (Leite de Oliveira et al., 2011).  
 
With respect to this last aspect, the identification and validation of predictable 
biomarkers is as relevant as the development of “drugable” targets. Faithful 
biomarkers will allow for the personalization of therapeutic regimes, for the evaluation 
of efficacy and toxicity of these treatments and, ideally, the prediction of resistance.  
Thus, it is compelling to further investigate the complex interplay of signalling 
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molecules and cells which are involved in tumour angiogenesis in order to overcome 
these limitations and to improve the efficacy of anti-angiogenic therapy in the clinics.  
 
The importance of tumour microenviroment (TME) in promoting tumour growth and 
progression is now-increasingly accepted (Quail and Joyce, 2013). The stromal 
compartment also significantly affects tumour cells’ abilities of developing resistance 
to treatments. Stromal cells, infiltrating immune cells and cancer associated 
fibroblasts can all produce pro-angiogenic molecules and recruit bone marrow 
derived cells, resulting in increased tumour angiogenesis independently of VEGF 
(receptor) inhibition. Furthermore, distinct signals can regulate angiogenesis in 
primary compared to metastatic tumours, implying that the efficacy of treatment is 
context- and time-dependent; nevertheless, treatments themselves can select for 
more aggressive tumour cell clones (Hanahan and Coussens, 2012).  
 
Anti-angiogenic therapy, compared to traditional cancer therapies, has significant 
advantages; namely easy accessibility, broad applicability and, overall reduced 
toxicity when compared to the detrimental side effects of chemo/radiotherapies. 
However, given the current limitations, it seems unlikely that a single anti-angiogenic 
therapy will ever prove entirely effective. The challenge is to define an effective and 
rational combinational therapy that overcomes these limitations. Aside from targeting 
tumour vessel structure thereby improving the delivery of drugs and oxygen to 
tumours, as a complementary approach to improve traditional anti-angiogenic 
therapy, another new concept that is emerging is to target vascular sprouts by 
manipulating endothelial cell metabolism (Rivera and Bergers, 2014). Additionally 
combining therapeutic approaches over single therapies is potentially a way of 
synergizing therapeutic effect as well as overcome resistance.  
 
1.8 Aims of  the study 
 
This study was undertaken to elucidate the role of endothelial β3-integrin in 
pathological angiogenesis in vivo. 
 
My aims were: 
 
To generate two different endothelial-specific β3-integrin-deficient mouse models:   
 
• a constitutively-deleted β3-integrin-floxed Tie1Cre model, 
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• a drug inducible β3-integrin-floxed Pdgfb-iCreERT2 model, 
 
and to then use these two models to dissect the role of endothelial β3-integrin during 
tumour angiogenesis; 
 
2) For any phenotype observed in (1) to begin to unravel the molecular basis of β3-
integrin function in endothelial cells (in vitro and ex vivo); 
 
3) To develop spontaneous metastasis models in order to further investigate the 
involvement of endothelial β3-integrin in tumour invasion and metastatic 
dissemination in vivo. 
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2 MATERIALS AND METHODS 
 
2.1 MATERIALS 
 
2.1.1 Chemicals 
Bulk chemicals were obtained from the following companies: 
• Sigma-Aldrich (Poole, UK)  
• Thermo Scientific (Rockford, USA,) 
 
2.1.2 Consumables 
• Plates (6-12-96-wells) flasks (T25-75-175), dish for tissue culture (10 cm): Thermo 
Scientific 
• Test tubes (0.5-1.5 ml): Eppendorf (Stevenage, UK) 
• Test tubes (10-50 ml falcon): BD Bioscience (Oxford, UK) 
• FACS tubes: BD Bioscience 
• Syringe (20 ml) and needles (19 G): Plastipack (St Leonards-on-Sea, UK)/BD 
Bioscience 
• Filters (0.4-0.7 µm): Millipore (Watford, UK) 
• Poly-L-Lysine coated microscope slides and glass coverslips (10 mm): Thermo 
Scientific 
 
2.1.3 Equipment and software 
 
• UV BioDoc-It Imaging System: UVP (Cambridge, UK) 
• FUJIFILM Luminescent Image Analyzer LAS-1000plus: Fujifilm UK (Bedford, UK). 
• NanoDrop: Thermo Scientific 
• 96-well Fast Thermal Cycler: Applied Biosystems (Invitrogen) 
• UV/Vis Spectrometer Microplate Reader: BMG Labtech (Aylesbury, UK) 
• Axioplan epifluorescent microscope: Zeiss (Cambridge, UK) 
• Microtome and vibratome: Leica (Milton Keynes, UK) 
• Tissue Lyser: Qiagen (Manchester, UK) 
• Accurie C6 flow cytometer: BD Bioscience 
• ImageJ software for densitometric analysis: software available at the 
National Institutes of Health web site 
• GraphPad Prism software for statistical analyses 
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• Axiovision software for fluorescent image analysis 
• CELLQUEST software for flow cytometry analysis 
 
2.1.4 PCR 
 
2.1.4.1 Primers 
PCR analysis of genetically engineered mice was carried out using the following 
oligonucleotide primers: 
 
β3-floxed PCR 
Forward primer: 5'-TTGTTGGAGGTGAGCGAGTC-3 
Reverse primer: 5'-GCCCAGCGGATCTCCATCT-3' 
 
Tie1Cre PCR 
Forward primer: 5’-GCC TGC ATT ACC GGT CGA TGC AAC GA-3’ 
Reverse primer: 5’-GTG GCA GAT GGC GCG GCA ACA CCA TT-3’ 
 
Pdgfb-iCreERT2 PCR 
Forward primer: 5’-GCC GCC GGG ATC ACT CTC-3’ 
Reverse primer: 5’-CCA GCC GCC GTC GCA ACT-3’ 
 
TdTomato PCR 
oIMR9020: 5’-AAG GGA GCT GCA GTG GAG TA-3’ 
oIMR9021: 5’-CCG AAA ATC TGT GGG AAG TC-3’ 
oIMR9103: 5’-GGC ATT AAA GCA GCG TAT CC-3’ 
oIMR9105: 5’-GGC ATT AAA GCA GCG TAT CC-3’ 
 
Semi-qPCR 
RT-PCR analysis of peripheral blood mononuclear cells was carried out using the 
following oligonucleotide primers: 
 
Luciferase 
Forward primer: 5’-GTTCGTCACATCTCATCTACCTCC-3’ 
Reverse primer: 5’-CTTTAGGCAGACCAGTAGATCCAG-3’ 
 
GADPH  
Forward primer: 5-‘TCACTGCCACCCAGAAGAC-3’ 
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Reverse primer: 5’-TGTAGGCCATGAGGTCCAC-3’ 
 
2.1.4.2 Solutions and reagents 
 
• Tail lysis buffer was made of 0.2% SDS, 100 mM Tris-base, 200 mM NaCl, 5 mM 
EDTA and 0.5 mg/ml proteinase K. 
• PCR Master Mix (MegaMix Blue, Cambio; Cambridge, UK) consists of a licensed Taq 
DNA polymerase, dNTPs, MgCl2, reaction buffer and enzyme stabiliser. 
• TE buffer consists of 10 mM Tris-base and 1 mM EDTA. 
• TAE buffer 50X solution consists of 104 g Tris-base, 55 g orthoboric acid and 10 ml 
0.2 M EDTA made up to 1 litre in distilled H2O. 
• RNA isolation kit: Qiagen 
• M-MLV RT kit: Promega (Southhampton, UK) 
 
2.1.5 Animals 
 
2.1.5.1 Surgical materials and reagents 
• Suture wound clips, surgical sutures: VetTech (Congleton, UK) 
• Syringe (2 ml) and needles (21 G): Plastipack/BD Bioscience 
• Sterile dissection instruments 
• Isoflurane: Baxter (Newbury, UK) 
• Tamoxifen (21-day-slow release 5 mg pellet): Innovative Research of America 
(Sarasota, Florida, USA) 
• Matrigel (0.7% solution): BD Bioscience 
• FITC-dextran (low MW 4300): Sigma-Aldrich 
 
2.1.6 Histology 
 
2.1.6.1 Solutions and reagents 
 
• Paraformaldehyde fixing solution consists of 4% paraformaldehyde in PBS. 
• PBLEC consists of PBS containing 1% Tween-20, 1mM CaCl2, 1mM MgCl2 and 0.1 
mM MnCl2. 
• Washing solution consists of 0.1% TRITON X-100 in PBS. 
• Permeabilising solution for aortic rings consists of 0.25% TritonX-100 in PBS. 
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• Sodium citrate antigen retrieval buffer consists of 10mM tri-sodium citrate and 0.05% 
Tween-20 at pH 6. 
• Trypsin-based antigen retrieval buffer consists of 0.0025% trypsin in 0.1% CaCl2 at 
pH 7.8. 
• Mayer’s Hemotoxylin: Sigma-Aldrich 
• Eosin-phloxine B: Sigma-Aldrich 
• Sudan Black (0.1% solution): Sigma-Aldrich 
• Formamide: Life Technologies 
• Prolong Gold Antifade reagent with DAPI: Invitrogen (Paisley, UK) 
• Vectashield mounting medium with DAPI: Vector Laboratories (Peterborough, UK) 
• DePeX mounting solution: Fisher Scientific (Loughborough, UK). 
• Protein block (serum free): Dako (Ely, UK) 
 
2.1.7 Cells and tissues 
 
2.1.7.1 Cell Cultures 
 
• Mouse Lung Endothelial Cell (MLEC) medium consists of: 
1:1 mixture of DMEM low glucose+Glutamax (Invitrogen):Ham’s F12+Glutamax 
(Invitrogen) 
20% Fetal bovine serum (FCS), heat inactivated (HyClone, Invitrogen) 
50 µg/ml Heparin from sodium salt, from porcine intestinal mucosa (Sigma-Aldrich) 
25 mg of endothelial mitogen (AbD Serotec, Oxford,UK) 
2 mM L-Glutamine (Invitrogen) 
100 U/ml Penicillin/ 100 µg/ml Streptomycin (Invitrogen) 
 
• Immortalized Mouse Lung Endothelial Cell (Im-MLEC) medium consists of: 
1:1 mixture of DMEM low glucose+Glutamax (Invitrogen):Ham’s F12+Glutamax 
(Invitrogen) 
10% Fetal bovine serum (FCS), heat inactivated (HyClone, Invitrogen) 
50 µg/ml Heparin from sodium salt, from porcine intestinal mucosa (Sigma-Aldrich) 
2 mM L-Glutamine (Invitrogen) 
100 U/ml Penicillin/ 100 µg/ml Streptomycin (Invitrogen) 
 
• Tumour cell medium consists of: 
DMEM high glucose+Glutamax (Invitrogen) 
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10% Fetal bovine serum (FCS), heat inactivated (HyClone, Invitrogen) 
2 mM L-Glutamine (Invitrogen) 
100 U/ml Penicillin/ 100 µg/ml Streptomycin (Invitrogen) 
 
• GgP+E packaging cell culture medium consists of: 
DMEM high glucose+Glutamax (Invitrogen) 
15% Fetal bovine serum (FCS), heat inactivated (HyClone, Invitrogen) 
2 mM L-Glutamine (Invitrogen) 
100 U/ml Penicillin/ 100 µg/ml Streptomycin (Invitrogen) 
 
2.1.7.2 Solutions and reagents 
 
• Solution for tumour digestion consists of Hank’s Balanced Salt Solution (HBSS, 
Invitrogen) supplemented with 0.2% collagenase IV (Invitrogen), 0.01% 
hyaluronidase (Invitrogen) and 0.01% DNase I (Invitrogen). 
• Solution for lung digestion consists of PBS supplemented with 0.1% collagenase I 
(Invitrogen), 1 mM CaCl2 and 1mM MgCl2. 
• Anti-coagulant buffer solution consists of 38 mmol/L citric acid, 75 mmol/L sodium 
citrate and 100 mmol/L dextrose. 
• Matrix coating solution consists of PBS supplemented with 0.1% gelatin (Sigma-
Aldrich), Purecol (30 µg/ml, Nutacon BV, Netherlands), human plasma fibronectin (10 
µg/ml, Millipore) and mouse multimeric vitronectin (2 µg/ml; Patriecell, Nottingham, 
UK)). 
• FACS buffer consists of PBS supplemented with 1% Fetal bovine serum and 10mM 
HEPES (1M solution, Invitrogen). 
• Permeabilising solutions for cells consists of PBS supplemented with 0.5% NP40 
(Sigma-Aldrich).  
• Blocking solution for cells consists of PBS supplemented with 0.1% Bovine Serum 
Albumin (BSA, Thermo Scientific) and  0.2% Triton X-100 (Sigma-Aldrich).   
• VEGF-A164 was made in house according to the method published by Krilleke et al., 
(2007) 
• bFGF: Peprotech (London, UK) 
• Collagen I (rat tail): Millipore 
• Laminin (L2020): Sigma-Aldrich 
• Fibrinogen from bovine plasma: Sigma-Aldrich 
• Thrombin from bovine plasma: Sigma-Aldrich 
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• Aprotinin from bovine lung: Sigma-Aldrich 
• OptiMEM: Invitrogen 
• Dulbecco’s phosphate buffered saline (PBS): Invitrogen 
• Dynabeads sheep anti-rat IgG: Life Technologies 
• 0.25% trypsin/EDTA: Gibco, Invitrogen 
• Red blood lysis buffer (10X): eBioscience (Hatfield, UK) 
• Polybrene: Sigma-Aldrich 
• Dimethlysulfoxide (DMSO): Sigma-Aldrich 
 
2.1.7.3 Kits 
• Dynabeads Antibody Coupling Kit: Life Technologies 
• Vybrant MTT Cell Proliferation Assay Kit: Life Technologies 
 
2.1.8 Western Blotting 
 
2.1.8.1 Equipment 
• Vertical gel and transfer apparatus/1mm-thick gel cassettes/10- or 15-well combs: 
Bio-Rad Laboratories (Hertfordshire, UK) 
• PROTRAN nitrocellulose membrane: Fisher Scientific  
• Filter paper/sponges: Whatman (GE Healthcare) 
 
2.1.8.2 Solutions and reagents 
 
• ESB lysis buffer consists of 65mM Tris-HCl, 60mM sucrose and 3% SDS at pH 7.4. 
• NuPAGE LDS Sample Buffer (4X): Invitrogen 
• NuPAGE Sample Reducing Agent (10X): Invitrogen 
• Ponceau solution consists of 0.1% Ponceau red (Sigma-Aldrich) and 1% acetic acid 
in distilled H2O. 
• Primary antibody solution consists of 5% BSA and 0.1% Tween-20 (Thermo 
Scientific) in PBS. 
• Blocking solution consists of 5% non-fat milk protein (Thermo Scientific) and 0.1% 
Tween-20 in PBS.  
 
• Acrylamide resolving gel consists of: 
8% acrylamide solution (Protogel, National Diagnostics; Hessle, UK) 
0.1% SDS  
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0.1% ammonium persulfate  
TEMED  
distilled H2O  
 
• Acrylamide stacking gel consists of: 
5% acrylamide solution (30%, Protogel, National Diagnostics) 
0.1% SDS 
0.1% ammonium persulphate  
TEMED 
distilled H2O  
 
• Running buffer (in 1L of distilled H2O) consists of: 
25 mM Tris-base 
192 mM glycine 
0.1% SDS  
 
• Transfer buffer (in 1L of distilled H2O) consists of: 
25 mM Tris base 
192 mM glycine 
20% ml methanol  
 
2.1.8.3 Kits 
• Bio-Rad DC Protein Assay kit: Bio-Rad Laboratories (Hertfordshire, UK) 
• ECL kit: Bio-Rad Laboratories  
 
2.1.9 Antibodies 
 
• Antibodies for immunohistological analysis were as follows: anti-endomucin (clone 
V.7C7, Santa Cruz Biotechnology, Santa Cruz, CA, USA); anti-αSMA (clone 
EPR5368, Abcam, Cambridge, UK); anti-nidogen (made in house, kind gift from 
Ulrike Mayer; UEA, Norwich, UK); FAK (clone 77/FAK, BD Bioscience); NG-2 (clone 
132.39, Millipore); FITC-IB4 (Sigma-Aldrich) and FITC-conjugated anti-F4/80 (clone 
BM8, eBioscience). Appropriate Alexa Fluor (488-546-555) conjugated secondary 
antibodies (Invitrogen) were used at 1:500. 
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• Antibodies for systemic injection were as follows: PE-conjugated anti-β3-integrin 
(clone 2C9.G3, eBioscience) and PE-conjugated anti-CD31 (Clone 390, 
eBioscience).  
 
• Antibodies for magnetic sorting were as follows: anti-CD31 antibody (Cat.no. 
MCA1334GA, AbD Serotec) and anti-ICAM-2 (Cat.no. MCA2295EL, AbD Serotec). 
 
• Primary antibodies for flow cytometry were all used at 1:200 in FACS buffer and 
purchased from eBioscience: FITC-conjugated anti-CD45 (clone A20); FITC-
conjugated anti-Ly6G (clone RB6-8C5); FITC-conjugated anti-CD3 (clone 17A2); 
Alexa Fluor 488-conjugated anti-CXCR4 (CD184, clone 2B11); FITC-conjugated anti-
F4/80 (clone BM8); PE-conjugated anti-CD11b (clone M1/70); PE-conjugated anti-
α1 (clone Ha31/8, Cambridge Bioscience, Cambridge, UK); PE-conjugated anti-α2 
(clone DX5); PE-conjugated anti-α5 (clone HMa5-1); PE-conjugated anti-αv (clone 
RMV-7) and PE-conjugated anti-β1 (clone HMb1-1). Appropriate PE/FITC labelled 
isotype-matched controls were from eBioscience. 
 
• Primary antibodies for Western Blot analysis were all used at 1:1000 and purchased 
from Cell Signaling Techology (Hitchin, UK), unless noted otherwise: anti-phospho 
(Y1175) VEGFR2 (clone 19A10); anti-VEGFR2 (clone 55B11); anti-β3-integrin 
(Cat.no. 4702); anti-β5 integrin (Cat.no.4708); anti-phospho (Thr202/Tyr204) p44/42 
MAPK ERK1/2 (clone D13.14.4E); anti-p44/42 MAPK ERK1/2 (clone 137F5 ); anti- 
phospho (Ser 1248) PLCγ1 (clone D25A9); anti-PLCγ1 (clone D9H10); anti-phospho 
(Y416) c-Src (clone D49G4); anti-c-Src (clone 36D10); anti-phospho (Y397) FAK 
(clone D20B1); anti-phospho (Y861) FAK (Millipore, Cat.no.PS1008); anti-FAK 
(Cat.no.3285); anti-phospho (Thr180/Y182) p38 (clone 12F8); anti-p38 (clone 
D13E1); anti-phospho (Y731) VE-cadherin (Abcam, Cat.no.27776) anti-VE-cadherin 
(Abcam, Cat.no.33168); and anti-HSC70 (clone B-6, Santa Cruz Biotechnology). 
Appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies 
(Invitrogen) were all used at 1:2000. 
 
2.2 METHODS 
 
2.2.1 Animals 
 
All mice were bred in the Disease Modelling Unit of the Biomedical Research Centre 
at the University of East Anglia, and used in accordance with UK Home Office 
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Regulations and the European Legal Framework for the Protection of animals used 
for scientific purposes (European Directive 86/609/EEC). 
 
2.2.1.1 β3-integrin-floxed transgenic mice  
 
In order to examine the role of endothelial β3-integrin specifically in pathological 
angiogenesis, I took advantage of endothelial-specific β3-integrin-deficient mice 
(Morgan et al., 2010). The β3-integrin-floxed allele was generated by gene target 
insertion of embryonic stem cells that resulted in the insertion of loxP sites flanking 
exon 1 of the Itgb3 (β3-integrin) gene. Mice carrying a loxP-flanked allele of the Itgb3 
gene (Itgb3 flox) were kindly provided by Katherine Weilbaecher (School of Medicine, 
Washington University of St. Louis). Homozygous mice (Itgb3floxflox) were crossed with 
Tie1Cre or Pdgfb-iCreERT2 transgenic mice `in order to generate Tie1Cre;Itgb3floxflox 
and Pdgfb-iCreER;Itgb3floxflox on a mixed C57BL6/129 background. They will be 
hereafter be referred to as β3-floxed/Tie1Cre and β3-floxed/Pdgfb-iCreERT2 mice for 
consistency with our published work (Steri et al, 2014). 
 
2.2.1.2 Tie1Cre transgenic mice  
 
In Tie1Cre transgenic mice (Gustafsson et al., 2001), Cre Recombinase (Gu et al., 
1993) expression is directed to endothelial cells by the mouse Tie1 promoter (Iljin et 
al., 1999). Tie1Cre mice were originally provided by Reinhard Fässler (Max Planck, 
Martinsried, Germany). This promoter has been reported to drive Cre-induced 
expression of the LacZ reporter gene in endothelial cells as early as E8, and 
expression in endothelial cells persists throughout embryogenesis and in adult mice 
(Gustafsson et al., 2001). Therefore, the use of this transgenic mouse strain allows 
excision of floxed gene in endothelial cells during embryogenesis after E8 and into 
adulthood. β3-floxed mice on a mixed C57BL6/129 genetic background were crossed 
with Tie1Cre transgenic mice on C57BL6 genetic background to generate mice with 
the conditional deletion of β3-integrin in endothelial cells. Mice will be hereafter be 
referred to as β3-floxed/Tie1 Cre positive and, their negative counterparts, β3-floxed 
/Tie1Cre negative will be used as control. 
 
2.2.1.3 Pdgfb-iCreERT2 transgenic mice 
 
To further examine the role of β3-integrin in pathological angiogenesis in a more 
clinically relevant model, I took advantage of an inducible endothelial cell-specific β3-
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integrin-deficient mouse model. Pdgfb-iCreERT2 transgenic mice were kindly provided 
by Marcus Fruttiger (UCL Institute of Ophthalmology, UCL, London). In Pdgfb-
iCreERT2 transgenic mice, the tamoxifen inducible form of Cre Recombinase 
(iCreERT2) is under the transcriptional control of Pdgfb gene, which is predominantly 
expressed by endothelial cells; therefore allowing the genetic targeting of the 
endothelium in postnatal mice. In the absence of tamoxifen, the iCreERT2 protein is 
expressed in endothelial cells but retained in the cytoplasm because it is sequestered 
by HSP-90 (Claxton et al., 2008). Whereas in presence of tamoxifen (referred to as 
tamoxifen or OHT), iCreERT2 is translocated to the nucleus where it induces the 
deletion of the β3-floxed gene. β3-floxed mice on a mixed C57BL6/129 genetic 
background were crossed with Pdgfb-iCreERT2 transgenic mice on a mixed 
C57BL6/129 genetic background to generate mice with the inducible deletion of β3-
integrin in endothelial cells. They will be hereafter be referred to as β3-floxed/Pdgfb-
iCreERT2 positive mice and, their negative counterpart, β3-floxed/Pdgfb-iCreERT2 
negative mice as control. Tamoxifen has been administered equally in β3-
floxed/Pdgfb-iCreERT2 positive and negative mice. 
 
2.2.1.4 tdTomato reporter mice 
 
To verify that both endothelial specific Cres induced equally efficient and specific 
recombination of the target gene in endothelial cells, Tie1Cre and Pdgfb-iCreERT2 
positive mice were crossed with tdTomato reporter line (Madisen et al., 2010) on a 
C57BL6/129 mixed background. TdTomato Cre reporter mice (kindly provided by 
Professor Ulrike Mayer; UEA, Norwich, UK) were generated by the insertion in the 
Rosa26 locus of a loxP-flanked DNA STOP cassette under the transcriptional control 
of a strong and ubiquitous promoter, preventing the expression of the downstream 
tomato reporter gene. When crossed with Tie1Cre and Pdgfb-iCreERT2 positive mice, 
the STOP sequence is removed by Cre, therefore the fluorescent reporter is strongly 
expressed. TdTomato heterozygous mice were used for the crossing with endothelial 
specific Cre transgenics. Endothelial cells isolated from Tie1Cre positive/TdTomato 
heterozygous or Pdgfb-iCreERT2 positive/TdTomato heterozygous cells displayed a 
bright red fluorescence which was used to compare the pattern of Cre expression in 
the two endothelial specific models. 
 
2.2.2 PCR genotyping 
 
2.2.2.1 Genomic DNA isolation from tissues 
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Ear (at weaning) or tail (at the end of each in vivo experiment as internal control) 
snips from mice were used for genotyping. Tissues were digested overnight at 56°C 
in a 96-well PCR plate in 100 µl of tail buffer supplemented with 0.5 mg/ml proteinase 
K. DNA was precipitated by adding 100 µl of isopropanol to each well and then 
centrifuging the plate at 2500 rpm for 20 minutes. Isopropanol was removed by gently 
inverting the plate and the pellet was dried at 56°C for about 30 minutes. DNA was 
then resuspended in 200 µl of TE buffer and solubilised overnight at room 
temperature. 
 
2.2.2.2 Genomic DNA isolation from cells 
 
For this purpose, endothelial cells were plated at 2x105 cells/well in a 6-well-plate, 
grown to 80-90% confluency and lysed in 500 µl/well of Tail Lysis Buffer 
supplemented with 0.5 mg/ml proteinase K. Cell lysates were collected in eppendorf 
tubes and incubated overnight at 56°C. NaCl 5M (250 µl/tube) was added and tubes 
were vortexed for 30 seconds. Samples were then centrifuged at 14000 rpm for 10 
minutes and the supernatant was carefully transferred to fresh tubes. DNA was 
precipitated by adding 100 µl of isopropanol to each tube, then samples were 
centrifuged at 2500 rpm for 20 minutes. Isopropanol was removed by pipetting, DNA 
was resuspended in 200 µl of TE buffer and solubilised overnight at room 
temperature. 
 
2.2.2.3 β3-floxed PCR 
 
For each PCR reaction (total 10 µl), 1 µl of DNA template was mixed with 0.04 µl of 
10 µM forward primer, 0.04 µl of 10 µM reverse primer and 8.2 µl of MegaMix Blue 
reagent. PCR reaction conditions were as follows: denaturation at 95°C, 30 seconds; 
extension at 56°C, 30 seconds and annealing at 72°C, 30 seconds. Thirty-five 
amplification cycles were performed, preceded by an initialisation step at 95°C for 2 
minutes and terminated with a final elongation step at 72°C for 8 minutes. PCR 
products are 182-bp (wild-type) and 272-bp (β3 integrin-floxed allele). 
 
2.2.2.4 Tie1Cre PCR 
 
For each PCR reaction (total 10 µl), 0.8 µl of DNA template was mixed with 0.08 µl 
of 10 µM forward primer, 0.08 of µl10 µM reverse primer and 9.1 µl of MegaMix Blue 
reagent. PCR reaction conditions were as follows: denaturation at 95°C, 1 minute; 
63 
 
annealing at 67°C, 90 seconds and extension at 72°C, 1 minute. Thirty-five 
amplification cycles were performed, preceded by an initialisation step at 95°C for 4 
minutes and terminated with a final elongation step at 72°C for 10 minutes. The Tie1-
Cre transgene PCR product is 600-bp. 
 
2.2.2.5 Pdgfb-iCreT2 PCR 
 
For each PCR reaction (total 10 µl), 0.8 µl of DNA template was mixed with 0.08 µl 
of 10 µM forward primer, 0.08 µl  of 10 µM reverse primer and 9.1 µl  MegaMix Blue 
reagent. PCR reaction conditions were as follows: denaturation at 94°C, 30 seconds; 
annealing at 57.5°C, 45 seconds and extension at 72°C, 1 minute. Thirty-four 
amplification cycles were performed, preceded by an initialisation step at 94°C for 4 
minutes and terminated with a final elongation step at 72°C for 10 minutes. The 
Pdgfb-iCreT2 PCR product is 443-bp. 
 
2.2.2.6 TdTomato PCR 
 
For each PCR reaction (total 10 µl), 0.8 µl of DNA template was mixed with 0.08 µl 
7.5 µM of each of the fourt primers, and 8.8 µl MegaMix Blu reagent. PCR reaction 
conditions were as follows: denaturation at 94°C, 20 seconds; annealing at 61°C, 30 
seconds and extension at 72°C, 30 seconds. Thirty-five amplification cycles were 
performed, preceded by an initialisation step at 94°C for 3 minutes and terminated 
with a final elongation step at 72°C for 2 minutes. PCR products are 297-bp (wild-
type) and 196-bp (TdTomato allele). 
 
2.2.2.7 Agarose gel electrophoresis 
 
PCR products from all above described PCRs were separated on a 1.8% agarose 
gel. Agarose gels were made by mixing 1.8 g of agarose with 70 ml distilled H2O, 
microwaving at full power for 3-5 minutes until the agarose dissolved, and adding 28 
ml distilled H2O, 2 ml 50X TAE buffer and 5 µl of 10 mg/ml Ethidium Bromide. The 
agarose solution was poured into a large gel and 20-well-forming combs were 
inserted into the gel. The amplified PCR products (10 µl) were loaded into the gel and 
separated at 100 V for about 1 hour. Bands of PCR products were visualised under 
UV light and photographed using the UV Gel Image Capture System box. 
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2.2.3 In vivo tumour growth and metastasis assays 
 
2.2.3.1 Tumour cell lines 
 
B16F0 
 
B16F0 mouse melanoma cell line was employed for in vivo tumour growth assays 
(Fidler, 1973). B16F0 were passaged when they reached ~80-90% confluency. 
Tumour cells were detached with 0.25% trypsin:EDTA, collected in Falcon tubes, 
counted and then centrifuged for 5 minutes at 1200 rpm. The supernatant was 
removed and tumour cells were washed in PBS. They were finally resuspended in 
PBS (1x106 cells/100 µl per injection) according to the total number of injections and 
kept on ice until their use.  
 
CMT19T 
 
CMT19T is a mouse lung carcinoma cell line derived from the CMT167 cell line and 
was employed for in vivo tumour growth assays (Layton and Franks, 1986). CMT19T 
were passaged when they reached ~80-90% confluency. Tumour cells were 
detached with 0.25% trypsin:EDTA, collected in Falcon tubes, counted and then 
centrifuged for 5 minutes at 1200 rpm. The supernatant was removed and tumour 
cells were washed in PBS. They were finally resuspended in PBS (1x106 cells/100 µl 
per injection) according to the total number of injections and kept on ice until their 
use.  
 
CMT19T F1 
 
CMT19TF1 carcinoma cell line was derived from a single round of in vivo selection 
of CMT19T cells, which had spontaneously metastasised to lung. CMT19TF1 
metastatic cells were isolated by digesting the lung tissue as described in paragraph 
2.2.6.4, expanded and Mycoplasma tested. CMT19TF1 were passaged when they 
reached ~80-90% confluency. Tumour cells were detached with 0.25% trypsin:EDTA, 
collected in Falcon tubes, counted and then centrifuged for 5 minutes at 1200 rpm. 
The supernatant was removed and tumour cells were washed in PBS. They were 
finally resuspended in PBS (1x106 cells/100 µl per injection) according to the total 
number of injections and kept on ice until their use.  
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B6 LV-1 
 
B6 LV-1 breast carcinoma cell line was derived from multiple rounds of in vivo 
selections of C57BL/6 compatible MMTV-PyMT cells, which had spontaneously 
metastasised to bone after left ventricle injection. B6-LV1 tumours cells are also 
green fluorescent protein (GFP) and luciferase (LUC) tagged. B6 LV-1 cell line was 
generated and kindly provided by Katherine Weilbaecher (School of Medicine, 
Washington University of St.Louis).  B6 LV-1 were passaged when they reached ~80-
90% confluency. Tumour cells were detached with 0.25% trypsin:EDTA, collected in 
Falcon tubes, counted and then centrifuged for 5 minutes at 1200 rpm. The 
supernatant was removed and tumour cells were washed in PBS. They were finally 
resuspended in PBS (2x105 cells/50 µl per injection in 1:1 Matrigel mix) according to 
the total number of injections and kept on ice until their use.  
 
2.2.3.2 Growth and maintenance of tumour cell lines 
 
Cell lines were grown in tissue culture flasks and maintained in the appropriate culture 
media at 37°C with a humidified atmosphere of 5% CO2 in air. Tumour cells were 
expanded through subsequent passages to obtain the desired number of cells as 
required for injections. Additional tumour cells were further grown to be frozen down 
in freezing medium (10% DMSO in Foetal Bovine Serum) at 106 cells/cryogenic vial. 
Vials were initially stored at -80°C for and subsequently transferred to a liquid nitrogen 
tank for long-term storage. 
 
2.2.3.3 Allografts 
 
6 to 8-week-old age-matched mice (β3-floxed/Tie1Cre positive and negative mice, 
β3-floxed/Pdgfb-iCreERT2 positive and negative mice,  Tie1Cre positive/tdTomato 
heterozygous and Pdgfb-iCreERT2 positive/tdTomato heterozygous) were 
anaesthetized with isoflurane inhalant and B16F0, CMT19T and CMT19TF1 tumour 
cells were administered by subcutaneous injection (1x106 cells resuspended in PBS, 
100 µl per injection), while B6 LV-1 were administered by mammary fat pad injection 
with Hamilton syringe (2x105 cells resuspended in PBS, 50 µl per injection in 1:1 
Matrigel mix, final volume 100 µl per injection). Tumour growth curves were 
established measuring tumours in two dimension with digital callipers from the 
outside of the mice every other day starting from the onset of a palpable mass. 
Tumour volumes were calculated according to the formula for the volume of a sphere: 
66 
 
tumour volume (mm3) = width2 × length × 0.52. The day of sacrifice (between day 12 
and 20 depending on tumour cell line/experimental scheme) mice were euthanized 
by cervical dislocation and their tumours were excised with surgical scissors, 
photographed for macroscopic appearance and weighed in addition to a final caliper 
measurement. 
 
2.2.3.4 Tamoxifen treatments 
 
β3-floxed/Pdgfb-iCreERT2 positive and negative and Pdgfb-iCreERT2 
positive/tdTomato heterozygous mice were anaesthetized with isoflurane inhalant 
and slow release (5 mg, 21-day release) tamoxifen pellets were implanted 
subcutaneously into the scruff of the neck 3 days before tumour cell injection 
(PREVENTION SCHEME) or 8 days after tumor cell injection (INTERVENTION 
SCHEME). For long OHT treatment a second pellet was implanted 21 days after the 
first pellet, at the same time as tumour cell injections.  
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2.2.3.5 Surgical resections 
 
In order to be able to investigate distant site metastases, surgical resection of the 
primary tumour was performed to allow metastasis to occur. β3-floxed/Tie1Cre 
positive and negative mice were anaesthetized with isoflurane inhalant. The day of 
resection (between day 14 and 20 depending on tumour cell line), CMT19TF1 or B6 
LV-1 tumours were surgically resected after taking measurements with a digital 
caliper. Mice were housed for a further 2 to 4 weeks (depending on tumour cell line) 
before they weresacrificed in order to harvest lungs/bones (sites of metastases). 
They were euthanized by cervical dislocation and lungs were inflated with 3.7% 
formaldehyde in PBS by tracheal injection. 
 
 
 
2.2.3.6 Quantification of tumour circulating cells 
 
B6 LV-1 tumour cells are luciferase tagged and this allowed for their quantification in 
peripheral blood samples by LUC-RT PCR. To quantify the amount of tumour 
circulating cells, peripheral blood from 14-day-B6 LV-1 tumour bearing mice was 
collected in order to isolate nucleated cells. Mice were lethally anaesthetized and 
blood from the vena cava was collected in eppendorf tubes containing anticoagulant 
buffer. Blood samples were centrifuged for 7 minutes at 300 rpm. The resulting cell 
enriched plasma fraction was transferred to a fresh tube and resuspended in 1 mL of 
Red blood lysis buffer. After 5 minutes, samples were centrifuged for 7 minutes at 
2000 rpm. The supernatant was carefully discarded and PBS was added for washing.  
Samples were centrifuged again (7 minutes at 2000 rpm) and the final pellet was 
resupended in 1 mL RNA-Bee for RNA extraction and isopropanol precipitation.  
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RNA quality and concentration were assessed via NanoDrop. cDNA synthesis was 
performed using Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV 
RT) according to the manufacturer’s protocol.  Luciferase PCR conditions were as 
follows: denaturation at 95°C, 10 seconds; extension at 55°C, 30 seconds and 
annealing at 72°C, 10 seconds. Thirty-nine amplification cycles were performed, 
preceded by an initialisation step at 95°C for 3 minutes and terminated with a final 
elongation step at 72°C for 1 minute. Luciferase PCR product is 182-bp. As control 
for the reaction, total RNA and subsequent cDNA synthesis from cultured B6 LV-1 
tumour cells was included. GADPH RT-PCR was performed as a loading control.  
 
2.2.3.7 In vivo tumour permeability assay 
 
In pathological conditions that promote increased vascular permeability (such as 
tumour angiogenesis) the endothelium becomes permeable to small proteins. This 
condition allows for extravasation of low molecular weight FITC Dextran in the tumour 
tissues which can be assessed by quantitative measurement of the fluorescent dye 
incorporated per weight or volume of tissue.  14-day-B6 LV-1 tumour bearing mice 
β3-floxed/Tie1Cre positive and negative mice were lethally anaesthetized and 
injected systemically with low molecular weight FITC-dextran (final 1% in 200 µl PBS 
per injection). After 30 minutes, tumours were harvested, measured and FITC-
dextran was extracted by immersion in formamide buffer for 48 hours at 37°C. 200 µl 
of formamide solution was taken from each sample and transferred to a 96-well-plate 
for fluorescence quantification (excitation wavelength 490 nm; emission wavelength 
520 nm). Fluorescence reading values were then normalized to tumour volumes. 
 
2.2.3.8 Experimental metastasis assay 
 
CMT19T F1 tumour cells were injected systemically (0.5x106 cells/100 µl per tail vein 
injection) in β3-floxed/Tie1Cre positive and negative mice. Prior to injection, mice 
were warmed (10-15 minutes) by placing the animal in warming box to dilate the 
veins. After 2 weeks, mice were euthanized and lungs were harvested for histological 
analysis and metastasis evaluation. 
 
2.2.4 Immunohistochemical analyses  
 
2.2.4.1 Tumour sections 
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For subsequent immunohistochemical analysis, tumours were bissected at the 
midline and fixed in PFA for 24 hours. Fixed tumours were dehydrated through a 
graded series of ethanols (50% - 70% - 90% - 95% - 100%, 2 changes 1 hour each) 
to xylene (overnight), and finally embedded with the cut face toward the blade in liquid 
paraffin (62°C, two changes of two hour each under vacuum). Tumours were 
transferred to histology cassettes and left to solidify at room temperature. Paraffin 
blocks were sectioned on a microtome, 5µm-thick sections were mounted onto glass 
slides and dried overnight at 37°C.  Before staining, paraffin sections were 
deparaffinazed in xylene and rehydrated in a graded series ethanol (100% - 95% - 
90% - 70% - 50%, two changes of ten minutes each). 
 
2.2.4.1.1 Endomucin staining 
 
To quantify tumour blood vessels, paraffin sections of size-matched tumours were 
stained for endomucin (a blood vascular endothelial cell marker; Morgan et al., 1999). 
Paraffin sections were rinsed in PBS and blocked by incubating with serum-free 
blocking solution for 30 minutes at 37°C. Subsequently, sections were incubated with 
rat anti-mouse endomucin antibody diluted 1:500 in PBLEC overnight at 4°C. Paraffin 
sections were washed in PBLEC 3 times for 5 minutes at room temperature, then 
incubated for 2 hours with Alexa-546 donkey anti-rat antibody diluted 1:200 in 
PBLEC. Paraffin sections were washed in PBS 0.1% TRITON X-100, 3 times for 5 
minutes. Sections were finally counterstained with 0.1% Sudan Black for 10 minutes, 
cleared and mounted with Prolong Gold Antifade reagent containing DAPI.  
 
2.2.4.1.2 αSmooth Muscle Actin/endomucin co-staining 
 
To evaluate vessel-pericyte association in tumour vessels, paraffin sections of size-
matched tumours were double-stained for α Smooth Muscle Actin (αSMA, a perycite 
marker; Gerhardt and Betsholtz, 2003) and endomucin.  Paraffin sections were rinsed 
in PBS and antigen retrieval was carried out by boiling sections in sodium citrate 
buffer for 20 minutes. Paraffin sections were then incubated with serum-free blocking 
solution for 30 minutes at 37°C. Subsequently, sections were incubated with rabbit 
anti-mouse αSMA antibody diluited 1:1000 and rat anti-mouse endomucin diluted 
1:500 antibody in PBLEC overnight at 4°C.  Paraffin sections were washed in PBLEC 
3 times for 5 minutes at room temperature, then incubated for 2 hours with Alexa-546 
donkey anti-rabbit and Alexa-488 donkey anti-rat antibodies, diluted 1:200 in PBLEC.  
Paraffin sections were then washed in PBS 0.1% TRITON X-100, 3 times for 5 
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minutes. Sections were finally counterstained with 0.1% Sudan Black for 10 minutes, 
cleared and mounted with Prolong Gold Antifade reagent containing DAPI.  
 
2.2.4.1.3 Nidogen/endomucin co-staining 
 
To assess endothelial basement membrane deposition in tumour vessels, paraffin 
sections of size-matched tumours were double-stained for nidogen (an endothelial 
basement membrane marker; Kohfeldt et al., 1998) and endomucin. Paraffin sections 
were rinsed in PBS and antigen retrieval was carried out by boiling sections in sodium 
citrate buffer for 20 minutes. Paraffin sections were incubated with serum-free 
blocking solution for 30 minutes at 37°C. Subsequently, sections were incubated with 
rabbit anti-mouse nidogen antibody diluted 1:1000 and rat anti-mouse endomucin, 
antibody diluted 1:500 in PBLEC overnight at 4°C. Paraffin sections were washed in 
PBLEC 3 times for 5 minutes at room temperature, then incubated for 2 hours with 
Alexa-546 donkey anti-rabbit and Alexa-488 donkey anti-rat antibodies, diluted 1:200 
in PBLEC. Paraffin sections were then washed in PBS 0.1% TRITON X-100, 3 times 
for 5 minutes. Sections were finally counterstained with 0.1% Sudan Black for 10 
minutes, cleared and mounted with Prolong Gold Antifade reagent containing DAPI.  
 
2.2.4.1.4 Focal Adhesion Kinase/endomucin co-staining 
 
To examine focal adhesion complexes along tumour vessels, paraffin sections of 
size-matched tumours were double-stained for Focal Adhesion Kinase (FAK, Petit 
and Thiery, 2000) and endomucin. Paraffin sections were rinsed in PBS and antigen 
retrieval was carried out by boiling sections in sodium citrate buffer for 20 minutes. 
Paraffin sections were incubated with serum-free blocking solution for 30 minutes at 
37°C. Subsequently, sections were incubated with rabbit anti-mouse FAK antibody 
diluted 1:100 and rat anti-mouse endomucin antibody diluted 1:500 in PBLEC 
overnight at 4°C. Paraffin sections were washed in PBLEC 3 times for 5 minutes at 
room temperature, then incubated for 2 hours with Alexa-546 donkey anti-rabbit and 
Alexa-488 donkey anti-rat antibodies, diluted 1:200 in PBLEC. Paraffin sections were 
then washed in PBS 0.1% TRITON X-100, 3 times for 5 minutes. Sections were finally 
counterstained with 0.1% Sudan Black for 10 minutes, cleared and mounted with 
Prolong Gold Antifade reagent containing DAPI.  
 
 
 
71 
 
2.2.4.1.5 Live staining of luminal CD31   
 
To examine tumour vessel function in terms of patency and perfusion, 10 minutes 
prior to sacrifice, tumour bearing-mice were lethally anaesthetized and injected 
systemically with PE-conjugated anti-mouse CD31 antibody (5µg/100µl in PBS).   
Before tumour harvest, mice were perfuse-fixed by systemic injection of PFA. 
Tumours were fixed for an 2 additional hours and then embedded in 5% melted 
agarose. Agarose blocks were left to solidify at room temperature and then sectioned 
on a vibratome. 20-40 µm vibratome sections were collected in 24-well-plates, 
permeabilised in 0.25% Triton X-100 for 30 minutes, washed in PBLEC 3 times for 
15 minutes and then incubated with serum-free blocking solution for 30 minutes at 
37°C. Sections were incubated with rat anti-mouse-endomucin antibody diluited 
1:500 in PBS overnight at 4°C. Sections were then washed in PBS 0.1% TRITON X-
100 three times for 15 minutes and then incubated with Alexa-488 donkey anti-rat 
antibody, diluted 1:200 in PBLEC for 2 hours at room temperature. Vibratome 
sections were finally washed in PBS 0.1% TRITON X-100 3 times for 15 minutes, 
transferred to glass slides and then mounted with Prolong Gold Antifade reagent 
containing DAPI.  
 
2.2.4.1.6 Analysis of tumour vascular phenotype  
 
Images were acquired on an Axioplan epifluorescent microscope and tissue area was 
quantified using ImageJ software. The characterisation of tumour vascular phenotype 
was performed as follows: 
 
- tumour blood vessel density was assessed as number of endomucin positive vessels 
across the entire tumour area; 
- pericyte coverage was assessed as number of double positive αSMA/endomucin  
vessels per field. Ten fields for each tumour section were counted; 
- endothelial basement membrane deposition was assessed as number of double 
positive nidogen/endomucin vessels per field. Ten fields for each tumour section were 
counted; 
- endothelial FAK levels were assessed as number of double positive FAK/endomucin  
vessels per field. Ten field for each tumour section were counted; 
- pattern of vessel distribution was visualized as the distribution of endomucin staining 
in the whole tumour area; 
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- depth of perfusion was quantified as maximum depth of double positive 
CD31/endomucin  vessels from the tumour border (in µm). Ten fields for each tumour 
section were measured. 
 
2.2.4.2 Lung sections 
 
Lungs from β3-floxed/Tie1Cre positive and negative mice were fixed in PFA for 24 
hours. Fixed lungs were dehydrated through a graded series of ethanols (50% - 70% 
- 90% - 95% - 100%, 2 changes 1 hour each) to xylene (overnight), and finally 
embedded in in liquid paraffin (62°C, two changes of two hour each under vacuum). 
Lungs were transferred to histology cassettes and left to solidify in paraffin at room 
temperature. Paraffin blocks were sectioned on a microtome, 5µm-thick sections 
were mounted onto glass slides and dried overnight at 37°C.  Before staining, paraffin 
sections were deparaffinased in xylene and rehydrated in a graded series ethanol 
(100% - 95% - 90% - 70% - 50%, two changes of ten minutes each). 
 
2.2.4.2.1 H&E staining 
 
Following deparaffinisation, lung sections were stained with Mayer’s Hemotoxylin for 
8 minutes and then rinsed under warm tap water for 10 minutes. Following a rinse in 
distilled water and 95% ethanol (10 dips), sections were counterstained in eosin-
phloxine B solution for 1 minute. Slides were then dehydrated as follows: 70% - 95% 
- 100% - xylene two changes of ten minutes each. Slides were finally mounted with 
DEPEX mounting solution.  
 
2.2.4.2.2 Endomucin staining 
 
To examine lung blood vessels, sections of were stained for endomucin as described 
in 2.2.4.1.1. 
 
2.2.4.2.3 F4/80 staining 
 
Following deparaffinisation, antigen retrieval of lung sections was performed in 
trypsin buffer where slides were immersed at 37°C for 5 minutes. Paraffin sections 
were rinsed in PBS and blocked by incubating with serum-free blocking solution for 
30 minutes at 37°C. Subsequently, sections were incubated with rat anti-mouse 
F4/80-FITC conjugated antibody diluted 1:100 in PBS overnight at 4°C. Paraffin 
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sections were then washed in PBS 0.1% TRITON X-100, 3 times for 5 minutes. 
Sections were finally counterstained with 0.1% Sudan Black for 10 minutes, cleared 
and mounted with Prolong Gold Antifade reagent containing DAPI.  
 
2.2.4.2.4 Analysis of lung metastatic phenotype  
 
Images were acquired on an Axioplan epifluorescent microscope and tissue area was 
quantified using ImageJ software. The characterization of lung metastatic phenotype 
was performed as follows: 
 
- total number of lung metastases; 
- area of lung covered by metastases expressed as ratio of metastatic area against 
total lung area (%); 
- blood vessel density in metastases was assessed by counting the total number of 
endomucin positive vessels within metastatic lung areas; 
- infiltrating macrophages were assessed as total number of F4/80 positive cells within 
metastatic lung areas. 
 
2.2.4.3 Wholemounts of tumours 
 
To assess Cre Recombinase activity, tomato fluorescence in tumours grown in 
Tie1Cre positive/tdTomato heterozygous and Pdgfb-iCreERT2 positive/tdTomato 
heterozygous mice was used as a readout for its distribution in tumour tissue. Before 
tumour harvest, mice were perfuse-fixed by systemic injection of PFA. Tumours were 
dissected, fixed for 2 additional hours and then embedded in 5% melted agarose. 
Agarose blocks were left to solidify at room temperature and then sectioned on a 
vibratome. 20-40 µm vibratome sections were collected in 24-well-plates, 
permeabilised in 0.25% Triton X-100 for 30 minutes, washed in PBS 3 times for 15 
minutes and then incubated with serum-free blocking solution for 30 minutes at 37°C. 
Sections were incubated with rat anti-mouse endomucin antibody diluited 1:500 in 
PBS overnight at 4°C. Sections were then washed in PBS 0.1% TRITON X-100 3 
times for 15 minutes and then incubated with Alexa-488 donkey anti-rat antibody 
diluted 1:200 in PBLEC for 2 hours at room temperature. Vibratome sections were 
finally washed in PBS 0.1% TRITON X-100 3 times for 15 minutes, transferred to 
glass slides and then mounted with Prolong Gold Antifade reagent containing DAPI. 
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2.2.4.3.1 Live staining of lumenal β3-integrin  
 
To assess Cre endothelial specificity in vivo, endothelial β3-integrin was stained in 
vivo within the tumour vasculature. 10 minutes prior to sacrifice, β3-floxed/Tie1Cre 
and β3-floxed/Pdgfb-iCreERT2 positive and negative tumour bearing mice were 
lethally anaesthetized and injected systemically with PE-conjugated anti-β3-integrin 
(5µg/100µl in PBS).  Before tumour harvest, mice were perfusion-fixed by systemic 
injection of PFA. Tumours were dissected, fixed for 2 additional hours and then 
embedded in 5% melted agarose. Agarose blocks were left to solidify at room 
temperature and then sectioned on a vibratome. 20-40 µm vibratome sections were 
collected in 24-well-plates, permeabilized in 0.25% Triton X-100 for 30 minutes, 
washed in PBS 3 times for 15 minutes and then incubated with serum-free blocking 
solution for 30 minutes at 37°C. Sections were incubated with FITC-conjugated 
Isolectin-B4 (IB4, 2 µg/ml in PBS) overnight at 4°C. Vibratome sections were finally 
washed 3 times PBS 0.1% TRITON X-100 3 times for 15 minutes, transferred to glass 
slides and then mounted with Prolong Gold Antifade reagent containing DAPI. 
 
2.2.4.3.2 Analysis of Cre activity and specificity in vivo 
 
Images were acquired on an Axioplan epifluorescent microscope and tissue area was 
quantified using ImageJ software. The analysis of Tomato Cre Recombinase reporter 
activity in vivo was performed as follow: 
 
- endothelial specific Cre activity was assessed as double positive endomucin/tomato 
vessels across the whole tumour area;  
- endothelial specific Cre efficiency was assessed as double positive β3-integrin/IB4 
vessels across the whole tumour area. 
 
2.2.5 Ex vivo aortic ring assay 
 
The aortic ring assay was performed as described by Baker et al., (2011). Animals 
were euthanized by cervical dislocation and sterilized by spraying with 70% ethanol. 
The chest cavity was opened using surgical scissors. Thoracic aortae from β3-
floxed/Tie1Cre positive and negative mice, β3-floxed/Pdgfb-iCreERT2 positive and 
negative mice, Tie1Cre positive/tdTomato heterozygous and Pdgfb-iCreERT2 
positive/tdTomato heterozygous mice (2 months or older) were dissected, cut into 
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rings of approximately 0.5 mm in width and serum-starved in OptiMEM overnight at 
37°C.  
 
 
 
2.2.5.1 VEGF aortic angiogenesis in collagen gel 
 
Aortic rings were embedded in a 96-well-plate (one ring per well) containing Collagen 
I gel (1 mg/ml in DMEM-H20 mix) on ice to prevent polymerisation, while embedding 
the ring under the dissection microscope. After collagen polymerisation (for 30 
minutes at 37°C), rings were fed with OptiMEM supplemented with 2.5% FBS and 
VEGF (30 ng/ml), then incubated at 37°C. Aortic rings from β3-floxed/Pdgfb-iCreERT2 
positive and negative mice and from Pdgfb-iCreERT2 positive/TdTomato 
heterozygous mice were also supplemented with OHT (1 µM). Unstimulated rings 
were used as controls. Rings were fed every 2 days with fresh medium with or without 
VEGF (30 ng/mL). Sprouting microvessels were counted after 6 days after fixation 
and staining. For intervention scheme, OHT (1 µM) was added 3 days after ring 
embedding and the sprouting microvessels were counted at day 8.  
 
2.2.5.2 bFGF aortic angiogenesis in fibrin gel 
 
Aortic rings were embedded in a 96-well-plate (one ring per well) containing fibrin gel. 
The catalysis of polymerization of fibrinogen (3 mg/ml) into fibrin required thrombin 
addition (1U/ml) to the fibrinogen solution on ice. After fibrin polymerisation (for 10 
minutes at room temperature), rings were fed with OptiMEM supplemented with 
bFGF (30 ng/ml) and aprotonin (10 ng/ml), then incubated at 37°C. Aortic rings from 
76 
 
β3-floxed/Pdgfb-iCreERT2 positive and negative mice and from Pdgfb-iCreERT2 
positive/tdTomato heterozygous mice were also supplemented with OHT (1 µM). 
Unstimulated rings were used as control. Rings were fed every 2 days with fresh 
medium with or without bFGF (30 ng/mL). Sprouting microvessels were counted after 
6 days after fixation and staining.   
 
2.2.5.3 Aortic ring staining 
 
6 or 8 day-rings were fixed with 4% PFA, permeabilized with 0.25% Triton X-100 and 
incubated with serum-free blocking solution for 30 minutes at 37°C. Aortic rings were 
stained with FITC-conjugated IB-4 diluted 1:2000 in PBLEC overnight at 4°C. Rings 
were then washed PBS 0.1% TRITON X-100 3 times for 15 minutes, excised from 
the gel, transferred to glass slides and then mounted with Vectashield mouting 
medium.  
 
Aortic rings from Tie1Cre positive/tdTomato heterozygous and Pdgfb-iCreERT2 
positive/tdTomato heterozygous mice were costained with FITC-conjugated IB4 
diluted 1:2000, plus rabbit anti-mouse NG-2 (a perycite marker; Gerhardt and 
Betsholtz, 2003) antibody diluted 1:1000 in PBLEC overnight at 4°C. For NG-2 
detection, rings were then washed PBS 0.1% TRITON X-100 3 times for 15 minutes 
and then incubated with Alexa-546 donkey anti-rabbit antibody, diluted 1:200 in 
PBLEC for 2 hours at room temperature. Rings were finally washed in PBS 0.1% 
TRITON X-100 3 times for 15 minutes, excised from the gel, transferred to glass 
slides and then mounted with Vectashield mounting medium.  
 
Phase contrast and fluorescent images were taken using an inverted microscope 
equipped with a camera. Microvessel sprouting was quantified by counting the 
number of sprouts per ring, whereas endothelial specific Cre Recombinase activity 
was evaluated as double positive endomucin/tdTomato microvessels and single 
tdTomato positive/NG-2 negative microvessels. 
 
2.2.5.4 Protein isolation from aortae 
 
Aortae from β3-floxed/Tie1Cre and β3-floxed/Pdgfb-iCreERT2 positive and negative 
mice were separately collected for protein isolation. Whole aortae (3 per genotype) 
were transferred to eppendorf tubes and mashed with a 1.5-ml tube pestle. Aortic 
tissue was then lysed in ESB sample buffer for subsequent Western blot analyses 
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(see paragraph 2.2.7.6). The efficiency of Cre recombinase was measured by 
densitometry as a reduction of β3-integrin protein level in aortic tissue. 
 
2.2.6 Cell isolations 
 
2.2.6.1 Isolation of bone marrow cells 
 
Bone marrow cells were isolated from long bones (femurs and tibiae) of β3-
floxed/Tie1Cre positive and negative mice to investigate Tie1Cre-non-specific activity 
as the Tie1 gene is expressed in bone marrow cells. β3-floxed/Pdgfb-iCreERT2 
positive and negative mice were included in the analysis for the sake of consistency. 
Mice were euthanized by cervical dislocation, sterilized by spraying with 70% ethanol 
and back legs were dissected using surgical scissors. Skin and muscle tissues were 
removed from bones and their extremities cut off. Bones were transferred into a 0.5 
ml eppendorf with a hole in its end and placed within a bigger 1.5 ml eppendorf. 
Samples were centrifuged for 2 minutes at 7000 rpm.  
 
Bone marrow cells were pelleted in the 1.5 ml eppendorf, while the 0.5 eppendorf 
containing the bones was discarded. Cells were then resupended in FACS buffer and 
counted to be plated at the cell concentration of 5x105 cells/well in a 96-well-plate for 
subsequent flow cytometry.  Bone marrow cells were co-stained with and PE-
conjugated anti-β3-integrin and the following antibodies for hematopoietic cell lineage 
markers: FITC-conjugated anti-CD45, FITC-conjugated anti-Ly6G, FITC-conjugated 
anti-CD3, Alexa Fluor488-conjugated anti-CXCR4 (CD184) and FITC-conjugated 
anti-F4/80. All antibodies were diluted 1:200 in FACS Buffer. After incubating 20 
minutes on ice, bone marrow cells were washed 2 times in PBS to remove unbound 
antibody and pelleted by centrifugation.  
 
Acquisition of samples was performed on Accuri C6 flow-cytometer (1x105 cells per 
sample were collected). FACS analyses included unstained and isotope control 
samples which were used to determine appropriate gates and voltages. Data were 
analysed with CELLQUEST software. The gating strategy was as follows: a polygon 
gate was created on a FSC-A (Forward Scatter Area) vs. SCA-A (Side Scatter Area) 
plot to select for viable cells and exclude debris (Live gate), followed by a quadrant 
plot displaying the resulting daughter population to compare the percentage of bone 
marrow cell subpopulations (CD45+, Ly6G+, CD3+, CXCR4+), which were co-
expressing β3-integrin or not. 
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2.2.6.2 Isolation of platelets 
 
Platelet isolation from peripheral blood was performed in β3 flox/flox/Pdgfb-iCreERT2 
positive and negative mice to investigate Pdgfb-iCre-non-specific activity, as the 
Pdgfb gene is expressed in megakariocytes. β3-floxed/Tie1Cre positive and negative 
mice were included in the analysis for the sake of consistency. Mice were lethally 
anaesthetized and peripheral blood from the vena cava was collected in 1.5 ml 
eppendorf tubes containing anti-coagulant buffer. Blood samples were centrifuged 
for 7 minutes at 300 rpm. The resulting platelet rich plasma was transferred to a fresh 
tube and centrifuged for 7 min at 2000 rpm. The supernatant was carefully discarded 
and the final pellet was lysed in ESB lysis buffer in order to be processed by Western 
blot to quantify total levels of β3 integrin protein in platelets (see paragraph 2.2.7.6). 
 
2.2.6.3 Isolation of tumour endothelial cells  
 
Tumour bearing β3-floxed/Tie1Cre and β3-floxed/Pdgfb-iCreERT2 positive and 
negative mice were euthanized by cervical dislocation and sterilized by spraying with 
70% ethanol. B16F0 or CMT19T tumours were dissected using surgical scissors and 
placed in Hank’s Balanced Salt Solution (HBSS). They were finely minced with a 
scalpel and enzymatically digested in HBSS containing 0.2% collagenase IV, 0.01% 
hyaluronidase and 0.01% DNase I for 1 hour at 37°C under gentle agitation. Tumour 
cell digests were passed 3 times through a 19G needle by using a 20 ml syringe and 
then filtered through a 70µm mesh to produce a single cell suspension. Tumour cells 
were pelleted by low speed-centrifugation for 5 minutes at 1000 rpm. After 
centrifugation, cells were resuspended in HBSS containing 2% BSA and 0.6% 
sodium citrate. Cell yield was determined in a hemocytometer and viability assessed 
by trypan blue exclusion.  
 
Tumour endothelial cell separation was performed by magnetic separation using rat 
anti-mouse CD31 coupled to magnetic beads. Dynabeads Antibody Coupling Kit was 
used to covalently couple the anti-CD31 antibody to the surface of magnetic beads 
according to the manufactures’ instructions. Tumour cells suspensions were 
incubated with anti-CD31 coupled-Dynabeads at a ratio of 30 beads per target cell 
(estimated at 1% of total cell count) at 4°C for 25 minutes and with occasional 
agitation. Bound cells were separated from unbound cells on a magnetic sorter, which 
allowed the bead-bound cells to be separated from the non-bead-bound cells and the 
remaining cell suspension was discarded carefully. To assess the degree of Cre 
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Recombinase efficiency in vivo, CD31 positive tumour endothelial cells were lysed in 
ESB lysis buffer and prepared for Western blot (see paragraph 2.2.7.6). 
 
2.2.6.3.1 Analysis of Tumour-Associated Macrophages 
 
In order to assess β3-integrin expression levels in Tumour-Associated Macrophages 
(TAMs), tumour cells were isolated from tumours grown in β3-floxed/Tie1Cre positive 
and negative mice. Tumour cell suspensions (isolated as described in 2.2.6.3, but 
without performing CD31 magnetic separation) were collected in FACS tubes and 1 
ml of red blood lysis buffer was added for 1 minutes. Cell were centrifuged for 5 
minutes at 1000 rpm and resuspended in FACS buffer.Tumour cells were then plated 
in a 96-well-plate (5x105 cells/well) and co-stained with PE-conjugated anti-mouse 
β3-integrin and FITC-conjugated anti-mouse F4/80 (macrophage marker, Schmieder 
et al., 2012) diluted 1:200 in FACS buffer. After a 20 minute incubation with primary 
antibodies on ice, tumour cells were washed 2 times in PBS to remove unbound 
antibody and pelleted by centrifugation.  
 
Acquisition of samples was performed on Accuri C6 flow-cytometer (1x105 cells per 
sample were collected). FACS analysis included unstained and isotope control 
samples which were used to determine appropriate gates and voltages. Data were 
analysed with CELLQUEST software. The gating strategy was as follows: a polygon 
gate was created on a FSC-A (Forward Scatter Area) vs. SCA-A (Side Scatter Area) 
plot to select for viable cells and exclude debris (Live gate), followed by a quadrant 
plot displaying the resulting daughter population to compare the percentage of tumour 
associated macrophages (F4/80+), which were co-expressing or not β3-integrin. 
 
2.2.6.4 Isolation of lung endothelial cells  
 
Primary lung endothelial cell isolation from β3-floxed/Tie1Cre and β3-floxed/Pdgfb-
iCreERT2 positive and negative 6 to 8 week-old mice was carried out in multiple steps 
as described below. 
 
2.2.6.4.1 Collagenase treatment of lung 
 
All dissection procedures were performed under sterile conditions in a tissue culture 
hood. Animals were euthanized by cervical dislocation and sterilized by spraying with 
70% ethanol. The chest cavity was opened using surgical scissors and lungs 
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dissected using forceps. Lungs were rinsed briefly by immersing first in 70% ethanol 
and subsequently in Ham’s F12 medium supplemented with penicillin and 
streptomycin.  
 
Tissues were minced with a scalpel into small pieces until a fine homogenate was 
produced and digested in 0.1 % Collagenase I supplemented with 1 mM CaCl2 and 
1mM MgCl2 for 1 hour at 37°C. Lung digests were passed 3 times through a 19G 
needle by using 20 ml syringe and then filtered through a 70µm mesh to produce a 
single cell suspension. Lung cells were then centrifuged for 5 minutes at 1200 rpm 
and resuspended in Mouse Lung Endothelial Cell (MLEC) medium. Cell suspensions 
were plated into pre-coated-tissue culture 6-well-plates which were coated with 
coating solution which was removed just prior to cell plating. Lung endothelial cells 
from each mouse were cultured as single isolates. After overnight incubation at 37°C 
and 5% CO2, lung endothelial cells were washed 3 times with PBS to remove cell 
debris and red blood cells, and refed with fresh MLEC medium. 
 
2.2.6.4.2 ICAM-2 magnetic sorting  
 
Positive magnetic sorting was performed using an antibody against an endothelial 
cell marker, ICAM-2 (Intracellular Cell Adhesion Molecule 2). When cells reached 
approximately 70% confluency, the medium was removed, replaced with fresh MLEC 
and cells were incubated at 4°C for 30 minutes. Cells were then washed in PBS and 
incubated at 4°C for 30 minutes in PBS containing rat anti-mouse ICAM-2 antibody 
diluited 1:1000. Following antibody incubation, cells were washed in PBS and 
incubated with MLEC containing 1 µl/ml of sheep anti-rat IgG Dynabeads at 4°C for 
30 minutes. Cells were washed three times to remove unbound beads and then 
trypsinized with 0.25% trypsin:EDTA. Detached cells were resuspended in MLEC, 
collected in an eppendorf tube and put on a magnetic sorter, which allowed the bead-
bound cells to be separated from the non-bead-bound cells. Since the beads were 
attached to ICAM-2 positive cells, the remaining cell suspension was carefully 
discarded. Bound cells were resuspended in MLEC and plated into a pre-coated-
tissue culture 6-well-plate. Cells were fed every 2 days until colonies of approximately 
20-30 cells were apparent.  When they neared confluency, an additional ICAM-2 
positive sorting was performed in order to enhance the endothelial cell purity. 
 
2.2.6.4.3 Generation of immortalized lung endothelial cells 
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Due to their slow growth and limited capacity to divide in culture, it is difficult to obtain 
sufficient quantities of primary lung endothelial cells to perform extensive in vitro 
analyses. I therefore opted to immortalize lung endothelial cells via Polyoma-Middle-
T-antigen lentiviral infection (May et al., 2005). The mouse GgP+E cell line was 
employed for the production of polyoma-middle-T-antigen lentiviral vectors (May et 
al., 2005).  After thawing, GgP+E packaging cells were seeded at 1.5x106 cells in T25 
flasks and, when cultures were confluent, cells were detached with 0.25% 
trypsin:EDTA. At the following passage, GgP+E cells were seeded 2x106 cells/T25 
flask, fed the next day with 2 ml of culture medium and, on the third day, the 
conditioned medium was collected.  
 
The Polyoma-Middle-T virus conditioned medium centrifuged at 2800 rpm for 15 
minutes and filtered through a 0.45µm strainer. After filtration, the supernatant was 
aliquoted and stored at -80°C. ICAM-2 positive lung endothelial cells were 
immortalized by incubating with polyoma-middle-T-antigen virus conditioned medium 
in presence of polybrene (8 µg/ml) to increase infection efficiency. The virus-
containing medium was replaced 6 hours later with fresh MLEC medium and the 
same procedure was repeated the following day. 
 
2.2.6.4.4 Growth and maintenance of immortalized lung endothelial cells 
 
Immortalized lung endothelial cells were cultured at 37°C with 5% CO2 in air in Mouse 
Immortalized Lung Endothelial Cell medium (ImMLEC). Cells were usually passaged 
when they reached ~80-90% confluency and used up to passage 15. Early passage 
(3-6) immortalized lung endothelial cells were frozen down in freezing medium (10% 
DMSO in Foetal Bovine Serum) at 106 cells/cryogenic vial. Vials were initially stored 
at -80°C and subsequently transferred to a liquid nitrogen tank for long-term storage. 
 
2.2.6.4.5 Phenotypic analysis of immortalized lung endothelial cells 
 
In order to characterize the phenotype of immortalized lung endothelial cell cultures, 
flow cytometry, immunocytochemistry and Western blot analyses were performed. 
The endothelial cell markers ICAM-2 and CD31 were evaluated by flow cytometric 
analyses. Subconfluent immortalized lung endothelial cells were trypsinized, 
resuspended in FACS buffer and plated in a 96-well-plate (5x105 cells/well). Staining 
was performed using PE-conjugated anti-mouse ICAM-2 antibody and PE-
conjugated anti-mouse CD31 antibody, diluted 1:200 in FACS buffer. After a 20 
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minute incubation with primary antibody on ice, cells were washed 2 times in PBS to 
remove unbound antibody and pelleted by centrifugation.  
 
Acquisition of samples was performed on an Accuri C6 flow-cytometer (1x105 cells 
per sample were collected). FACS analysis included unstained and isotope control 
samples which were used to determine appropriate gates and voltages. Data were 
analysed with CELLQUEST software. The gating strategy was as follows: a polygon 
gate was created on a FSC-A (Forward Scatter Area) vs. SCA-A (Side Scatter Area) 
plot to select for viable cells and exclude debris (Live gate), followed by a histogram 
plot displaying the resulting daughter population to visualize the subpopulations 
expressing ICAM-2 and CD31 respectively. The endothelial cell marker VE-cadherin 
(VEC) was evaluated by immunocytochemistry. Subconfluent immortalized lung 
endothelial cells were trypsinized and seeded in a 6-well-plate (2x105 cells/well) 
containing 10 mm glass coverslips (previously acid washed and coated with a coating 
solution overnight at 4°C).  Cells were left to adhere overnight and then fixed with 
PFA on coverslips for 10 minutes at room temperature. Cells were washed with PBS 
3 times for 5 minutes and permeabilised with NP40 solution for 10 minutes at room 
temperature. 
 
Cells were washed again in PBS for 3 times for 5 minutes and blocked for 10 minutes 
at room temperature. Cells were then incubated with rabbit anti-mouse VEC antibody 
diluited 1:100 for 1 hour at room temperature. Following antibody incubation, cells 
were washed with PBS to remove unbound antibody and incubated with Alex Fluor-
555 anti-rabbit antibody diluited 1:200 in PBS for 1 hour at room temperature. Finally 
coverslips were washed in PBS and mounted on glass slides with Prolong Gold Anti-
fade reagent containing DAPI.  Images were acquired on an Axioplan epifluorescent 
microscope. To assess the degree of Cre recombinase efficiency in vitro, 
immortalized lung endothelial cells were plated at 2x105 cells/well in a 6-well-plate, 
grown until ~ 80-90% confluency and lysed in 500 µl/well in ESB lysis buffer for 
Western blot analyses to quantify total level of β3-integrin protein (see paragraph 
2.2.7.6). 
 
2.2.6.4.6 Analysis of macrophages in the pre-metastatic lung 
 
To examine myeloid cells infiltration in the lung during the pre-metastatic phase, flow 
cytometry analysis was performed. Lungs from β3-floxed/Tie1Cre positive and 
negative mice in which CMT19TF1 cells had been grown, were isolated at the time 
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of surgical resection of the primary tumour. Lung cell suspensions (isolated as 
described in 2.2.6.4.1) were collected in FACS tubes and 1 ml of red blood lysis buffer 
was added for 1 minutes. Cells were centrifuged for 5 minutes at 1000 rpm and 
resuspended in FACS buffer. Lung cells were then plated in a 96-well-plate (5x105 
cells/well). Staining was performed with FITC anti-CD45 and PE anti-CD11b 
antibodies to detect myeloid cells and FITC anti-F4/80 and APC-eFluor 780 anti-β3-
integrin antibodies. All antibodies were diluted 1:200 in FACS buffer. After a 20 
minute incubation with primary antibodies on ice, lung cells were washed 2 times in 
PBS to remove unbound antibody and pelleted by centrifugation.  
 
Acquisition of samples was performed on an Accuri C6 flow-cytometer (1x107 cells 
per sample were collected). FACS analysis included unstained and isotope control 
samples which were used to determine appropriate gates and voltages.  The gating 
strategy was as follows: a polygon gate was created on the FSC-A (Forward Scatter 
Area) vs. FSC-H (Forward Scatter Height) plot to select for Single cells that passed 
by the lasers individually. These cells were then viewed on a FSC-A vs. SCA-A (Side 
Scatter Area) plot to select for viable cells and exclude debris (Live gate), following 
by a quadrant plot displaying the resulting daughter population to quantify myeloid 
cell (CD45+/CD11b+) and β3-integrin expressing macrophage (β3+/F4/80+) 
subpopulations. 
 
2.2.7 In vitro cell assays 
 
β3-floxed/Tie1Cre and β3-floxed/Pdgfb-iCreERT2 positive and negative immortalized 
lung endothelial cells were employed to study the cellular and molecular differences 
between the two transgenic models in vitro. 
 
2.2.7.1 Staining for endothelial cell markers and surface integrins 
 
In order to examine changes in surface integrin expression upon β3-integrin deletion, 
I performed flow cytometry analyses. Subconfluent immortalized lung endothelial 
cells were trypsinized, resuspended in FACS buffer and plated in a 96-well-plate 
(5x105 cells/well). The presence of α1, α2, α5, αv, β1 and β3-integrin subunits on the 
cell surface were examined using PE-fluorescently labelled anti-mouse antibodies 
diluted 1:200 in FACS buffer. After a 20 minute incubation with primary antibodies on 
ice, cells were washed 2 times in PBS to remove unbound antibody and then pelleted 
by centrifugation.   
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Acquisition of samples was performed on an Accuri C6 flow-cytometer (1x105 cells 
per sample were collected). FACS analysis included unstained and isotope control 
samples which were used to determine appropriate gates and voltages. Data were 
analysed with CELLQUEST software. The gating strategy was as follows: a polygon 
gate was created on a FSC-A (Forward Scatter Area) vs. SCA-A (Side Scatter Area) 
plot to select for viable cells and exclude debris (Live gate), followed by a histogram 
plot displaying the resulting daughter population to visualize the subpopulation 
expressing the single integrin subunits. 
 
2.2.7.2 MTT Proliferation assay 
 
Immortalized lung endothelial cells were seeded at 1×104 cells/well in OptiMEM 
supplemented with 2% FBS in a 96-well-plate and stimulated with VEGF (30 ng/ml). 
Unstimulated cells were used as a control.  After 24 and 48 hours the medium was 
removed and replenished with fresh before adding 12 mM MTT 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide. Cells were then incubated for 
4 hours at 37°C. The insoluble product of MTT conversion was solubilized by the 
addition of DMSO (50µl/well) and absorbance was measured at 540 nm. Absorbance 
values were normalized to the DMSO negative control and the rate of proliferation 
was determined as relative to absorbance values in unstimulated cells. 
 
2.2.7.3 Scratch wound assay 
 
Immortalized lung endothelial cells were seeded in 6-well-plates (4×105 cells/well) 
and cultured until they reached confluence. Cells were serum-starved for 3 hours in 
OptiMEM, then a scratch wound was introduced with a 200µl-pipette tip and 
photographed as a zero time point. OptiMEM was replaced to remove scratched cells 
and cells were incubated with fresh OptiMEM supplemented with VEGF (30 ng/ml). 
Unstimulated cells were used as a control. To assess the rate of migration cells were 
photographed in the following 24 hours, using an inverted phase-contrast 
microscope. Axiovision software was used for measuring the scratch width and the 
average distance between leading cells in 3 positions (three points of the scratch 
wound; top, centre, bottom). Scratches were re-photographed, and the percentage 
of migration was determined relative to the scratch width at the zero time point. 
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2.2.7.4 Endothelial cell adhesion assay 
 
96-well-plates were coated with single matrix compounds (collagen I, 10µg/ml; 
fibronectin, 10µg/ml; laminin I, 10µg/ml; vitronectin, 10µg/ml) at 4°C overnight. The 
following day, the coating solution was removed and 96-well-plates were blocked with 
2% BSA for 1 hour at 37°C. BSA and plastic only separate wells were used as 
negative and positive controls for cell adhesion, respectively. Immortalized lung 
endothelial cells were seeded at 1×104 cells/well into the coated well and incubated 
for 60 minutes at 37°C. Cells were gently washed with PBS 3 times to remove non-
adhered cells. Attached cells were fixed with PFA for 10 minutes and subsequently 
stained with Methylene Blue (0.01% in 0.01M borate buffer) for 30 minutes. Stained 
cells were then washed with water and incubated with destain solution (1:1 mix 
EtOH:HCl 0.1M) for 10 minutes. Absorbance was measured at 630 nm and assessed 
in 8 replicates per condition. The OD value of cells adhered to fibronectin was 
assigned the value of 100% and relative adhesion was calculated. 
 
2.2.7.5 VEGF stimulation time course 
 
Changes in expression of total and phosphorylated levels of VEGFR2 and its 
downstream effectors (ERK1/2, FAK, p38, PLCɣ) were assessed by Western blot 
analyses after a time course of VEGF stimulation. 4x105 cell/well were plated in a 6-
well-plate and grown until they reached 80-90% confluency. Cells were starved for 3 
hours in OptiMEM and then stimulated with VEGF (30 ng/ml) for 5-10-15-30-60 
minutes at 37°C.  Unstimulated cells were used as a control. Cells were washed three 
times with PBS, scraped off using a cell scraper and lysed in ESB lysis buffer for 
subsequent Western blot analyses.  
 
2.2.7.6 Western blot analysis 
 
2.2.7.6.1 Sample preparation 
 
ESB lysed cells and tissues were transferred to cap-locked tubes containing acid 
washed glass beads and homogenized with a tissue lyser at 50 Hertz for 2 minutes. 
Homogenates were centrifuged at 10000 rpm for 10 minutes at room temperature, to 
pellet insoluble material. Supernatants were transferred to new tubes and analysed 
for protein concentration. Samples were either immediately used or stored at -20°C 
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for future use. Frozen samples were thawed on ice and then vortexed briefly to obtain 
homogeneous lysates. 
 
Protein concentrations were quantified using the Bio-Rad DC Protein Assay Kit. BSA 
standards of known concentrations were prepared alongside unknown samples. The 
protein concentration in each sample was determined as follows: 5 µl of standard or 
unknown sample was mixed with 200 µl of Bio-Rad Reagent B and with 25 µl of a 
solution obtained by mixing 1 ml of Reagent A with 20ul of Reagent S, and incubated 
for 15 minutes at room temperature. After incubation, the absorbance was measured 
at 750 nm using a spectrophotometer. The protein concentrations of the unknowns 
were obtained from the standard curve plotted using GraphPad Prism software. 
 
2.2.7.6.2 SDS-PAGE protein separation 
 
A vertical gel apparatus was used for all polyacrylamide gels electrophoresis. For the 
proteins of interest (ranging from 40-kDa to 250-kDa) 8% acrylamide running gels 
were used. The running gel was poured into a gel cassette. After polymerisation, the 
stacking gel was loaded onto the resolving gel. Immediately, a 10- or 15-well comb 
was inserted and the gel was left to polymerise.  
 
The gel apparatus was assembled and running buffer was poured into the gel tank. 
Equal amounts of protein from the lysates (10–20 µg) were prepared for 
electrophoresis by diluting with 1X NuPAGE-LDS sample buffer supplemented with 
DTT. Samples were boiled at 95°C for 5 minutes, centrifuged at 10000 rpm for 1 
minute and loaded into separate wells along with a well containing molecular weight 
protein ladder. The proteins underwent electrophoresis at 100 V, until the samples 
reached the bottom of the gel. 
 
2.2.7.6.3 Wet Transfer 
 
Once the proteins had been separated, the gel was removed from the electrophoresis 
cassette and transferred from the gel to nitrocellulose membrane using a transfer 
apparatus. The gel was positioned in a cassette next to the nitrocellulose membrane 
and between filter paper and fibre sponges all pre-wetted in cooled transfer buffer. 
Air bubbles during the assembly of the cassette were removed by rolling out with a 
plastic pipette. The cassette was assembled in the transfer apparatus, immersed in 
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transfer buffer, and proteins transferred to the membrane at 30 V for 2 hours at room 
temperature. 
 
2.2.7.6.4 Immunoblotting  
 
Once transferred, the membrane was stained with 0.1% Ponceau red to ensure 
complete and even transfer of all proteins. The membrane was rinsed with distilled 
H2O to remove excess stain. Nitrocellullose membranes were blocked in 5% milk 
protein, 0.1% Tween-20 in PBS for 30 minutes at room temperature, rinsed 3 times 
for 5 minutes with PBS 0.1% Tween-20 and incubated overnight at 4°C with primary 
antibody. Primary antibodies were all used at 1:1000 in PBS, 5% BSA, 0.1% Tween-
20. The blots were then washed 3 times for 5 minutes with PBS 0.1% Tween-20, and 
incubated with the appropriate horseradish peroxidase (HRP)-conjugated secondary 
antibody diluted 1:2000 in 5% milk 0.1% Tween-20 for 2 hours at room temperature.  
 
The membranes were finally washed 3 times with PBS for 5 minutes with 0.1% 
Tween-20 and developed. Immunoreactive bands were visualised by incubating the 
membranes with ECL chemiluminescence reagents for 1 minute. 
Chemiluminescence was detected on a Fujifilm LAS-3000 darkroom. Densitometry 
of band intensities was obtained using ImageJ software. Band densities were 
normalised to HSC-70 to make quantitative measurements of proteins of interest. 
 
2.2.8 Analysis of statistical significance 
 
Data sets were analysed for significance using Student’s t test. P<0.05 was 
considered statistically significant. Unless otherwise indicated, results are the mean 
+/- SEM from at least 3 independent experiments. 
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3. THE TIMING OF ENDOTHELIAL β3-INTEGRIN DELETION 
AFFECTS TUMOUR GROWTH AND ANGIOGENESIS IN VIVO 
 
Since αvβ3-integrin is expressed by a variety of cells, all of which can contribute to 
angiogenesis (Robinson and Hodivala-Dilke, 2011), I took a genetic in vivo approach 
to dissect the role of the endothelial-specific expression of β3-integrin and test how 
its genetic targeting influences tumour growth and angiogenesis. In this chapter, I will 
describe my findings on the effect of the ablation of β3-integrin on tumour growth and 
angiogenesis in two different endothelial specific Cre models where, unexpectedly, I 
observed divergent effects depending on when deletion occurred. I will also present 
validation data which confirm that β3-integrin was effectively and specifically deleted 
in a similar fashion in the two Cre models.  
 
RESULTS AND FIGURES 
 
3.1 Inducible loss of endothelial β3-integrin reduces tumour growth and 
inhibits angiogenesis, while the constitutive one does not 
 
In order to investigate whether ablation of β3-integrin in endothelial cells had any 
effect on tumour growth and tumour associated angiogenesis, a genetic strategy 
based on Cre-loxP recombination was employed. β3-integrin floxed mice (Morgan et 
al., 2010), whereby the first exon of  the β3-integrin subunit gene (Itgb3) is flanked by 
loxP sites, were crossed with Tie1Cre transgenic mice (Gustaffson et al., 2001) and 
with Pdgfb-iCreERT2 transgenic mice (Claxton et al., 2008).  
 
Both Tie1 and Pdgfb promoters drive Cre expression in endothelial cells, thereby 
restricting β3 integrin deletion to vascular cells. The timing of deletion is different in 
the two transgenic lines.  The Tie1 promoter is expressed from E 8 allowing excision 
of floxed genes in endothelial cells by Cre recombinase activity during embryogenesis 
and in adulthood, acting as a cell-specific knock-out (as described in paragraph 
3.1.1). Pdfgb-iCreERT2 generates tamoxifen inducible endothelial cell-specific 
edeficient mice, whereby Cre recombinase is activated in upon 4-hydroxytamoxifen 
administration, thereby mimicking a pharmacological treatment (as described in 
paragraph 3.1.2). 
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3.1.1 Constitutive deletion of endothelial β3-integrin  
 
Itgb3 floxed mice are viable and demonstrate functional activity of the Itgb3 floxed 
allele (Morgan et al., 2010). They will be hereafter be referred to as β3-floxed mice. 
Mice expressing Cre recombinase under the control of the Tie1 promoter (Gustafsson 
et al., 2001) were intercrossed with homozygous β3-floxed mice through multiple 
generations in order to generate β3-floxedTie1Cre positive progeny, where β3-
integrin was genetically ablated in endothelial cells.  
 
By cross-breeding to ROSA26R-lacZ reporter mice (Soriano, 1999), Gustaffson et al 
(2001) have shown that Cre expression in Tie1Cre transgenic mice is expressed in 
endthelial cells as early as E8-E8.5. However, Cre recombinase activity in Tie1Cre 
positive animals was also reported to be present in certain neuronal populations and 
in a proportion (20%) of hematopoietic cells. 
 
The presence of Tie1Cre transgene (600 bp) was determined by PCR analysis of 
DNA from tissues (earsnip or tail) or from cultured lung endothelial cells isolated from 
β3-floxed/Tie1Cre mice (Figure 3.1A). Furthermore, the efficiency of Cre mediated 
recombination of the β3-flloxed gene was demonstrated by Western blot analysis, 
whereby lysates from β3-floxed/Tie1Cre positive lung endothelial cells showed β3-
integrin protein expression reduction by approximately 70% when compared to 
protein lysates from β3-floxedTie1Cre negative lung endothelial cells (Figure 3.1C).  
 
3.1.2 Inducible deletion of endothelial β3-integrin  
 
Alongside the endothelial specific Tie1Cre transgenic line, mice expressing Cre 
recombinase under the control of the Pdgfb promoter (Claxton et al., 2008) were 
intercrossed with homozygous Itgb3 floxed mice through multiple crosses in order to 
generate β3-integrin/Pdgfb-iCreERT2 positive progeny, where the genetic deletion of 
β3-integrin could be induced in endothelial cells upon 4-hydroxytamoxifen 
administration. Claxton et al. (2008) have generated a modified Cre recombinase by 
fusion to a mutant form of the human estrogen receptor (ERT2), which is insensitive 
to naturally occurring estrogen; but selectively responsive to the artificial ligand 4-
hydroxytamoxifen (hereafter referred to as OHT).  
 
In β3-floxed/Pdgfb-iCreERT2 positive mice, Cre recombinase activity is present in 
endothelial cells within 48 hours after administration of 3-mg-OHT dose via oral 
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gavage, as assessed by X-Gal staining in a ROSA26R-lacZ background (Soriano, 
1999). Nonetheless, recombination activity was also described in megakaryocytes. 
 
The presence of the Pdgfb-iCreERT2 transgene (473 bp) was evaluated by PCR 
analysis of DNA from tissues (earsnip or tail) or from cultured lung endothelial cells 
isolated from β3-floxed/Pdgfb-iCreERT2 mice (Figure 3.1A). The effective induction of 
β3-integrin deletion was further confirmed at the protein level by Western blot 
analysis, whereby lysates from β3-floxed/Pdgfb-iCreERT2 positive lung endothelial 
cells showed β3-integrin protein expression reduction by approximately 75%, when 
compared to protein lysates from β3-floxed/Pdgfb-iCreERT2 negative lung endothelial 
cells (Figure 3.1C). 
 
3.1.3 Tumour models 
 
B16F0 is a non-metastatic variant of the B16 cell line (Fidler, 1973). CMT19T is a 
mouse lung carcinoma cell line which has been derived from the more aggressive 
CMT167 (Layton and Franks, 1986). Both tumour cell lines are commonly used in 
tumour studies (Giavazzi and Decio, 2014; Kostourou et al., 2013; Tavora et al., 
2014).  
 
To determine whether the genetic background of the two endothelial Cre transgenic 
mice affected the ability of tumour cells to grow, tumour growth was assessed over 
time. Tie1Cre and Pdgfb-iCreERT2 transgenic mice were injected subcutaneously 
with CMT19T tumour cells. Tumour growth was monitored by external caliper 
measurement every other day, starting from day 6 until day 12, when mice were 
sacrificed and tumours were harvested. No significant difference was detected in 
tumour growth when comparing β3-floxed/Tie1Cre and β3-floxed/Pdgfb-iCreERT2 
negative tumours, implying that tumour cells could equally grow in both transgenic 
models (Figure 3.2). 
 
3.1.3.1 B16F0  
 
To study the effect of endothelial β3-ntegrin deletion on tumour growth, Tie1Cre and 
Pdgfb-iCreERT2 transgenic mice were injected subcutaneously with B16F0 
melanoma cells. In β3-floxed//Pdgfb-iCreERT2 mice, Cre activity (therefore β3-
integrin deletion) was induced in endothelial cells by subcutaneous implantation of 
slow release 5-mg-tamoxifen pellets.   
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Unless otherwise specified, OHT treatment was administered 3 days before tumour 
cells injection (PREVENTION SCHEME) and both Pdgfb-iCreERT2 positive and 
negative mice were treated. This allowed equal treatment of both mice groups and 
β3-floxed/Pdgfb-iCreERT2 negative mice served as control for possible OHT-induced 
side effects.  
 
Over the time frame of 12 days, B16F0 allograft tumours grew significantly less in β3-
floxed//Pdgfb-iCreERT2 positive mice as compared to their Cre negative littermate 
controls (Figure 3.3A). In contrast, tumour size was not significantly affected in β3 
flox/flox/Tie1-Cre mice (Figure 3.3A). If anything, there was a trend for 
subcutaneously-injected B16F0 tumours to grow larger in Tie1Cre positive mice 
compared to their Cre negative littermate controls.   
 
To examine the effect of endothelial β3-integrin deletion on tumour angiogenesis, 
blood vessel density was quantified by counting the numbers of endomucin+ blood 
vessels (a blood vascular endothelial cell marker; Morgan et al., 1999) per unit area, 
across entire midline tumour sections from size-matched tumours which had been 
processed for immunohistological analysis (Figure 3.3C-3.4C). Consistent with 
growth, tumour angiogenesis was also significantly decreased in β3-floxed//Pdgfb-
iCreERT2positive tumours as compared to β3-floxed//Pdgfb-iCreERT2 negative 
tumours (Figure 3.3A); whilst not in tumours grown in β3-floxed/Tie1Cre mice, where 
no significant difference was observed between Cre positive and negative tumours 
(Figure 3.4A).  
 
Taken together, these results suggest that β3-integrin expression on endothelium 
only affects tumour growth and angiogenesis when its inducible deletion, but not 
when its deletion has occurred through development (constitutive deletion). 
 
3.1.3.2 CMT19T  
 
Further confirmation of the role of endothelial β3-integrin in tumour growth and 
angiogenesis was accomplished by using the CMT19T cell line. CMT19T tumours 
were grown subcutaneously for 12 days in β3-floxed//Tie1Cre and β3-floxed/Pdgfb-
iCreERT2 mice following a prevention scheme. Both tumour size and tumour 
angiogenesis were significantly decreased in β3-floxed//Pdgfb-iCreERT2 positive 
mice as compared to β3-floxed//Pdgfb-iCreERT2 negative mice (Figure 3.3B) 
consistent with the results I obtained in the B16F0 model.  
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In contrast, Tie1Cre induced deletion had no effect on either CMT19T tumour growth 
or angiogenesis (Figure 3.4B), suggesting that the constitutive deletion of endothelial 
β3-integrin behaved differently than the inducible deletion. CMT19T tumour growth 
and vessel density in β3-floxed//Tie1Cre positive and negative mice actually reflected 
the same pattern observed in B16F0 studies, whereby they were both slightly 
increased in β3-floxed/Tie1Cre positive mice compared to β3-floxed/Tie1Cre 
negative mice, although neither of them reached statistical significance.  
 
Overall using two mouse tumour cell lines, B16F0 melanoma and CMT19T 
carcinoma, I obtained similar results; this contributes to strengthening our findings. 
Therefore, I conclude that endothelial β3-integrin is affecting tumour growth and 
tumour angiogenesis in a time dependent manner. 
 
3.2 β3-integrin does not impact on tumour vessel structure or function 
 
Tumour vasculature is structurally and functionally abnormal (Jain, 2005). Given the 
importance of pericyte coverage and endothelial basement membrane support for 
vessel structure and function, I asked whether reduced tumour growth and 
angiogenesis in the presence of the inducible endothelial β3-integrin deletion was 
linked to vascular defects in tumour vessels.  Therefore, I assessed pericyte coverage 
and endothelial basement membrane deposition in B16F0 and CMT19T allografts by 
colocalization with pericyte and basement membrane markers through 
immunohistological analyses. Further, I characterized the pattern of vascular 
distribution and the degree of blood perfusion through the tumour vasculature by 
intravenous injection of phycoerythrin (PE) conjugated CD31 (also known as Platelet 
endothelial cell adhesion molecule - PECAM) to highlight vessel lumens in vivo. 
 
3.2.1 Structural analyses: pericyte and endothelial basement membrane 
coverage  
 
Histological analyses of 12-day CMT19T tumour vessels by double immunostaining 
for endomucin and αSmooth Muscle Actin (αSMA which identifies vSMCs and 
pericytes; Gerhardt and Betsholtz, 2003) revealed that the absence of β3-integrin in 
endothelial cells had no effect on pericyte recruitment or organization along vessels, 
regardless of the time of the deletion.  Indeed, there was no significant difference in 
the number of endomucin+/ αSMA+ vessels in either β3-floxed/Tie1Cre positive or 
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β3-floxed//Pdgfb-iCreERT2 positive tumours compared to their Cre negative 
counterparts (Figure 3.5A-3.5B). 
 
A similar immunohistological analysis based on the colocalization of endomucin and 
nidogen (an endothelial basement membrane marker; Kohfeldt et al., 1998) in 12-day 
CMT19T tumour vessels showed no difference in endothelial basement membrane 
deposition either in the presence or absence of endothelial β3-integrin. Likewise, the 
time when deletion occurred seemed to be irrelevant: no significant difference in the 
number of endomucin+/nidogen+ vessels was detected when drawing comparisons 
between β3-floxed/Tie1Cre and β3-floxed/Pdgfb-iCreERT2 positive tumours (Figure 
3.5A-3.5B). 
 
3.2.2 Vascular functions: distribution and perfusion  
 
To evaluate defects in vessel function, vessel distribution and perfusion were 
assessed by immunohistological analysis in vibratome sections. This analysis was 
conducted only in CMT19T tumours because of the softness of B16F0 tumours which 
makes them unsuitable for vibratome/thick sectioning. Vessel distribution was 
analysed by endomucin staining in vibratome sections of tumours grown in β3-
floxed/Tie1Cre and β3- floxed/Pdgfb-iCreERT2 mice. No difference in the pattern of 
distribution of tumour vessels was observed when comparing β3-floxed/Tie1Cre 
negative and positive and β3-floxed/Pdgfb-iCreERT2 negative tumours to one another 
(Figure 3.6A). However, vessels were significantly reduced in number in β3-floxed 
/Pdgfb-iCreERT2 positive tumours, likely due to the fact that they were significantly 
less vascularized after 12 days of growth (Figure 3.3B).  
 
The degree of vessel perfusion was assessed by in vivo intravenous injection of PE-
CD31 in β3-floxed/Tie1Cre and β3-floxed/Pdgfb-iCreERT2 CMT19T tumour bearing 
mice, just before sacrifice (day12). The quantification of the depth of perfusion was 
performed on histological sections, whereby CD31+ patent vessels were colocalized 
with endomucin+ staining (Figure 3.6B). The depth of patent vessels was similar 
when comparing β3-floxed/Tie1Cre negative and positive and β3-floxed/Pdgfb-
iCreERT2 negative tumours to one another. However, patent vessels penetrated 
deeper in β3-floxed/Pdgfb-iCreERT2 positive tumours, likely due to the fact that they 
were significantly smaller after 12 days of growth (Figure 3.6C).  
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Taken together these data indicate that during B16F0 and CMT19T tumour 
associated angiogenesis, neither pericyte coverage, endothelial membrane 
deposition, vessel distribution, nor vessel patency are altered by endothelial β3-
integrin deletion, irrespectively of when the deletion occurs. 
 
3.3 Validation of the two endothelial Cre models 
 
My findings uncover a time-dependent role for endothelial β3-integrin in regulating 
tumour growth and angiogenesis, which likely is not due to structural and/or functional 
alterations of the tumour vasculature. In order to investigate this effect 
mechanistically, I first decided to test whether the non-endothelial expression of the 
two promoters, accounting for β3-integrin deletion in cell types other than endothelial 
cells, was responsible for the difference between the two models. In fact, both Tie-1 
and Pdgfb promoters reportedly have some degree of non endothelial activity: Tie-1 
is also expressed by a proportion (≈20%) of bone marrow derived hematopoietic cells 
(Gustaffson et al., 2001), while Pdgfb is also expressed by megakaryocytes which 
are platelet precursors (Claxton et al., 2008). To address this point, I examined β3-
integrin expression levels in bone marrow derived cells and platelets isolated from 
β3-floxed/Tie1Cre and β3-floxed/Pdgfb-iCreERT2 mice. 
 
3.3.1 Bone marrow cell analysis 
 
To characterise β3-integrin expression in the hematopoietic compartment, bone 
marrow derived cells isolated from femours of β3-floxed/Tie1Cre positive and 
negative mice were analyzed by flow cytometric analyses. Cell suspensions were co-
stained with PE-conjugated anti-β3 integrin and Fluorescein isothiocyanate (FITC)-
conjugated antibodies against the hematopoietic markers CD45, Ly6G, CD3, CXCR4 
(CD184) as described by Feng et al., (2008) to selectively quantify the level of β3-
integrin within each bone marrow derived cell sub-population.  
 
I found that the percentage of β3-floxed/Tie1Cre positive bone marrow derived cells 
expressing β3-integrin was significantly decreased in all the hematopoietic sub-
populations, except for CXCR4+ bone marrow derived cells, when compared to β3- 
floxed/Tie1Cre negative bone marrow derived cells (Figure 3.6A). In line with Feng 
findings, that β3 integrin expression on CXCR4+ BMDC is required for their 
recruitment and retention at sites of angiogenic site, this suggest that the angiogenic 
phenotype observed in β3-floxed/Tie1Cre mice is not likely the result of the leakiness 
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of the Tie1 promoter in the bone marrow compartment. In contrast, the same analysis 
performed on bone marrow derived cells isolated from β3-floxed/Pdgfb-iCreERT2 
positive and negative mice showed no difference in β3-integrin expression in any of 
the subpopulations assessed, thus confirming that Pdgfb is not active in bone marrow 
derived cells (Figure 3.6A).  
 
The same authors have also shown that tumour infiltrating bone marrow derived cells 
localizing in perivascular areas of tumours were predominantly F4/80+ macrophages. 
In line with these observations, I analysed β3-integrin expression in F4/80+ tumour-
associated macrophages isolated from β3-floxed/Tie1-Cre positive and negative 
tumours. Cell suspensions from tumour digests were double-stained with PE-
conjugated anti-β3 integrin and FITC-conjugated anti-F4/80, and the level of 
expression of β3-integrin in F4/80+ cells was quantified by flow cytometric analysis. 
No significant difference was found in the percentage of β3-integrin+/F4/80+ cells 
when comparing tumour associated macrophages isolated from β3-floxed/Tie1Cre 
positive and negative tumours (Figure 3.7B), despite total bone marrow F4/80+ cells 
were reduced in β3-floxed/Tie1Cre positive mice. This finding supports the 
conclusion that the angiogenic phenotype in β3-floxed/Tie1Cre mice is not due to 
difference in tumour associated macrophage infiltration. 
 
3.3.2 Platelet analyses 
 
Peripheral blood was collected from the vena cava of anesthetized Tie1Cre and 
Pdfgb-iCreERT2 mice before sacrifice and processed for platelet separation. Isolated 
platelets were lysed and Western blot analysis was performed to quantify β3-integrin 
expression levels. They were unaltered between β3-floxed/Pdfgb-iCreERCreERT2 
positive and negative platelets (Figure 3.7C). Further, I confirmed that there was no 
change in β3-integrin expression in platelets isolated from in β3-floxed/Tie1Cre 
positive and negative mice as expected (Figure 3.7C).  
 
These data support the hypothesis that the difference observed in tumour growth and 
angiogenesis between the two transgenic models is likely due to endothelial cell 
specific deletion of β3 integrin. 
 
3.3.3 Analysis of Tomato Cre reporter activity 
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Following on from the analysis of the non-endothelial activity of the Tie1 and Pdfgb 
promoters, it was compelling to validate the two endothelial models in terms of activity 
and specificity of the Cre recombinase in the context of the tumours themselves.  
 
In order to assess Cre recombinase activity in vivo, a reporter transgenic mouse line 
was employed. Tie1Cre and Pdfgb-iCreERT2 positive mice were crossed with the 
tdTomato reporter line (Madisen et al., 2010), whereby the Rosa26  locus  has been 
modified by targeted insertion of a strong and ubiquitous promoter, followed by a 
floxed-STOP cassette controlling the tdTomato gene (as shown below). 
 
 
 
 
 
CMT19T tumours were grown in Tie1-Cre positive/tdTomato heterozygous and  
 
Pdgfb-iCreERCreERT2 positive/tdTomato heterozygous mice, harvested after 12 
days and thick whole-mount sections were examined after.co-staining for endomucin 
to highlight vessels. At high magnification, tomato positive cells (representing active 
Cre recombinase) colocalized with endomucin+ vessels in both Tie1Cre 
positive/tdTomato heterozygous and Pdgfb-iCreERT2 positive/tdTomato 
heterozygous tumours, suggesting that Cre recombinase is specifically active in 
endothelial cells within the tumour tissue in both transgenic models (Figure 3.8A). In 
addition to that, analysis of CMT19T whole-mount tumour sections at lower 
magnification, showed that Tomato Cre reporter activity was widespread in both Cre 
models, confirming that substantial deletion was achieved (Figure 3.8A). 
 
3.3.4 Analysis of Cre deletion efficiency 
 
Cre recombinase activity as measured by fluorescence of the tdTomato reporter gene 
is an indirect evaluation and is not necessarily equivalent to effective protein ablation. 
Therefore, the efficiency of Cre driven deletion has been assessed by measuring β3-
integrin protein levels by Western blot analysis from 12-day tumour endothelial cells 
comparing Cre positive against Cre negative tumour endothelial cells isolated from 
both transgenic models (Figure 3.1B).  
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Importantly, the decrease of β3-integrin protein level was similar when comparing in 
β3-floxed/Tie1Cre and β3-floxed/Pdgfb-iCreERT2 positive tumour associated 
endothelial cells, proving the efficiency of the deletion was comparable in the two 
models. In addition, Cre driven deletion within the tumour vasculature was evaluated 
in vivo by colocalization of FITC IsolectinB4 (IB4) with intravenously injected PE-
conjugated anti-β3 integrin antibody (which allowed endothelium targeting) on whole-
mount tumour sections. The histological analysis revealed that β3-integrin in tumour 
vessels was effectively deleted in both Cre models (Figure 3.7B). 
 
From these additional analyses, I conclude that Cre recombinase is similarly specific 
and efficient in deleting β3-integrin in tumour endothelial cells in both transgenic 
models, thereby allowing for a more direct comparison between them. 
 
3.4 The length of β3-integrin deletion dictates the angiogenic response 
 
The validation data, heretofore, are likely to exclude the possibility that intrinsic 
differences between the two endothelial transgenic models explains the dichotomous 
effects I observed when comparing the two models. Rather, they suggest they differ 
in the amount of time β3-integrin has been depleted. 
 
3.4.1 Rationale of the long OHT treatment in the inducible model of β3-integrin 
deletion 
 
In order to pinpoint the time dependency of endothelial β3-integrin inhibitory effect on 
tumour growth and angiogenesis, I performed an in vivo “rescue” tumour experiment, 
whose rationale is based on the following question: could the effect of the inducible 
β3-integrin deletion be abrogated by extending the time of its deletion?   
In other words, would extending OHT treatment prior to allograft implantation in β3-
floxed/Pdgfb-iCreERT2 mice mimick the angiogenic phenotype observed in β3-floxed 
/Tie1-Cre mice?  
 
3.4.2 Abrogation of the inhibitory tumour phenotype by long OHT treatment of 
β3-floxed/Pdgfb-iCreERT2 mice 
 
The rescue experiment consisted of administering OHT treatment to β3-floxed/Pdgfb-
iCreERT2 mice for 21 days (referred to as “long OHT”) before subcutaneous tumour 
cell injections. Since OHT was administered by subcutaneous implantation of slow 
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release pellets, which lasted for only 3 weeks, a second OHT pellet was implanted at 
the same time as CMT19T tumour cell injection. CMT19T tumours were then 
harvested 12 days later, corresponding to a total of 33 days of OHT treatment; their 
size and vessel density were assessed.  
 
Consistent with the hypothesis that it is the length of endothelial β3-integrin deletion 
which affects tumour growth and angiogenesis, no differences were observed in 
either tumour size or degree of vascularization when comparing long OHT β3-
floxed/Pdgfb-iCreERT2 positive and negative mice (Figure 3.9A-3.9C). In line with 
these findings, no structural defects in tumour vasculature were noted after 
immunofluorescent analysis of pericyte coverage and endothelial basement 
membrane deposition, as described in paragraph 3.2 (Figure 3.9D). Therefore, the 
inhibitory effects observed upon inducible deletion of endothelial β3-integrin (15 days 
of OHT treatment in total - referred to as “short OHT”) were completely abolished if 
the OHT treatment was extended prior to allograft administration. 
 
In order to ascertain that Cre recombinase was active in vivo over an extended time 
course, endothelial cells from long OHT β3-floxed/Pdgfb-iCreERT2 tumours were 
isolated at the end of the experiment (day 33) and β3-integrin protein levels were 
quantified by  Western blot analyses. Indeed, long OHT β3-floxed/Pdgfb-iCreERT2 
positive tumour endothelial cells displayed a significant reduction of β3-integrin 
expression compared to their Cre negative counterparts (Figure 3.9B). These results 
strongly support the conclusion that it is the length of endothelial β3-integrin deletion 
which dictates the angiogenic response during tumour growth. 
 
3.4.3 The inhibitory effects of inducible endothelial β3-dntegrin deletion are 
transient                    
 
To further investigate whether the effect of inducible endothelial β3-integrin deletion 
on tumour growth and angiogenesis was durable, I extended the time of growth of 
CMT19T allografts in β3-floxed/Pdgfb-iCreERT2 mice after short OHT treatment. 
CMT19T tumours were grown until day 18 (corresponding to an additional 6 days) 
after their injection. These analyses could not be performed with B16F0 allografts 
because they grow extremely rapidly beyond day 12 and were likely to exceed the 
legal size limit allowed for tumour growth in mice in accordance with UK Home Office 
Regulations.  
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Tumour growth was monitored with external caliper measurements in live mice while 
tumours were growing. Tumours were significantly smaller in β3-floxed/Pdgfb-
iCreERT2 positive mice compared β3-floxed/Pdgfb-iCreERT2 negative mice at day 8 
and 13 (Figure 3.10A).  
 
However, at day 18 when tumours were harvested and analyzed to assess their 
growth and angiogenesis, there was no significant difference in size when comparing 
β3-floxed/Pdgfb-iCreERT2 positive and negative tumours,  even though vessel density 
still was significantly decreased (Figure 3.10A). Endothelial cells from β3-
floxed/Pdgfb-iCreERT2 positive and negative tumours were isolated at the end of the 
experiment (day 18) and β3-integrin protein levels were quantified by Western blot 
analyses. β3 flox/flox/Pdgfb-iCreERT2  positive tumour endothelial cells displayed a 
significant reduction of β3-integrin expression compared to their respective Cre 
negative controls, proving that endothelial β3-integrin was effectively deleted for the 
extended time of the experiment (Figure 3.10A). 
 
Unfortunately, but perhaps not surprisingly, these findings show that the inhibitory 
effects observed with the inducible endothelial β3-integrin deletion are transient and 
dissipate over time.  This also suggests that β3-integrin independent compensation 
mechanisms take over as tumour growth progresses in the continued presence of 
β3-integrin suppression. 
 
3.4.4 Endothelial β3-integrin is not required when tumours have already 
established                                                       
 
To test whether inducible endothelial β3-integrin deletion had an effect also on tumour 
progression, I used a more clinically relevant model of tumour growth whereby 
CMT19T tumour cells were implanted subcutaneously and OHT was administered 8 
days later (hereafter referred to as “INTERVENTION SCHEME”), after angiogenic 
tumours had already been established. 
 
CMT19T tumour sizes were then assessed 5 and 10 days after OHT treatment 
(corresponding to days 13 and 18 from point of allograft implantation). Despite β3-
integrin being effectively deleted in tumour associated endothelial cells at day 18, no 
significant differences in size were observed at either time point when comparing β3-
floxed/Pdgfb-iCreERT2 positive and negative mice (Figure 3.10B).  
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In addition, CMT19T tumours were harvested and processed for histological analyses 
and vessel density quantification. In line with the tumour growth data, angiogenesis 
did not appear to be altered in β3-floxed/Pdgfb-iCreERT2 positive tumours (Figure 
3.10B).  
 
Overall, these data suggest that the effects of an inducible endothelial β3-integrin 
deletion during tumour angiogenesis are context dependent: the deletion exerts an 
inhibitory effect by preventing establishing tumours to grow by reducing their degree 
of angiogenesis, but the deletion has no effect on already established tumours. 
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DISCUSSION 
 
3.5 The αvβ3-integrin conundrum  
 
Integrins play a crucial role in angiogenesis, both in physiological and pathological 
conditions and their functions and the molecular mechanisms involved in their 
regulation have been extensively studied (Robinson and Hodivala-Dilke, 2011). The 
interest beyond this is not purely from a fundamental interest in cell biology, but has 
gathered attention because of the clinically relevant potential of this knowledge to be 
translated into therapeutical options for a host of vascular and oncological diseases. 
With respect to tumour angiogenesis, after ten years of largely failed attempts at anti-
angiogenic therapy, we have to take the lesson and go back to the bench because 
there are clearly aspects of pathological angiogenesis we do not understand fully and 
there are still issues which remain controversial (Atkinson et al., 2014). 
 
αvβ3-integrin undoubtedly falls in this latter category. Its expression is upregulated 
during angiogenesis and is linked to endothelial cell proliferation, migration and 
survival (Hodivala-Dilke, 2008). Given that, it is surprising that genetic ablation of the 
αv- or β3-subunits, does not lead to any major vascular defects: αv-deficient mice die 
perinatally but without any obvious changes in blood vessel development or structure 
(Bader et al., 1998), and β3-deficient mice are viable, fertile and adult mice develop 
normal vasculature (Hodivala-Dilke et al.1999). The yet unsolved conundrum of 
αvβ3-integrin stems from the unexpected discrepancies between genetic data 
showing that β3-deficient mice support enhanced pathological angiogenesis 
(Reynolds et al., 2002), whereas pharmacological inhibition of αvβ3-integrin can 
block angiogenesis in some models (Brooks et al., 1995); in fact αvβ3-integrin 
antagonists have been investigated in clinical trials. This thesis was an attempt to 
shed light on these seeming discrepancies with the hope of adding a contribution to 
the clinical translation of αvβ3-integrin as a therapeutic target.   
 
I took a genetic approach to elucidate the role of endothelial αvβ3-integrin in tumour 
angiogenesis, even though αvβ3-integrin antagonists were available (Stupp et al., 
2007). Genetics offered at least two advantages: cell-specificity achieved with the 
use of endothelial specific promoters and temporal regulation achieved with the use 
of an inducible promoter. 
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Cell specificity is fundamental as αvβ3-integrin is expressed by different cells all of 
which can contribute to angiogenesis: fibroblasts, macrophages, bone-marrow 
derived cells, pericytes, platelets and tumour cells themselves (Robinson and 
Hodivala-Dilke, 2011). For this reason previous genetic studies based on the global 
β3-integrin knockout were muddied by the fact that β3-integrin deletion was not 
restricted only to endothelial cells. In fact it has been shown that other cell types, such 
as bone marrow derived cells, contribute to the phenotype of increased pathological 
angiogenesis observed in β3-integrin knockout mice (Taverna et al., 2004; Watson 
et al., 2010).   
 
With respect to cell specific analysis, it has already been shown that β3-integrin 
conditional deletion in platelets leads to a bleeding phenotype but has no effect on 
tumour growth and angiogenesis; whereas β3-integrin deletion in myeloid cells 
caused osteopetrosis similar to that observed in β3-null mice (Morgan et al., 2010). 
My studies are the first to look at the effects of the endothelial-specific deletion of this 
molecule. I was able to show that the acute deletion of β3-integrin in endothelial cells 
reduced tumour growth and angiogenesis in two different tumour models B16F0 
melanoma and CMT19T lung carcinoma, drastically reducing the possibility that this 
effect is tumour specific. Therefore, my findings support the argument that endothelial 
αvβ3-integrin remains a valid target for anti-angiogenic tumour therapy.  
 
Temporal regulation is a fundamental concept.  Classically, there has been a distinct 
conceptual separation of angiogenesis studies into either 
developmental/physiological or adult/pathological.  This is approach, perhaps,  is too 
reductionist in the context of cancer, which by definition is susceptible to selection 
and adaptation and as such a continuum of both “types” of angiogenesis are likely 
occuring in the same tissue at any one time.  
 
Time matters and this is also reflected by the variability observed in clinical settings 
when applying anti-angiogenic therapies.  When to start a therapeutical regime and 
how long to continue it are crucial parametres to consider to pinpoint exactly when 
β3 integrin dependent functions take place in order to target it effectively. In line with 
this, the use of an inducible promoter enabled me to dissect specifically the time-
dependency of αvβ3-integrin functions in tumour angiogenesis. Interestingly,  I 
observed that  the inhibitory effect on tumour growth and angiogenesis was transient, 
dissipated over time, and was not effective if tumour angiogenesis had already been 
established.   
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These findings indicate that the anti-tumourigenic/anti-angiogenic effects observed 
with the inducible deletion of endothelial β3-integrin is time dependent, as 
demonstrated by the ability to escape the inhibitory effects of  β3-integrin blockade 
simply by extending the duration of the deletion in the inducible model.  It is tempting 
to speculate that the these findings help explain why long term pharmacological 
inhibition of  αvβ3-integrin functions do not work in the clinic: the molecule really only 
plays an essential role in the early stages of tumour growth.  
 
This also correlates nicely with the finding that the constitutive deletion of endothelial 
β3-integrin has no effect on tumour growth and angiogenesis. This might be 
explained by hypothesising that constitutive β3-integrin deletion leads to the build up 
of compensatory mechanisms which circumvent β3-integrin directed inhibition over 
time. Therefore, the constitutive model of β3-integrin deletion might be a powerful tool 
to investigate the molecular and cellular changes which take over as a consequence 
of long term deletion of β3-integrin and which might be responsible for acquired 
resistance to treatment in clinical settings.  Taken as a whole, my findings highlight 
that both when to target β3-integrin and for how long to to target β3-integrin to prevent 
tumour growth and angiogenesis are key aspects to consider for translational 
approaches.  
 
The question of whether a genetic deletion elicits the same effect as a 
pharmacological inhibition is still open for debate.  However, for the purpose of my 
studies a genetic approach was the most appropriate to accomplish an endothelial 
cell specific analysis of the role of β3-integrin in tumour angiogenesis which cannot 
be achieved with pharmacological agents that will, of course, hit multiple cellular 
targets.  Nonetheless, the light my studies shed on fundamental biology will certainly 
help improve pharmacological strategies. 
 
3.6 Cre issues 
 
The Cre/loxP system is widely used in mice to achieve cell-type-specific gene 
deletion (Gu et al., 1993), in particular for genes whose conventional null mutation is 
lethal. In my studies, I employed two endothelial specific Cre transgenic lines, where 
Cre expression was driven by Tie1 and Pdgfb promoters which have been already 
used to study the functions of other endothelial integrins and of Focal Adhesion 
Kinase (Germain et al., 2010; da Silva et al., 2010; Tavora et al., 2010). 
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Tie1 promoter is active from E8.5 and allows Cre recombinase activity during 
embryogenesis and into adulthood (Gustafsson et al., 2001), whereas Pdgfb-
iCreERT2 is a inducible promoter as Cre recombinase is activated only upon 4-
hydroxytamoxifen administration (Claxton et al., 2008).  
 
Despite being extensively used, there are two main issues that need to be addressed 
when working with Cre transgenics: specificity and activity. The non-endothelial 
specificity of both Tie1 and Pdgfb promoters was known since it had been extensively 
characterized in the pubblications in which these trangenic mice were originally 
described. This phenomenon also referred to as “leakiness of the promoter” involved 
certain neuronal populations and a small proportion of hematopoietic cells in Tie1Cre 
mice (Gustafsson et al., 2001) and megakaryocytes in Pdgfb-iCreERT2 mice (Claxton 
et al., 2008). This issue was addressed by evaluating Cre recombinase  activity and, 
β3-integrin deletion, in these non-endothelial cell populations. This analysis was 
extremely relevant because both hematopoietic cells and megakaryocytes (which 
produce platelets), can contribute to angiogenesis to some extent. While no leakiness 
was detected in platelets, deletion of β3-integrin was detected in bone marrow 
derived cells isolated from Tie1Cre positive bone marrow derived cells, but notably 
not  in CXCR4+ (CD184) expressing cells. Therefore, I argued that the absence of 
β3-integrin deletion in CXCR4+ bone marrow derived cells (mostly macrophages) 
explained why β3-floxed/Tie1Cre positive mice did not exhibit enhanced tumour 
growth and angiogenesis in vivo, in marked contrast to β3-integrin knockout mice 
(Reynolds et al., 2002).  This speculation was further supported by the finding that 
there was no change in β3-integrin expression levels in tumour associated 
macrophages from β3-floxed/Tie1Cre positive mice.  
 
Nevertheless, it would be interesting to confirm this speculation by performing bone 
marrow transplant experiments in order to directly rule out the contribution of β3-
integrin expressed by bone marrow cells to the tumour growth and angiogenesis 
phenotype observed with the constitutive β3-integrin deletion. This would require 
transplantation of wildtype (β3-floxed/Tie1Cre negative) bone marrow into irradiated 
β3-floxedTie1Cre positive mice. If my hypothesis is correct, I would expect to see no 
difference when comparing transplanted to non-transplanted mice.   
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With respect to Cre activity, this type of analysis was essential to enable a more direct 
comparisons between the two transgenic models. It was achieved by combining 
Western blot analyses to quantify the efficiency of β3-integrin deletion in both lung 
and tumour associated endothelial cells and by performing Cre reporter analyses, 
which involved crossing the endothelial Tie1Cre and Pdgfb-iCreERT2 lines with a 
Tomato Cre reporter line (Madisen et al., 2010) to investigate  the pattern of Cre 
activity in vivo and ex vivo. These combined strategies showed that Cre recombinase 
in both transgenic models behaved similarly, helping to rule out the possibility that 
differences observed when comparing the two models were due to intrinsic Cre 
related differences rather than to real biological ones. 
 
The use of the inducible promoter requires Cre recombinase activation via tamoxifen 
administration. Difference in duration of induction required for activation of Cre might 
be influenced by the sensitivity of Cre recombinase itself  (Weis et al., 2008) and by 
the routes throught which OHT is administered (for example intraperitoneal injection, 
oral gavage, tamoxifen enriched diet, slow release tamoxifen pellet). Since I have 
been comparing one Cre inducible system to a constitutive one (which does not 
require Cre activation), these considerations were not as relevant as they might have 
been if I were comparing two different inducible models; but they were still important 
with respect to investigating time-dependent effects of incucibly deleted genes.  
  
Therefore, the choice of using 21-day-slow release tamoxifen pellets seemed to be 
the most preferable. It has been shown that efficient floxed gene deletion requires 
only 2 days in Pdgfb-iCreERT2 mice (Indra et al., 1999).  I also confirmed it in aortic 
rings isolated from Pdgfb-iCreERT2 positive/tdTomato heterozygous mice whereby I 
could detect Cre activity after 2 day of ex vivo OHT treatment.  Moreover, tamoxifen 
pellets ensured controlled drug release in animals for 3 weeks, thereby reducing the 
variability of repeated OHT administration (intraperitoneal injection, oral gavage) or 
of relying on mice eating regularly (tamoxifen enriched diet) as confirmed by 
significantly reduced β3-integrin protein levels in endothelial cells isolated from 
tumours grown β3-floxed/Pdgfb-iCreERT2 mice upon both short (3 days) and long (21 
days) OHT treatments. 
 
3.7 Endothelial αvβ3-integrin deficiency in the tumour vasculature 
 
Vessel density is a measure of how vascularised a tumour is. It is generally accepted 
that larger tumours have more vessels than smaller ones, but this is not necessarily 
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always true. Vessels can be present but function poorly or be leaky. Some tumours 
have been reported to have vessel pores 100 times bigger in size than those present 
in healthy vessels (Hobbs, 1998). Moreover, there is no definitive correlation between 
blood flow or oxygen consumption and tumour growth rate in vivo (Gullino, 1982). 
 
However, my findings established a direct correlation between the reduction in 
tumour growth observed in the presence of an acute endothelial β3-integrin deletion 
and reduction in vessel density. This angiogenenic phenotype of increased tumour 
vascularization was shown not to be specific to a single tumour model; similar findings 
were observed in two strikingly different tumour models.  These results are consistent 
with previuos data from Mahabeleshwar et al. (2006) who showed that mice 
expressing a mutant of the β3-integrin subunit in which both cytoplasmic tyrosine 
residues were mutated to phenylalanine and, unable to undergo phosphorylation 
(DiYF β3 mutant mice); were deficient in angiogenesis thereby indicating a pro-
angiogenic function for β-integrin in tumour angiogenesis. My studies narrowed down 
this pro-angiogenic function of β3-integrin to endothelial cells and temporally defined 
it as important in the very early stages of angiogenesis. My findings suggest 
endothelial β3-integrin plays a pivotal role in the early angiogenic processes; its acute 
deletion impairs tumour angiogenesis, thereby reducing tumour growth rate. 
However, when angiogenesis is already in full-swing endothelial β3-integrin function 
becomes dispensable.  
 
Abnormalities in pericyte and basement membrane support are associated with 
vessel structural deformities and reflect impaired vessel function (Jain, 2005).  My 
structural analysis looking at perycite coverage and endothelial basement membrane 
deposition, ruled out the involvement of endothelial β3-integrin in these processes. In 
fact, despite the loss of endothelial β3-integrin, tumour vessels exhibited normal 
pericyte and basement membrane support in line with findings of Taverna et al. 
(2004) showing enhanced tumour angiogenenesis in mice lacking β3 and β3/β5 
integrins; whereas no difference in the structure of the vessels was reported. This 
was also described by McCarthy and collegues (McCarthy et al., 2002) who showed 
that cerebral microvessels were ultrastructurally normal in mice lacking αv integrin.   
 
Overall, I conclude  that endothelial β3-integrin is dispensabale for vessel maturation 
and stabilization. Since the data indicate endothelial β3-integrin as early pro-
angiogenic regulator, some other functional parametres such as vessel leakiness and 
intratumoural hypoxia (Sadawa et al., 2012) were not included in the functional vessel 
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analyses, as the absence of defects in vessel structure and function would at least in 
theory exclude them. However, I believe this evalutation would be extremely valuable 
to future studies investigating αvβ3-integrin as a tumour endothelium targeted agent 
(Danhier et al., 2012), but this is beyond the scope of this thesis. 
 
CONCLUSIONS 
 
In this chapter, I have shown that:  
 
• in vivo tumour growth and angiogenesis are inhibited by inducible BUT 
NOT constitutive deletion of endothelial β3-integrin; 
 
•  the in vivo efficiency of Cre induced deletion of endothelial β3-integrin 
and  the in vivo pattern of Cre activity are similar in both Tie1Cre and 
Pdgfb-iCreERT2 models; 
 
• extending the length of β3-integrin deletion abrogates the in vivo 
inhibitory effect arising from its inducible deletion; 
 
•  the inhibitory effect of an inducible β3-integrin deletion is transient and 
dissipates with time; 
 
• an inducible β3-integrin deletion has no effect when tumours have 
already been established. 
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4. USING THE AORTIC RING ASSAY TO STUDY 
ENDOTHELIAL β3-INTEGRIN IN VESSEL SPROUTING  
 
In order to fully understand the process of pathological angiogenesis, in vivo tumour 
experiments are required. However, the involvement of other cell types in angiogenic 
processes in vivo makes it difficult to discriminate endothelial specific responses from 
the contribution of other cells. On the other hand, in vitro angiogenesis assays often 
occur without actual sprouting of lumenised vessels or without involving the 
recruitment of supporting cells. The aortic ring assay, however, provides a more 
relevant model for studying angiogenesis ex vivo, as it allows to reproduce many of 
the key steps of microvessel sprouting over a timescale similar to that observed in 
vivo (Baker et al., 2011).  As such, I employed the aortic ring model to refine our 
understanding of the involvement of endothelial β3-integrin in the angiogenic 
process, while at the same time excluding (at least to a degree) off-target contributors 
to in vivo phenotypes, such as bone marrow derived cells and inflammatory cells. 
 
In this chapter, I will present my studies on the effect of the deletion of endothelial β3-
integrin in aortic ring angiogenesis and show that it largely recapitulates what I 
observed in the context of tumour angiogenesis.  
 
RESULTS AND FIGURES 
 
4.1 Inducible deletion of β3-integrin inhibits VEGF-induced microvessel 
sprouting ex vivo, while its constitutive deletion has the opposite effect 
 
I evaluated the contribution of endothelial β3-integrin to VEGF-induced angiogenesis 
to address whether it was affecting ex vivo angiogenesis and, if so, whether it 
reflected the pattern of pathological angiogenesis observed in vivo.  In order to do 
that, I assessed microvessel sprouting in aortic ring explants from β3-floxed/Tie1Cre 
and β3-floxed/Pdgfb-iCreERT2 positive and negative mice. Aortic rings were isolated, 
embedded in collagen and stimulated with VEGF. Sprouting microvessels were 
counted after 6 days of VEGF stimulation under phase-contrast microscopy and 
afterward, they were visualized by fluorescent labelling of endothelial cells with FITC-
conjugated Isolectin B4 (IB4) (Baker et al., 2011). Unstimulated (no VEGF treatment) 
rings acted as negative controls (Figure 4.1A).   When compared to their Cre negative 
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counterparts, VEGF-induced sprouting was significantly enhanced in β3-
floxed/Tie1Cre positive rings; whereas it was inhibited in β3-floxed/Pdgfb-iCreERT2 
positive rings, suggesting that inducible and constitutive deletion of β3-integrin in 
endothelial cells elicited different angiogenic responses ex vivo. 
 
The data are reminiscent of those observed in vivo where inducible deletion of 
endothelial β3-integrin significantly inhibits tumour growth and angiogenesis; 
whereas its constitutive deletion does not. The data help strengthen the argument 
that endothelial β3-integrin plays a role in the early stages of sprouting angiogenesis. 
The early inhibitory effects of blocking its expression are abolished upon long term 
deletion of the molecule, suggesting compensatory mechanisms are established over 
time. 
 
4.2 bFGF-induced microvessel sprouting ex vivo is not affected by loss of 
endothelial β3-integrin expression 
 
Tumour cells secrete VEGF, whose expression is driven by hypoxic conditions, but 
they can also produce many other angiogenic growth factors, e.g. basic Fibroblast 
Growth Factor, bFGF) (Carmeliet and Jain, 2011). Aside from being a more 
physiologically relevant model over other in vitro methods, the aortic ring assay also 
allows one to test several conditions, for instance different angiogenic growth factors. 
Therefore, I took advantage of this model to expand the analyses of the effect of 
endothelial β3 integrin deletion in ex vivo angiogenic responses dependent on bFGF 
stimulation. 
 
Experimental studies have previously shown that bFGF stimulation requires 
embedding of aorting rings in a fibrin gel. (Nicosia, 2009; Zhu, 2003).  Therefore, 
aortic rings were isolated from β3-floxed/Tie1Cre and β3-floxed/Pdgfb-iCreERT2 
mice, embedded in fibrin and stimulated with bFGF. Sprouting microvessels were 
counted after 6 days of bFGF stimulation via phase-contrast microscopy. Vesssel 
sprouts were also visualised by fluorescent labelling of endothelial cells with FITC-
conjugated IB4 (Figure 4.1B). Unstimulated (no bFGF treatment) rings acted as 
negative controls. Microvessel sprouting was similar when comparing all groups to 
one another suggesting, at least in the context of this assay, that endothelial β3-
integrin was not essential for bFGF induced microvessel sprouting.  
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4.3 Ex vivo Cre activity in aortic rings 
 
A pre-requisite for these studies (as for the in vivo analyses) was determining the ex 
vivo pattern of Cre activity in the aortic ring model in both transgenic lines. 
Immunofluorescence analyses of collagen embedded Tie1Cre positive/tdTomato 
heterozygous and Pdgfb-iCreERT2 positive/tdTomato heterozygous aortic rings 
showed that Tomato Cre reporter activity was expressed in all microvascular sprouts 
after 6 days of VEGF stimulation.   
 
Cre activity appeared to be exclusively in endothelial cells, as demonstrated by 
overlapping fluorescent signals of Tomato and FITC-conjugated IB4+ angiogenic 
sprouts, but not overlapping signals when comparing Tomato fluorescence with 
NG2+ pericytes (Armulik et al., 2011).  This pattern was observed in both Tie1Cre 
positive/tdTomato heterozygous and Pdgfb-iCreERT2 positive/tdTomato 
heterozygous aortic rings (Figure 4.2A).  Since the Pdgfb promoter has been reported 
to be highly active in endothelial tip cells at the leading edge of angiogenic sprouts 
(Gerhardt et al., 2003), differences in Cre activity within this population of cells 
between the 2 transgenic models could account for differences in angiogenic 
responses. Nevertheless, no differences were evident in the distribution of Cre 
activity when comparing microvessel sprouting from Tie1Cre positive/tdTomato 
heterozygous and Pdgfb-iCreERT2 positive/tdTomato heterozygous aortic rings, 
suggesting that Cre activities ex vivo were similar in both tip and stalk cells in aortic 
ring sprouts (Figure 4.2A). 
 
In parallel, the efficiency of β3-integrin deletion was assessed by Western blot 
analysis whereby aortae were mechanically disrupted, aortic tissues lysed and then 
proteins extracted. Total β3-integrin levels were reduced in Cre positive aortas 
compared to their Cre negative counterparts (Figure 4.2B). However, the reduction 
in β3-integrin expression levels achieved in both transgenic model was only 
approximately 50% in β3-floxed/Tie1Cre positive aortas and 60% in β3-floxed/Pdgfb-
iCreERT2 positive aortas; this was likely due to the fact that β3-integrin levels were 
quantified from the whole aortas, rather than only from neo-angiogenic sprouts where 
deletion has occurred (Figure 4.2B).  
 
Overall these analyses show that ex vivo the two transgenic models behave similarly 
with respect to Cre specificity and efficiency.  As such, a direct comparison of ex vivo 
angiogenic responses can be drawn between them. 
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4.4 Microvessel sprouting is not suppressed by long OHT treatment of β3-
floxed/Pdgfb-iCreERT2 aortic rings 
 
In order to test whether it was the timing of β3-integrin deletion in endothelial cells 
that determined angiogenic responses to VEGF-stimulation ex vivo, I adopted a 
similar strategy to the one I used in vivo: I mimicked the constitutive deletion of 
endothelial β3-integrin that occurs in the Tie1Cre model by treating β3-floxed/Pdgfb-
iCreERT2 mice for extended periods of time with OHT prior to conducting aortic ring 
assays.  
 
This was achieved by taking aortic rings derived from β3-floxed/Pdgfb-iCreERT2  mice 
that had been treated with OHT in vivo for 33 days prior to embedding and by 
stimulating them with VEGF. Unstimulated rings were used as a negative control.  
Microvessel sprouts were visualized by fluorescent labelling of endothelial cells with 
FITC-conjugated IB4. I found that there was no difference in microvessel sprouting 
when comparing long OHT β3-floxed/Pdgfb-iCreERT2 positive and negative aortic 
rings, indicating that a prolonged deletion of endothelial β3-integrin was sufficient to 
abolish the previously described inhibitory effect on aortic ring sprouting that occurred 
with an acute deletion (Figure 4.3A).    
 
From these data, I conclude that the length of endothelial β3-integrin deletion 
determines VEGF-dependent angiogenic responses both ex vivo and in vivo: long-
term loss does not affect vessel sprouting, while acute loss significantly impairs it. 
 
4.5 β3-integrin deletion is ineffective when microvessel sprouting has already 
begun 
 
Based on the results presented here, it is reasonable to suggest that the timing of the 
deletion is critical in dictating whether VEGF-dependent angiogenic responses will be 
affected by the loss of endothelial β3-integrin ex vivo. In order to test this hypothesis, 
I applied an ex vivo intervention strategy where β3-integrin deletion in aortic rings 
derived from β3-floxed/Pdgfb-iCreERT2 animals was induced by OHT administration 
after microvessel sprouting had already begun, namely 3 days after the initiation of 
VEGFstimulation.  
 
Microvessel sprouting was quantified after fluorescent labelling of endothelial cells 
with FITC-conjugated IB4 at day 8, which corresponded to 5 days of OHT treatment. 
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No significant differences were observed in the degree of sprouting when comparing 
β3 flox/flox/Pdgfb-iCreERT2 positive and negative aortic rings (Figure 4.3B). 
Moreover, I showed that Cre recombinase became active within the first 24 hours of 
OHT treatment as displayed by Tomato fluorescence (Figure 4.3C). 
 
These findings help sustain the hypothesis that endothelial β3-integrin is required  in 
the early stages of the angiogenic process both in vivo and ex vivo, but its contribution 
to angiogenesis becomes dispensable later on, once angiogenic sprouting has been 
established. 
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DISCUSSION 
 
4.5 The aortic ring model  
 
The aortic ring model is based on the capacity of rat or mouse aortic explants to form 
new vessels in 3D gels. This was originally observed in the early 1980s by Joseph 
Leighton (Nicosia et al., 1982), with a very good timing in the angiogenesis field, in 
fact less than 10 years before, Folkman hypothesised that tumour growth was 
angiogenesis dependent (Folkman, 1971) and soon after Folkman’s group 
successfully isolated microvascular endothelial cells from bovine adrenal gland, 
showing they were capable of forming tubes in vitro (Folkman et al., 1980).  The aortic 
ring model rapidly became one of the most commonly used models of angiogenesis 
because it bridged the gap between in vitro and in vivo angiogenesis assays (Baker 
et al., 2011). 
 
The ex vivo microvessel sprouting produced by aortic rings is the result of the 
paracrine interaction between a mixed population of resident cells (endothelial cells, 
pericytes, fibroblasts, macrophages) under culture conditions. It mimicks the steps of 
the angiogenic process (Nicosia, 2009).  Briefly, the first cells to migrate out of the 
aortic rings after one or two days are fibroblasts and macrophages, originating from 
the aortic adventitia. Endothelial sprouts first appear at the edges of the explants after 
two or three days of culture and are made of migratory cells which extend filopodia-
like processes. As the outgrowth elongates, vessels develop a visible lumen and 
become surrounded by pericytes, which migrate and proliferate along the 
endothelium. After sprouting and branching for approximately one week, vessels stop 
growing and begin to regress. Therefore, this was a suitable model to investigate 
whether endothelium was positively regulating the early stages of physiological 
angiogenesis ex vivo (Nicosia, 2009). 
 
4.6 αvβ3-integrin in aortic angiogenesis 
 
The dualistic role αvβ3-integrin has been described also in aortic ring angiogenesis. 
A number of studies have shown that angiogenesis was significantly enhanced in β3 
deficient aortic explants (Reynolds et al., 2004), or by treating aortic cultures with 
nanomolar  concentrations of αvβ3/αvβ5 inhibitors (Reynolds et al., 2009); wheareas 
it was impaired in aortic rings from DiYF β3-mutant mice (Mahabeleshwar et al., 
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2006), mirroring the conflicting responses observed in tumour models of pathological 
angiogenesis. 
 
Consistent with the previously described in vivo phenotypes, my findings showed a 
time dependent inhibitory effect of endothelial β3-integrin in ex vivo aortic ring 
angiogenesis. I also showed that this effect was VEGF-specific, (bFGF dependent 
angiogenesis did not elicit the same response). Moreover, I was able to confirm that 
this effect dissipated over time and did not affect aortic ring angiogenesis if the 
deletion of endothelial β3-integrin was induced by ex vivo OHT treatment, when 
microvessel sprouting had already begun.  These data help strengthen the argument 
that endothelial β3-integrin plays a role in the early stages of sprouting angiogenesis 
(endothelial cell proliferation, migration and sprouting) which is really what ex vivo 
aortic ring model allows one to track precisely. 
 
Despite the consistency with the in vivo data, it may be argued that the reduced 
microvessel sprouting observed with the acute β3-integrin deletion might be due to a 
difference in functional Cre recombinase activity as it has been reported that the 
Pdgfb promoter is highly active in endothelial tip cells at the leading edge of 
angiogenic sprouts compared stalk cells (Gerhardt et al., 2003). Tomato reporter 
analysis of Cre activity of both β3-floxed/Tie1Cre and β3-floxed/Pdgfb-iCreERT2 
positive aortic explants excluded this hypothesis by showing equal distribution of 
Tomato Cre fluorescence along the entire length of aortic sprouts. 
 
Interestingly, VEGF aortic ring angiogenesis was enhanced in presence of 
constitutive endothelial β3-integrin deletion (phenocopying β3 knockout aortic rings - 
Reynolds et al., 2004). This might be partially explained by the complexity of the in 
vivo angiogenic responses in the tumour milieau, whereas the ex vivo aortic ring 
model is a more defined microenviroment (Baker et al., 2011) that largely excludes 
inflammatory and immune cells, although the involvement of macrophages has been 
reported  (Gelati et al., 2008).  This helps discriminate the contribution of off-target 
cells in determining the in vivo phenotype.   
 
Importantly, β3-integrin is expressed by different cell types, all of which can contribute 
to tumour angiogenesis, particularly bone marrow derived cells (Robinson and 
Hodivala-Dilke, 2011). Considering the leakiness of the Tie1 promoter on 
hematopoietic cells (Gustafsson et al., 2001) and their role in tumour angiogenesis 
as demonstrated by the rescue of the KO and DiYF angiogenic phenotypes by wild-
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type bone marrow transplants; I would speculate the effect of inducible β3-integrin 
deletion is endothelial cell specific (as observed both in vivo and ex vivo in the Pdgfb 
model), whereas what happens with its long term deletion clearly implicates other 
non-endothelial cells in mediating the antiangiogenic effects; thereby explaining the 
difference in the ex vivo and in vivo phenotype in the constitutive model. 
 
CONCLUSIONS 
 
In this chapter, I have shown that:  
 
• ex vivo VEGF-dependent angiogenesis is reduced by inducible BUT 
NOT constitutive loss of endothelial β3-integrin; 
 
• the ex vivo efficiency of Cre-induced β3-integrin deletion and the ex vivo 
pattern of Cre activity are similar in the Tie1 Cre and Pdgfb-iCreERT2 
models; 
 
• extending the length of β3-integrin deletion abrogates the inhibitory 
effect arising from its inhibition in the aortic ring model; 
 
• an inducible β3-integrin endothelial deletion has no effect when 
microvessel sprouting  has already begun. 
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5. MECHANISTIC ANALYSIS OF THE ROLE OF ENDOTHELIAL 
β3-INTEGRIN: IN VITRO STUDIES 
 
The two transgenic models I have described so far differ from each other in the timing 
of endothelial β3-integrin deletion. On whole, the results suggest that: (1) the 
expression of the molecule is required early on in primary tumour growth and 
angiogenesis; (2) long-term suppression of the molecule leads to β3-integrin 
independent escape mechanisms, taking over in the early stages of primary tumour 
growth; and (3) already established tumours have a decreased need for endothelial 
β3 integrin expression.  
 
To explore the potential mechanisms underlying some of these conclusions, I 
investigated VEGF-induced endothelial cell signalling, proliferation and migration, 
which are crucial components of the initial phases of angiogenic sprouting (Carmeliet, 
2000; Risau, 1997). I carried out these experiments in vitro using immortalized 
endothelial cells isolated from the lungs of Tie1Cre and Pdgfb-iCreERT2 animals for 
the reasons which will be discussed in paragraph 5.1.1.  
 
In this Chapter, I will describe some of the cellular and molecular changes I found in 
the two Cre models which correlated with the phenotypic differences described in 
previous chapters. 
 
RESULTS AND FIGURES 
 
5.1 In vitro cellular differences between the two Cre transgenic models  
 
I decided to investigate endothelial cell behaviour in vitro in order to characterize the 
cellular and molecular differences which may account for the in vivo phenotypic 
differences observed between inducible versus constitutive deletion of endothelial 
β3-integrin; differences which may help explain why long-term genetic inhibition of 
the molecule leads to “treatment escape”. 
 
5.1.1 Why use immortalized rather than primary endothelial cells? 
 
Due to their slow growth and limited capacity to divide in culture, it is difficult to obtain 
sufficient quantities of primary endothelial cells to perform the in vitro analyses I 
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needed to address mechanistically the time dependent differences observed in the 
two transgenic models. I therefore opted to immortalize lung endothelial cells via 
polyoma-middle-T-(PyMT) antigen retroviral infection (May et al., 2005).  Being aware 
of the potential issues associated with interpreting the findings from these cells (e.g. 
phenotype stability and potentially altered behaviour in culture), I routinely monitored 
cell morphology, compared cells at similar passages (and not older than passage 15), 
and checked for expression of a number of endothelial cell markers (VEC, CD31, 
ICAM-2) (Figure 5.B, 5.1C).  All cells appeared to maintain their endothelial cell 
identity and phenotypic characteristics over multiple passages in culture (Figure 
5.1A). 
 
5.1.2 Surface expression of endothelial integrin and adhesion properties 
 
Sprouting angiogenesis is dependent on the regulation of integrin expression 
(Avramides et al., 2008). Given the differences in angiogenic responses between β3-
floxed/Tie1-Cre and β3-floxed/Pdgfb-iCreERT2 models, it was conceivable to ask 
whether β3-integrin deletion changed the surface expression pattern of other integrin 
subunits, which might lead to changes in endothelial cell behaviour or function. 
Therefore, the expression and function of several other endothelial integrins was 
analysed.  
 
I used flow cytometric analyses to quantify the surface expression of endothelial α 
(α1, α2, α5, αv)  and β (β1, β3) integrin subunits (Figure 5.2A) in β3-floxed/Tie1Cre 
and β3-floxed/Pdgfb-iCreERT2 positive and negative endothelial cells. Whilst α2 
integrin levels appeared to decrease in Cre positive cells from both models, no 
significant changes in expression were detected in any of the other integrin subunits 
I examined (except for β3-integrin which decreased, as expected, in Cre positive 
endothelial cells). These findings suggest that integrin subunit expression at the cell 
surface was not altered by either an inducible or constitutive β3-integrin deletion.  
 
Since I was unable to detect surface expression of β5-integrin, I analysed its total 
level by Western blot. Interestingly, a significant decrease of this integrin subunit was 
observed in β3-floxed/Tie1Cre positive endothelial cells compared to β3-floxed/Tie1-
Cre negative endothelial cells; this difference was not observed in β3-floxed/Pdgfb-
iCreERT2 positive endothelial cells (Figure 5.2B). It would be tempting to speculate 
that cnstitutive endothelial deletion of β3-integrin is associated with a reduction in the 
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total level of β5-integrin expression, though it remains to be determined whether this 
translates to changes at the surface.  
 
Integrins are allosteric molecules that can exist in activated and non-activated states 
(Avramides et al., 2008), and even when expressed at the cell surface, their 
expression levels do not necessarily predict their activity. To test whether endothelial 
integrin function was affected by the absence of β3-integrin, adhesion capacity was 
tested on several extracellular matrices. Having observed minimal changes in the 
profile on surface integrin in the absence of β3-integrin, I did not expect to find 
significant differences in adhesion to extracellular matrix components, except for 
vitronectin, the canonical ligand of αvβ3-integrin.   
 
Adhesion to collagen I, fibronectin, laminin I and vitronectin was quantified in β3-
floxed/Tie1Cre and β3-floxed/Pdgfb-iCreERT2 positive and negative endothelial cells. 
BSA was used as a negative control and the degree of adhesion was expressed as 
a percentage of relative adhesion to fibronectin (Figure 5.2C). The data confirmed 
that endothelial specific β3-integrin deletion had no effect on adhesive properties to 
collagen I, fibronectin and laminin I. In contrast adhesion to vitronectin was 
significantly impaired. Similar results were obtained in both transgenic models 
supporting the conclusion that adhesion was not affected by the genetic deletion of 
β3-integrin.   
 
These data suggest the differences observed between the two transgenic models in 
vivo are not related to either changes in integrin expression at the cell surface (with 
the possible exception of β5-integrin)  or to changes in overall matrix adhesion. 
 
5.1.3 VEGF-induced migration and proliferation 
 
Sprouting angiogenesis involves the migration and proliferation of endothelial cells in 
response to growth factor signals (Carmeliet, 2000; Risau, 1997).  Given that β3-
integrin has been generally implicated in regulating both of these processes 
(Avramides et al., 2008), I decided to examine whether constitutive or indicible β3-
integrin deletion in endothelial cells affected their in vitro migratory responses and/or 
proliferative behaviour to VEGF.   
 
2D migration was examined by performing scratch wound healing assay on β3-
floxed/Tie1-Cre and β3-floxed/Pdgfb-iCreERT2 endothelial cell monolayers in the 
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presence or absence of VEGF stimulation. The scratch wound healing assay allows 
analysis of 2D in vitro non directional migration in response to a specific stimulus over 
time (until the scratch closes). VEGF treatment enhanced wound closure in both β3-
floxed/Tie1Cre positive and negative endothelial cells, but no differences were noted 
when comparing them to each other (Figure 5.3A). In contrast, VEGF-induced wound 
closure in β3-floxed/Pdgfb-iCreERT2 positive endothelial cells was significantly 
reduced in comparison to β3-floxed/Pdgfb-iCreERT2 negative endothelial cells 
(Figure 5.3A). 
 
Proliferation of β3-floxed//Tie1Cre and β3-floxed//Pdgfb-iCreERT2 endothelial cells 
was assessed over 48 hours in presence and absence of VEGF stimulation. Cell 
growth was measured indirectly as a function of the metabolic conversion of MTT 
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to a chromogenic 
substrate which was then solubilized and quantified by optical density.  No significant 
changes in proliferative rate were noted in either Cre model, when comparing Cre 
negative to Cre positive cells. Nor did I noted any differences when comparing the 
two Cre models to each other. This suggested that endothelial β3-integrin expression 
is dispensable for initiating the proliferative process (Figure 5.3B).  
 
Collectively, these results report a role for endothelial β3-integrin in promoting VEGF-
mediated cell migration, but not cell proliferation, in vitro. The effects on migration are 
seemingly dependent on the timing of the deletion. The inducible deletion of β3 
integrin in endothelial cells impaired 2D migration, but the impairment was overcome 
if the expression of the molecule was suppressed long term. 
 
5.2 In vitro molecular differences between the two Cre transgenic models  
 
5.2.1 VEGFR2 analysis: total, surface, and phosphorylated levels 
 
Aside from the well-established role of VEGF/VEGFR2 in endothelial cell proliferation 
and migration (Cebe-Suarez et al., 2006; Shibuya and Claesson-Welsh, 2006), 
another important function of αvβ3-integrin is the regulation of VEGFR2 recycling 
back to the cell surface (Caswell et al., 2009).  
 
Thus, I hypothesised that the differences in VEGF-mediated angiogenic responses 
between inducible versus constitutive deletion of endothelial β3-integrin might be 
reflected in a change in VEGFR2 expression at the cell surface and/or in its function.  
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VEGFR2 expression and activity were analysed in β3-floxed/Tie1Cre and β3-
floxed/Pdgfb-iCreERT2 endothelial cells following VEGF stimulation. Western blot 
analyses showed that total levels of VEGFR2 expression did not change upon 
endothelial-specific deletion of β3-integrin, regardless of the Cre driving the deletion 
(Figure 5.4B).  
 
I further characterised VEGFR2 function by analysing its phosphorylation at tyrosine 
1175 (Y1175) within the intracellular kinase domain, which has been extensively 
characterised as an important site in regulating intracellular downstream signalling 
pathways via phospholipase PLCγ (as described in paragraph 1.4.2). β3-
floxed//Tie1Cre and β3-floxed/Pdgfb-iCreERT2 endothelial cells were stimulated with 
VEGF and phosphorylated (Y1175) levels of VEGFR2 were assessed by Western 
blot (Figure 5.3B). β3-floxed//Pdgfb-iCreERT2 positive endothelial cells displayed a 
reduction in VEGF-induced VEGFR2 phosphorylation at Y1175; whereas no changes 
were observed in β3-floxed/Tie1-Cre positive endothelial cells, suggesting that 
VEGFR2 activity diminished only when endothelial β3 integrin was deleted acutely. 
 
Total expression levels may not reflect difference in expression at the cellular surface 
where receptors are meant to signal upon ligand binding. To address this point, 
surface levels of VEGFR2 were analysed by flow cytometry.  A small but significant 
(and similar to that observed in β3 knockout endothelial cells included as control) 
increase in surface expression of VEGFR2 was observed in β3-floxed//Tie1Cre 
positive endothelial cells compared withβ3-floxed//Tie1Cre negative endothelial cells 
(Figure 5.4A). However, surface VEGFR2 levels were similar when comparing β3-
floxed/Pdgfb-iCreERT2 positive and negative endothelial cells, suggesting that 
VEGFR2 expression was increased only when β3-integrin was deleted constitutively 
in endothelial cells. It is conceivable that this small increase contributes to the 
enhanced in vitro responses observed in β3-floxed/Tie1Cre positive endothelial cells 
(see below), though it is unclear why this did not correspond to an increase in 
VEGFR2 phosphorylation. 
 
Overall, these results highlight the plasticity of the cross-talk between β3-integrin and 
VEGFR2 in presence of VEGF in endothelial cells whereby the its inducible deletion 
impaired receptor signalling; whereas its constitutive one is partially compensated for 
by increased receptor surface expression of VEGFR2.  
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5.2.2 VEGF/VEGFR2 signalling analysis 
 
Given that my results showed a difference in VEGFR2 phosphorylation in the 
presence of acute deletion of β3-integrin in endothelial cells, I examined in greater 
detail VEGFR2 signalling (as described in paragraph 1.4.2) in an attempt to 
determine which pathways were affected. One of the main VEGFR2 downstream 
signalling pathways is the MAPK/ERK pathway.  
 
Therefore, I examined ERK1/2 levels (both total and phosphorylated) by Western blot 
analyses in a VEGF-stimulation time course in β3-floxed/Tie1Cre and β3-floxed 
/Pdgfb-iCreERT2 endothelial cells. ERK1/2 phosphorylation was enhanced in β3-
floxed/Tie1Cre positive compared to β3-floxed/Tie1Cre negative endothelial cells, but 
suppressed in β3-floxed/Pdgfb-iCreERT2 positive endothelial cells (Figure 5.4B). As 
for other intracellular signalling molecules, I further evaluated phosphorylated and 
total levels of c-Src and PLCɣ (as described in paragraph 1.4.2) by Western blot 
analyses in a VEGF-time course. No significant changes were noted between β3-
floxed/Tie1Cre and β3-floxed/Pdgfb-iCreERT2 positive and negative endothelial cells 
in either total or phosphorylated levels of c-Src or PLCɣ (Figure 5.4A). 
 
I therefore focused my analyses on the VEGFR2 downstream effectors Focal 
Adhesion Kinase (FAK) and stress-activated protein kinase-2/p38 (SAPK2/p38). FAK 
is a non-receptor protein-tyrosine kinase which acts as point of convergence of 
VEGF/VEGFR2 and integrin-mediated signals for migration (Zachary and Gliki, 
2001). Interestingly, I detected a reduction in the levels of total FAK in β3-
floxed/Tie1Cre positive endothelial cells compared to β3-floxed/Tie1Cre negative 
endothelial cells (Figure 5.4A). Since it has been recently shown that reduced FAK 
levels in FAK heterozygous mice display an imbalance in FAK phosphorylation at 
tyrosine 397 (Y397) and tyrosine 861 (Y861), which correlates with enhanced tumour 
growth and angiogenesis (Kostourou et al., 2013), I expanded my analyses to 
examine these phosphorylation sites of FAK.   
 
Western blot analyses indicated that no changes in FAK expression or 
phosphorylation were noted in β3 flox/flox/Pdgfb-iCreERT2 Cre positive endothelial 
cells when comparing them to their Cre negative counterpart (Figure 5.6A).  However, 
total FAK levels were reduced by 50% in β3-floxed/Tie1Cre positive endothelial cells 
when compared to β3-floxed/Tie1Cre negative endothelial cells, as were levels of 
phosphorylated Y397 (Figure 5.6A). On opposite, the levels of phosphorylated Y861 
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were similar between the two cell lines, suggesting that the misbalance in tyrosine 
phosphorylation that occurs in FAK heterozygous mice was partially recapitulated by 
a long term loss of endothelial β3-integrin. Importantly, immunohistochemical 
analysys of FAK expression in tumour vessels displayed the same result of reduced 
total FAK levels in β3-floxed/Tie1Cre positive, but not from β3-floxed/Pdgfb-iCreERT2 
positive tumours (Figure 5.6B).  With respect to SAPK/p38, no significant changes 
were noted between β3-floxed/Tie1Cre and β3-floxed/Pdgfb-iCreERT2 positive and 
negative endothelial cells in either total or phosphorylated levels (Figure 5.4A). 
 
These findings suggest that long-term deletion of endothelial β3-integrin leads to an 
increase in ERK phosphorylation, a reduction in FAK expression and a misbalance 
in FAK phosphorylation. Whilst still correlative (I have not tested the functional 
significance of these changes) these molecular changes may account for possible 
mechanisms of escape from long term genetic inhibition of β3-integrin. 
 
5.3 The differences observed in β3-integrin acutely deleted endothelial cells are 
abolished by long OHT treatment in vitro  
 
Given that the two transgenic models appear to mostly differ in the amount of time 
that β3 integrin has been deleted, extending the time of its deletion by long OHT 
treatment in the inducible model should abrogate the in vitro differences associated 
with its inducible deletion. To investigate further the time dependency of the 
differences noted above, I examined many of the same parameters in endothelial 
cells isolated from long OHT β3-floxed Pdgfb-iCreERT2 mice. 
 
5.3.1 Molecular differences upon long OHT treatment  
 
Flow cytometric analyses of endothelial integrin (α1, α2, α5, αv, β1, and β3) subunit 
expression levels were performed on β3-floxed/Pdgfb-iCreERT2 lung endothelial cells 
which had been isolated from 33-day OHT treated mice. No significant changes were 
noted when comparing long OHT β3-floxed/Pdgfb-iCreERT2 positive to long OHT β3-
floxed/Pdgfb-iCreERT2 negative endothelial cells (Figure 5.5A). On the other hand, 
Western blot analyses revealed a significant reduction in total levels of β5 integrin in 
β3-floxed/Pdgfb-iCreERT2 positive endothelial cells, mimicking what I observed in β3-
floxed/Tie1Cre positive endothelial cells (Figure 5.5A).  
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I further assessed VEGFR2 expression and activity by Western blot in long OHT β3 
β3-floxed/Pdgfb-iCreERT2 endothelial cells. Cells were stimulated with VEGF and 
protein lysates were Western blotted for phosphorylated (Y1175) VEGFR2 and then 
reblotted for total VEGFR2. Total VEGFR2 levels were unchanged between the two 
genotypes, as were phosphorylated VEGFR2 levels (Figure 5.6C). 
 
In parallel, flow cytometry was performed to quantify surface expression levels of 
VEGFR2 in long OHT β3-floxed/Pdgfb-iCreERT2 endothelial cells. Similarly to what 
was noted in β3-floxed/Tie1Cre positive endothelial cells, long OHT β3-floxed/Pdgfb-
iCreERT2 positive endothelial cells displayed increased VEGFR2 surface expression 
when compared to their Cre negative counterparts (Figure 5.6C).  
 
Likewise, I examined total and phosphorylated levels of ERK1/2 and FAK proteins by 
Western blot analyses in long OHT β3-floxed/Pdgfb-iCreERT2 endothelial cells over 
a time course of VEGF stimulation. Protein lysates were Western blotted for 
phosphorylated ERK1/2 and phosphorylated (Y397 and Y861) FAK, then reblotted 
for total ERK1/2 and total FAK. Densitometric quantification of phosphorylated ERK 
1/2 levels did not show any significant difference between long OHT β3-floxed/Pdgfb-
iCreERT2 positive and negative endothelial cells (Figure 5.6D). In contrast, total FAK 
levels showed a significant decrease in long OHT β3-floxed/Pdgfb-iCreERT2 positive 
endothelial cells compared to long OHT β3-floxed/Pdgfb-iCreERT2 negative 
endothelial cells. Moreover, the ratio between phosphorylated Y397 and Y861 was 
affected in long OHT β3-floxed/Pdgfb-iCreERT2 positive endothelial cells: 
phosphorylated Y397 decreased, but phosphorylated Y861 did not (Figure 5.7A). 
Consistently immunohistological analysis of tumour vessels revealed the same result 
of reduced total FAK levels in tumour vessels from long OHT β3-floxed/Pdgfb-
iCreERT2 positive tumours compared to long OHT β3-floxed/Pdgfb-iCreERT2 negative 
tumours (Figure 5.7B). 
 
To summarize, while the endothelial β3-integrin inducible deletion, driven by the 
Pdgfb-iCreERT2 promoter, resulted in reduced VEGFR2 phosphorylation at Y1175, 
following long OHT treatment this difference was no longer observed.  Moreover, long 
OHT β3-floxed/Pdgfb-iCreERT2 positive endothelial cells showed decreased total 
expression levels of β5 integrin, enhanced VEGFR2 surface levels, reduced FAK 
expression and misbalanced FAK phosphorylation; all of which seemingly 
phenocopied what was observed with constitutive endothelial β3-integrin deletion 
driven by the Tie1Cre promoter (as summarized below).  
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Taken together, these results represent compelling evidence supporting the 
conclusion that the timing of endothelial β3-integrin deletion is important in 
determining endothelial cell intracellullar signalling in response to VEGF stimulation. 
Extending the time during which β3-integrin has been deleted by lengthening the OHT 
treatment of β3-floxed/Pdgfb-iCreERT2 mice prior to the isolation of endothelial cells, 
abolished the inhibitory phenotype otherwise associated with β3-integrin inducible 
deletion. Indeed, in many respects, angiogenic responses in long OHT β3-floxed 
/Pdgfb-iCreERT2 positive endothelial cells mimicked those observed in β3-floxed 
/Tie1Cre positive endothelial cells. 
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DISCUSSION 
 
5.4 αvβ3 integrin and VEGFR2 in angiogenesis: a complex marriage  
 
The cross-talk between αvβ3-integrin and VEGFR2 on endothelial cells is crucial for 
angiogenesis. In fact it has been shown that αvβ3-integrin and VEGFR2 interact 
synergistically: VEGFR2 activation induces αvβ3-integrin tyrosine phosphorylation 
which, in turn, is essential for VEGF-induced receptor activation and downstream 
signalling (Somanath et al., 2009). The importance of this crosstalk has been shown 
both in vivo, in  β3 knockout mice whereby the  phenotype of enhanced tumour growth 
and angiogenesis could be normalized by administering VEGFR2 inhibitors 
(Reynolds et al., 2002); and in vitro, in β3 knockout endothelial cells where VEGFR2 
expression and signalling were found to be enhanced (Reynolds et al., 2004). 
Together this suggests that VEGFR2 dependent mechanisms can establish to 
compensate for the absence of αvβ3-integrin. 
 
Other studies have also described a functional mechanistic link between integrin 
genetic ablation and VEGFR2 expression and function.  For example, Germain et al. 
(2010) showed that α6-integrin knockout endothelial cells display increased levels of 
VEGFR2 and VEGF-mediated downstream ERK1/2 activation. In addition, da Silva 
et al. (2010) demonstrated that α3-ntegrin knockout endothelial cells regulate  
endothelial-VEGF production, which ultimately controls of VEGFR2 expression. 
Therefore, VEGFR2 was a likely candidate involved in the mechanisms leading to the 
escape from long term deletion of endothelial β3-integrin. Despite no differences in 
total VEGFR2 expression levels (in tumour and lung endothelial cells as well as in 
aortae explants), my findings showed small but significant increases in surface 
expression levels of VEGFR2 in endothelial cells isolated from β3-floxed/Tie1Cre 
animals and from long OHT β3-floxed/Pdgfb-iCreERT2.  
 
Receptor trafficking has been acknowledged as being essential for modulating 
temporal and spatial patterns of RTK signalling (Berger and Ballmer-Hofer, 2011). 
One may speculate that endothelial cells compensate for the long term loss of β3-
integrin by increasing the amount of VEGFR2 receptor present at the surface of the 
cell and, as such, its responsiveness to VEGF stimulation.  Although I have not tested 
it directly, there is precedent for suggesting that VEGFR2 trafficking is responsible 
for the changes I have noted in constitutively β3 integrin deleted cells: in fact, it has 
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been shown that the mechanism by which low doses of CILENGITIDE (an αvβ3/αvβ5 
inhibitor) elicit pro-angiogenic responses is by increasing the recycling at the cell 
surface of VEGFR2 via internalization in Rab11 vesicles (Reynolds et al., 2009)  
Note, I did attempt to examine VEGFR2 endocytosis and recycling directly but was 
never successful in my attempts to get the assays to work. 
 
In contrast, VEGFR2 phosphorylation appeared to be reduced (likely as a result of 
decreased interactions between αvβ3-integrin and VEGFR2), upon inducible but not 
constitutive endothelial β3-integrin deletion; suggesting the absence of αvβ3-integrin 
is compensated over time to restore VEGFR2 signalling. This was further sustained 
in lung endothelial cells isolated from long OHT β3-floxed/Pdgfb-iCreERT2 mice 
where extending the duration of endothelial β3-integrin deletion was sufficient to 
rescue the phenotype of reduced  VEGFR2 phosphorylation. Consistent with data 
from Germain et al. (2010), increased surface expression of VEGFR2 correlated with 
enhanced phosphorylation of ERK 1/2 (a known downstream effector VEGFR2 
signalling) in endothelial cells isolated from β3-floxed/Tie1Cre and from long OHT β3-
floxed/Pdgfb-iCreERT2 mice. In short, the early preventive benefit observed with 
inducible deletion of endothelial β3-integrin is transient and may be circumvented, at 
least in part, by enhancing VEGFR2 surface expression and function. 
 
Notably though, I did not detect any increase in proliferation in VEGF stimulated β3 
β3-floxed/Tie1Cre and long OHT β3-floxed/Pdgfb-iCreERT2 endothelial cells, which 
might have been expected as a result of enhanced VEGFR2/ERK1/2 signalling. It 
could be argued that this could be an artifact of immortalization. However, in a similar 
vein, β3-integrin DiYF mutant endothelial cells do not show any defects in cell 
proliferation. Although it has been used to study proliferation in endothelial cells in 
culture (Kostourou et al., 2013; Huang et al., 2005) it could be argued that the MTT 
assay I employed to assess proliferation is indirect, as it is an index of cell metabolic 
activity. Perhaps this method is not sensitive enough, or I have not extended my 
analyses over a long enough time frame to detect subtle changes in proliferation. If I 
had time to extend these studies it would be interesting to compare these results with 
other experimental approaches such as BrdU incorporation or Propidium Iodide DNA 
staining, and to extend the time frame beyond the 48 hours.  
 
Changes in VEGFR2 activity may help explain the molecular basis of the angiogenic 
changes observed with inducible and constitutive β3-integrin deletion in endothelial 
cells, but do not exclude the possibility that there are other mechanisms involved. 
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Further molecular signalling analyses based on Western blot revealed decreased 
expression and misbalanced phosphorylation of FAK in β3-floxed/Tie1Cre and long 
OHT β3-floxed/Pdgfb-iCreERT2 positive endothelial cells compared to Cre negative 
endothelial cells, suggesting it as a molecular adaptation occurring over time as a 
result of β3-integrin deletion.  This was strengthened by the same result of reduced 
total FAK levels in tumour vessels from β3-floxed/Tie1Cre and long OHT β3-floxed 
/Pdgfb-iCreERT2 mice. With respect to FAK phosphorylation, the results observed are 
in line with Kostourou et al. (2013), who have recently shown that reduced FAK levels 
in FAK heterozygous mice results in an imbalance in the ratio of phosphorylated FAK 
at Y397 and Y861 sites (whereby the ratio Y397/total FAK decreases while Y861/total 
FAK does not). This appears to ultimately lead to enhanced tumour growth and 
angiogenesis.  
 
Full phosphorylation of VEGFR2 induced by synergistic signalling interplay between 
VEGFR2 and αvβ3-integrin has shown to be required for the activation of cell motility 
pathways involving FAK and SAPK2/p38 in endothelial cells (Masson-Gadais et al., 
2003). Moreover, Tavora et al. (2010) have shown that endothelial FAK deficiency 
reduced VEGF-induced migration. Despite no difference in p38 levels (total and 
phosphorylated) across the three genotypes, it was reasonable to predict that the 
decrease in total FAK levels associated with constitutive deletion of endothelial β3-
integrin may affect endothelial cell migration.  
 
As expected, VEGF treatment enhanced 2D migration in scratch wound closure 
assays in β3-floxed/Tie1Cre positive endothelial cells; whereas it significantly 
inhibited it in β3-floxed/Pdgfb-iCreERT2 positive endothelial cells. Although this does 
not reflect what might be predicted based on the role of FAK in endothelial cell 
migration, it still could be explained by picturing a more complex scenario of 
molecular adaptation whereby different level of expression might regulate biological 
outcomes. Thus, wild-type levels of endothelial β3-integrin can positively regulate 
migration independently of FAK, in fact its acute deletion impairs 2D migration without 
any effects on FAK (neither expression nor phosphorylation). However, over time, 
β3-integrin loss can be circumvented by reducing FAK levels, whose partial loss has 
been shown to enhance angiogenic responses (Kostourou et al., 2013). 
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5.5 Molecular compensation of other endothelial integrins  
 
A conceivable consequence of the genetic deletion of the β3-integrin subunit would 
be the increased expression of other members of the integrin family, as a result of 
functional redundancy. It has been shown, for example, that αvβ5 integrin can 
compensate for the loss of α5β1 integrin (Yang et al., 1996). Most endothelial 
integrins I examined were unchanged in response to β3-integrin deletion (in both Cre 
models).  I did notice changes in α2 integrin levels which decreased in Cre-positive 
endothelial cells from both models.  As of yet, I have no explanation for this finding.    
However it might be interesting to explore because also α2β1 seems to play opposite 
functions: it is known to promote VEGF-driven signaling, tumor angiogenesis (Senger 
et al., 2002; Hong et al., 2004) and developmental angiogenesis (San Antonio et al., 
2009) it has also been repoterted that its ablation resulted in enhanced  angiogenesis 
in skin wound healing and sponge implants. 
 
Interestingly, however, β5-integrin (albeit total levels, as assessed by Western blot 
analysis because I was unable to detect its surface expression) was reduced in β3-
floxed/Tie1-Cre positive endothelial cells and long OHT β3-floxed/Pdgfb-iCreERT2 
positive endothelial cells, but not in β3-floxed/Pdgfb-iCreERT2 positive endothelial 
cells. The reduction of β5-integrin has not been observed before in β3-integrin genetic 
deletion models. One hypothesis may be that over time, β3-integrin is needed to 
stabilize β5-integrin and as a consequence of β3-integrin constitutive deletion, β5-
integrin levels decrease. The functional consequences of this loss have not been 
directly tested and the observation is, to date, strictly correlative.   
 
However, considering that β3 and β5-integrins seem to have discrete roles in 
angiogenesis (Friedlander et al., 1995), the concomitant loss (reduction) of both 
integrin heterodimers is surprising and may be significant. It is known that unligated 
integrins initiate apoptosis selectively via caspase-8 (Stupack et al., 2001).  This 
process, termed Integrin Mediated Death (IMD), occurs in response to the 
accumulation and apparent clustering of unligated integrins on the cell surface and it 
is a function of both the local microenvironment around the cell and the integrin 
‘‘repertoire’’ expressed by that cell (Lathi et al., 2006). The depletion of both integrins 
may, therefore, benefit cell survival, and the prediction arising would be that reduced 
levels of αvβ5-integrin would be advantageous because a natural pathway that keeps 
angiogenesis in check has been removed.   
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Any one of the changes described above (and likely a combination of these and 
others yet discovered) could contribute to an escape from angiogenic inhibition 
directed against β3-integrin. Similarly to β3 knockout endothelial cells (Reynolds et 
al., 2004), constitutive deletion of endothelial β3-integrin resulted in increased surface 
expression of VEGFR2.  However, unlike the β3 knockout studies, constitutive 
deletion of endothelial β3-integrin does not result in enhanced pathological 
angiogenesis in vivo, thereby highlighting that this aspect of the knockout phenotype 
is primarily a result of β3-integrin deletion in non-endothelial cells. In fact, it ispartially 
rescued by restoring wild-type expression of β3-integrin in BMDCs through bone 
marrow transplants (Feng et al., 2008). 
 
Together, these findings emphasise the complexity of β3-integrin regulation and 
when developing translation approaches, one should take into consideration its cell 
specific targeting and possible compensatory changes resulting from its suppression. 
 
CONCLUSIONS 
 
In this chapter, I have shown that:  
 
• the inducible loss of endothelial β3-integrin impairs VEGF dependent 
2D-migration albeit not proliferation in vitro; 
 
• the constitutive deletion of endothelial β3-integrin leads to molecular 
changes in vitro in the form of increased surface expression and 
phosphorylation of VEGFR2, enhanced ERK 1/2 phosphorylation, 
reduced total expression of β5-integrin,  and reduced and misbalanced 
FAK phosphorylation; 
 
• the constitutive deletion of endothelial β3-integrin does not result in 
overcompensation by other endothelial integrin subunits. 
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6. DEVELOPING MOUSE MODEL OF SPONTANEOUS METASTASIS TO 
ADDRESS THE ROLE OF ENDOTHELIAL β3-INTEGRIN  
 
In the previous chapters, I examined the role of endothelial β3-integrin during the 
initial stages of tumour growth; however there is certainly precedence for exploring 
its role in later stages of tumour progression. Clinical evidence suggests  β3-integrin 
may play a role in metastatic spread as its expression positively correlates with 
tumour grade, and it has been found to be highly expressed by bone and lymphatic 
metastases from several types of primary tumours including melanoma, prostate, 
breast, cervical and pancreatic carcinomas (Desgrosseliers and Cheresh, 2010).  
 
In the current chapter, I will describe the development of a model of spontaneous 
metastasis to the lung in order to investigate the role of endothelial β3-integrin in 
tumour progression and metastasis.  In parallel to this model, I also exploited a breast 
carcinoma cell line which spontaneously metastasises to lung and bone, which was 
developed in the laboratory of Katherine Weilbacher at the Washington University of 
St Louis where I spent a summer internship period. Using these models, I was able 
to collect preliminary data suggesting that long-term endothelial specific deletion of 
β3-integrin has the potential to reduce metastases to the lung, despite no changes in 
primary tumour growth or angiogenesis. Furthermore, I attempted to elucidate the 
cellular and molecular pathways associated with this phenotype. Although the 
findings from these studies are still very preliminary, they are clearly encouraging. 
They show there is merit in further investigating the potential targeting of endothelial 
β3-integrin therapeutically to reduce tumour metastasis. 
 
RESULTS AND FIGURES 
 
6.1 Mouse models of metastasis 
 
In vivo standard models of spontaneous metastasis include ectopic (subcutaneous) 
or orthotopic transplantation of metastatic variants of established tumour cells lines 
in mice. These metastatic tumour cells can be either syngeneic or xenografts, in 
which case they need to be transplanted in immunocompromised mice. Such 
spontaneous metastases assays involve establishing a primary tumour, which is then 
allowed to grow and spread, especially if the primary tumour is surgically resected 
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(for reasons that will be explained in the paragraph 6.1.1) to metastasise to distant 
sites. 
 
Additionally, genetically engineered mouse models (GEMMs) whereby oncogenes 
such us Polyoma Middle T (PyMT) or SV40 T antigen (Tag) have been expressed 
under the control of mouse viruses, such as the Mouse Mammary Tumour Virus 
(MMTV) or endogenous tissue specific promoters such as the Rat Insulin Promoter 
(RIP) to induce the tumourigenic process spontaneously, have been developed to 
investigate several aspects of tumour biology, including metastatic spread (Francia 
et al., 2011). These models offer the advantge of generating syngeneic orthotopic 
tumours which mimic the progression of the disease from benign to invasive 
malignant tumours; but, importantly in immune competent hosts containing the 
vasculature and the stroma of the same species.  
 
Alternatively, metastatic tumour cells can be injected systemically in mice 
(experimental metastasis assay). Despite the advantage of requiring a shorter time 
for the evidence of metastases compared to spontaneous metastases models, 
experimental metastases assays circumvent the initial growth and dissemination 
phases, as a result of injecting tumour cells directly in the circulation through, for 
example, the tail vein. As a consequence, the analysis of the metastatic cascade is 
limited to post-extravasation steps. 
  
6.1.1 CMT19T F1  
 
Instead of exploting the B16 melanoma cell line which I had already used for my initial 
studies and which is widely used in experimental metastastases experiments, my 
initial approach was to develop an in vivo model that would allow spontaneous 
metastases formation in endothelial specific β3-integrin transgenic mice, yet avoid 
the shortcomings associated with experimental metastases assays.  
 
I moved to the CMT19T tumour cell line (which was used in previous chapters in 
parallel with B16F0 cells) and tried to derive a highly mestastatic variant. I achieved 
this through a single round of in vivo selection, which involved subctutaneous 
CMT19T tumour cell implantation followed by tumour resection and, finally, isolation 
of metastatic cells from the lung. The metastatic variant generated from the parental 
CMT19T cell line will be, hereafter, referred to as CMT19T F1.  
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The next step I took was to characterize the biological behaviour of CMT19T F1 cells 
in order to establish the experimental conditions which would give the highest number 
of metastases in the least amount of time. Because I wanted, at least initially, to focus 
soley on the role of endothelial β3-integrin in regulating metastasis, for the sake of 
simplicity and reduced experimental costs, a comparative characterisation was  
performed between β3-floxed/Tie1Cre negative and positive mice.  
 
Since I opted for subcutaneous tumour cell implantation, which is known to have a 
less efficient rate of metastatic spread compared to orthotopic transplants (Cruz-
Munoz et al., 2008), I maximized the chance of getting distant metastasis by 
performing surgical resection of the primary tumours. Surgical resection of the 
primary tumour prolongs mouse surivival and allows extra time for metastatic cells 
originating from the primary tumour to develop into established metastases at distant 
sites.  The kinetics of CMT19T F1 growth in β3-floxed/Tie1Cre negative and positive 
mice was monitored every other day starting from day 10 by taking external caliper 
measurements. As I observed with CMT19T cells, there was no difference in primary 
tumour growth of the F1 variant when comparing β3-floxed/Tie1Cre negative and 
positive mice (Figure 6.1A).   
 
Tumours were grown until they reached 1 cm3 (the limit set out in our Home Office 
Project Licence).  In both genotypes, this corresponded to approximately 20 days 
after initial tumour cell injection and neither genotype showed any adverse effects of 
carrying this level of tumour burden; thus this defined the timepoint for tumour 
resection. Finally, in order to determine the optimal timing for detecting metastatic 
outgrowth without compromising animal welfare, health was monitored daily. Lungs 
were harvested at the first signs of cachexia. In β3-floxed/Tie1Cre negative animals 
this was first noted 12 days after tumour resection. Therefore, this timing was used 
in all subsequent experiments. I was able to observe macroscopically evident lung 
metastases upon visual examination (Figure 6.1D). Lungs were then processed for 
Hematoxylin and Eosin (H&E) staining. Macroscopic examinations  did not reveal 
metastastic spread to any other organs. 
 
Overall, these data describe the devolopment of a metastatic carcinoma model 
obtained through the derivation of a metastatic variant of the CMT19T tumour cell 
line, the CMT19T F1. The use of this line was optimised to allow for  the development 
of overt lung metastases ~5 weeks after ectopic transplantation followed by surgical 
resection of the primary tumour.  
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6.1.2  B6 LV-1  
 
B6 LV-1 is a breast carcinoma cell line which has been established in the laboratory 
of Katherine Weilbaecher. MMTV-PyMT is a reliable model of metastatic breast 
cancer, which recapitulate the stages of breast cancer from benign and well-
differentiated adenoma to metastatic and poorly differentiated adenocarcinoma. 
Existing models of breast cancer primarily metastasise to lung, but bone is a more 
common site of metastasis in humans, and is associated with high morbidity and pain.  
This is the reason why the Weilbaecher lab has generated, through multiple rounds 
of in vivo selection, a C57BL/6 compatible MMTV-PyMT-derived transplant cell line 
(B6 LV-1), which spontaneously metastasises to bone. In this model, B6 LV-1 cells 
are orthotopically transplanted in the inguinal mammary fat-pad, tumour resection 
(mastectomy) is performed after 2 weeks and bone metastases appear in another 3-
5 weeks. Furthermore, B6 LV-1 cells are GFP and luciferase tagged, thus allowing 
tumour cell tracking both in vitro in histological sections and in vivo by bioluminescent 
imaging, whereby tumour burden and metastatic dissemination can be quantified and 
followed over time without the need to kill the animal.  
 
B6 LV-1 cells (kindly provided to us by Katherine Weilbaecher) are the first-ever 
model of breast cancer that spontaneously metastasise to bone. The initial aim was 
to investigate the role of endothelial β3-integrin in the two different metastases tumour 
models just described.  However, without in vivo imaging capabilites, which have only 
very recently become available at UEA, characterising the B6 LV-1 model proved 
difficult (however, see paragraph 6.3.1). I therefore mainly focused my studies on the 
CMT19T F1 model.  
 
6.2 Endothelial β3-integrin deletion reduces CMT19T F1 spontaneous, but not 
experimental, metastasis 
 
To study the effect of endothelial β3-integrin deletion on lung metastasis, β3-
floxed/Tie1Cre negative and positive mice were injected subcutaneously with 
CMT19T F1 carcinoma cells. Tumours were grown until day 20 and then surgically 
resected under anaesthesia. Primary tumours were histologically processed to 
analyse the degree of tumour angiogenesis.  After 12 days, both genotypes were 
sacrificed and lungs were inflated via a tracheal injection of 4% PFA prior to overnight 
fixation. Lungs were subsequently processed for histological analysis and 
metastases evaluation. 
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In parallel, experimental metastases experiments were performed by injecting 
CMT19T F1 tumour cells into the tail vein of β3-floxed/Tie1Cre negative and positive 
mice. Lungs were harvested and processed, as described above, 14 days post 
injection.   
 
6.2.1 The number of spontaneous CMT19T F1 lung metastases is reduced, but 
not their size or vascularisation, in the absence of endothelial β3-integrin 
 
The histological quantification of lung metastases based on H&E staining revealed a 
significant decrease in the number of spontaneous lung metastases in β3-
floxed/Tie1Cre positive mice compared to β3-floxed/Tie1Cre negative mice (Figure 
6.1B). I decided to further investigate this unexpected phenotype by evaluating the 
average size of metastatic outgrowths on H&E stained sections (Figure 6.1E).  In 
parallel, I also examined the degree of angiogenesis within the metastatic area by 
immunofluorescent staining. No difference was observed with respect to average 
metastasis size when comparing the two genotypes to one another (Figure 6.2A), 
suggesting that once CMT19T F1 cells had established colonies in the lungs, their 
growth proceeded at the same rate.  Similarly, the number of vessels associated with 
the lung metastatic area was similar in both genotypes (Figure 6.2B), thus suggesting 
that metastatic cells can equally make up their own vessels at distant sites,  
regardless of the presence of β3-integrin in the endothelium. Resected tumours were 
also analysed for angiogenic markers.  There was no difference in the degree of 
angiogenesis in CMT19T F1 primary tumours grown in β3-floxed/Tie1Cre positive 
mice compared to β3-floxed/Tie1Cre negative mice, a result which is consistent with 
the tumour volume data. 
 
Taken together, these results suggest that endothelial β3-integrin facilitates the 
process of spontaneous lung metastasis through a mechanism which is independent 
of angiogenic potential at the metastatic site. 
 
6.2.2 Tumour-Associated macrophages are reduced in the CMT19T F1 
metastatic lung when endothelial β3-integrin is absent 
 
Over the last decade, a growing body of literature has highlighted the importance of 
the tumour microenvironment in cancer progression. The tumour microenvironment 
contains many resident cell types, such as adipocytes and fibroblasts, but it is also 
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populated by migratory bone marrow derived cells, which can play pivotal roles in the 
progression and metastasis of tumours (Kaplan et al., 2005).  
 
Macrophages are myeloid cells which represent an important cellular component of 
the tumour microenvironment. It is well established that tumour associated 
macrophages (TAMs) induce tumour growth (Sica and Mantovani, 2011), so I asked 
whether their recruitment to the lung was involved in supporting the establishment of 
metastatic outgrowth, thus potentially contributing to the difference in metastases 
observed in β3-floxed/Tie1Cre mice. To test this hypothesis the macrophage 
infiltration in the metastatic lung tissue was quantified by F4/80 (a macrophage 
marker, Schmieder et al., 2012) immunofluorescent staining of lung histological 
sections (Figure 6.2D). The number of F4/80 positive macrophages present in the 
metastatic lung tissue was significantly reduced in β3-floxed/Tie1Cre positive mice 
compared to lungs from β3-floxed/Tie1Cre negative mice (Figure 6.2C), thus 
correlating with the reduced number of lung metastases.  
 
These preliminary observations imply that the loss of endothelial β3-integrin affects 
the tumour microenviroment at the site of metastases by reducing the number of 
tumour associated macrophages in the lung. 
 
6.2.3 Loss of endothelial β3-integrin is sufficient to affect lung metastasis  
 
In order to understand the cellular basis of metastatic phenotype described above, I 
addressed the contribution of endothelial β3-integrin in the process of metastatic 
dissemination by performing an experimental metastasis experiment. CMT19T F1 
tumour cells were injected via the tail vein into β3-floxed/Tie1Cre mice. 14 days after 
tumour cell injection, lungs were processed for metastases evaluation.  Sections of 
lung tissues were stained with H&E and metastases counted. The number of 
metastatic foci was not statistically different between the two genotypes (Figure 
6.1C), implying that, once in the circulation, tumour cells can equally invade and 
colonise the lung, regardless of the expression of β3-integrin on the endothelium. 
Moreover, the number of experimental metastases was lower than the number of 
spontaneous metastases that developed in the spontaneous model. 
 
From these data, I concluded that endothelial β3-integrin is dispensable for the 
process of lung colonization, but it is required for establishing a pre-metastatic niche 
in the lung during the growth of the primary tumour. It would be tempting to speculate 
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that endothelial β3-integrin exerts a pro-metastatic function through the regulation of 
macrophage infiltration at the metastatic site and, as such, seeds the lung 
microenviroment to make it more permissive for metastasis. Since the establishment 
of the pre-metastatic niche precedes tumour colonization, this would also explain why 
in an experimental metastasis setting the difference in the number of lung metastases 
was abolished, regardless of endothelial β3-integrin absence. 
 
6.3 In vivo and in vitro mechanistic analysis of the role of endothelial β3-
integrin in metastasis  
 
In order to identify the mechanistic link underlying the role of endothelial β3-integrin 
in metastasis, I formulated two different, but not mutually exclusive, hypotheses 
based on my preliminary data and evidence from the literature: first, according to 
Paget’s theory of “Seed and Soil” (Paget 1989),  the primary tumour while growing is 
already sending out signals to prepare the soil to make it more permissive for 
metastatic tumour cells to grow at distant sites (a process referred to as “pre-
metastatic niche formation”) and/or second, the reduced number of lung metastases 
observed in β3-floxed/Tie1Cre positive mice mice might be due to a reduced number 
of metastatic cells leaving the primary tumour. 
 
6.3.1 F4/80+ macrophages are reduced in the CMT19T F1 pre-metastatic lung 
when endothelial β3-integrin is absent 
 
Since I observed a difference in the macrophage infiltration in the metastatic lung, I 
wanted to know if this difference was already established before metastases 
appeared in the lung, therefore suggesting macrophages were involved in favouring 
a pro-metastatic microenviroment. It has previously been shown that the recruitment 
of myeloid cells can predetermine lung metastases (Hiratsuka et al., 2006); therefore, 
with respect to my first hypothesis, I determined whether endothelial β3 integrin 
played a role in seeding the lung via mobilization of myeloid cells.  
 
In order to achieve this, I quantified the myeloid cell population in the lungs of 
CMT19T F1 tumour bearing mice during the pre-metastatic phase (i.e. at the time of 
tumour resection). Flow cytometric analyses of the pre-metastatic lung (Figure 6.3A) 
showed no difference in the total amount of infiltrating CD45+/CD11b+ myelo-
monocytes when comparing β3-floxed/Tie1Cre negative and positive mice (Figure 
6.3B).  However, when analysing specifically the macrophage subset (F4/80+ cells) 
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a significant difference became evident. The number of total F4/80+ macrophages 
was significantly reduced in the pre-metastatic lungs of β3-floxed/Tie1Cre positive 
mice (Figure 6.3C). This result agrees with the previously observed difference in 
macrophage infiltration in the metastatic lung and suggests endothelial β3-integrin 
modulates macrophage homing to metastatic sites, thus generating a pro-metastatic 
microenviroment.  
 
To recapitulate, reduced macrophage infiltration in the absence of endothelial β3-
integrin was observed before and once metastases had established in the lung and 
it correlated with a reduced number of metastatic foci. These observations are likely 
to indicate that endothelial β3-integrin is involved in the process of formation of a pre-
metastatic niche in the lung by promoting macrophage infiltration. 
 
6.3.2 Loss of endothelial β3-integrin within the tumour does not affect either 
vascular permeability, or circulating tumour cells in vivo 
 
My previous findings suggest that endothelial β3-integrin regulates metastases. I then 
asked whether endothelial β3 integrin was affecting tumour vascular permeability, 
which might lead to differences in the number of tumour cells entering the blood 
circulation. I investigated the effect on vessel permeability in vivo by performing FITC-
dextran perfusion assay and by quantifying blood tumour circulating cells at the time 
of tumour resection.  
 
Recent work from Jean et al. (2014) showed that inhibition of endothelial FAK did not 
alter primary tumour growth, but did result in reduced metastases in vivo by affecting 
primary tumour vascular permeability via VE-cadherin (VEC) barrier function. Since 
it is well established that FAK acts downstream of β3 integrin signalling, I wondered 
whether β3 integrin could affect tumour vascular permeability through a FAK/VEC 
dependent mechanism, thereby leading to decreased tumour cell extravasation in β3-
floxed/Tie1Cre positive mice. 
 
Increased vascular permeability causes endothelial cells to partially lose their close 
contacts and the endothelium becomes permeable to small proteins such as low-
molecular weight dextran. As such, FITC-dextran extravasation is considered a 
measure of vascular permeability (Eliceiri et al., 1999).  Day 20 B6 LV-1 tumour 
bearing β3-floxed/Tie1Cre negative and positive mice were injected systemically with 
low molecular weight FITC-dextran. 30 minutes later, specimens were harvested and 
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FITC-dextran was extracted by immersion in formamide buffer. The amount of FITC-
dextran in each tumour tissue sample was quantified by fluorescence emission at 
520 nm and normalized to tumour weight. No difference in tumour vascular 
permeability was detected when comparing B6 LV-1 tumours grown in the two 
genotypes (Figure 6.4A), suggesting the endothelial β3-integrin deletion was not 
altering tumour vascular permeability. 
 
In parallel, to test whether the loss of endothelial β3-integrin affected the number of 
circulating tumour cells the degree of circulating B6 LV-1 (luciferase tagged) cells 
was quantified by luciferase semiquantitative-PCR from nucleated cells isolated from 
peripheral blood. In agreement the with tumour permeability data, the relative number 
of tumour circulating cells indirectly measured by the quantification of luciferase gene 
expression showed no statistical difference between blood samples from β3-
floxed/Tie1Cre negative and positive mice (Figure 6.4B), suggesting that endothelial 
β3 integrin is not required for tumour cell extravasation during the metastatic process. 
 
Taken together these data help exclude the premise that endothelial β3-integrin 
exerts a pro-metastatic role by increasing the permeability of the vasculature in the 
primary tumour or by enhancing the process of tumour cell extravasation from the 
primary tumour, which would then result in an increased number of tumour cells in 
the circulation. Though negative, these results are very important because they help 
rule out two possible mechanisms contributing to the reduced metastatic potential 
observed in β3-floxed/Tie1Cre positive mice. 
 
I have presented preliminary data which are likely to imply a role for endothelial β3 
integrin in the establishment of a pre-metastatic niche.  However, I am fully aware 
that further investigation is needed. For example, it would be elegant to show that 
after systemic macrophage depletion the difference in lung metastasis is abolished. 
Moreover, it would be interesting to more fully characterize the immune cell infiltration 
in the pre-metastatic lung, as well as, investigate environmental changes in the pre-
metastatic lung by, for example, chemokine/cytokine and protease profiling (see 
DISCUSSION). 
 
6.3.3 VEC Y731 phosphorylation is affected by endothelial β3-integrin in vitro  
 
To address mechanistically how endothelial β3-integrin might affect macrophage 
recruitment to the pre-metastatic site, I moved to in vitro analyses. As the secondary 
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site in this model is the lung, endothelial cells isolated from the lung provided a 
realistic representation of the metastatic site. 
 
Recent work from Wessel et al. (2014) showed that different phosphorylation sites of 
VEC are involved distinctly and specifically in the induction of vascular permeability 
or leukocyte extravasation across the endothelium. In more detail, phosphorylation 
of VEC Y731 has been implicated in leukocyte transmigration and has a high baseline 
phosphorylation; while its de-phosphorylation, mediated by SHP-2, has been 
associated with an increase in leukocyte extravasation (Turowski et al., 2007; Wessel 
et al., 2014). In fact, Y731 phosphorylation has been shown to decrease by 50% 
following Tumour Necrosis Factor (TNF) stimulation of T cells and bone marrow 
derived cells, resulting in leukocyte extravasation (Wessel et al., 2014). Furthermore, 
in culture, VEC Y731 has been shown to be responsive to VEGF stimulation 
(Monaghan-Benson and Burridge, 2009). This evidence led me to hypothesise that 
endothelial β3 integrin can modulate macrophage extravasation to the lung via VEC 
Y731 phosphorylation.  
 
To investigate this hypothesis, quantification of phosphorylation of VEC Y731 
followed over a VEGF stimulation time course was performed by Western blot 
analyses on protein lysates from lung endothelial cells isolated from β3-
floxed/Tie1Cre mice. Interestingly, in β3-floxed/Tie1Cre negative lung endothelial 
cells, a significant reduction in the phosphorylation of VEC Y731 was observed over 
time (Figure 6.4C).  However, this change in VEC Y731 phosphorylation status did 
not occur in β3-floxed/Tie1Cre positive lung endothelial cells. 
 
This preliminary findings are likely to suggest that the absence of endothelial-β3 
integrin at metastatic sites causes the inability of VEC Y731 to dephosphorylate in 
response to VEGF and, as a consequence, endothelial junctions do not open to allow 
leukocyte extravasation. Therefore, the reduction in macrophage infiltration in 
presence of VEC Y731 at high levels is not conducive to tumour cell extravasation 
and therefore metastases are reduced. However, this is only one interpretation and 
our data, though promising, are not yet conclusive: in vitro adhesion and 
transmigration assays of macrophages across endothelium are essential to support 
this hypothesis, as well as the identification of the molecular player linking β3-integrin 
and VEC (see DISCUSSION). 
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DISCUSSION 
6.4 Metastasis: the real killer  
 
Metastasis is the leading cause of tumour related death, lung and bone being the 
most common site for metastasis in breast and prostate cancers. In the UK alone, 
12,000 women will die from breast cancer each year, the large majority as a result of 
metastatic disease (Eccles et al., 2013). In the US in 2014, one and a half million 
people were diagnosed with cancer and half a million died of cancer. This statistic 
reflects the 5 year overall survival index, which for cancer has been estimated to be 
66.1% in the latest 10 years (2004-2014) in the US. In other words 2/3 of people 
diagnosed with cancer are still alive after 5 years but the remaining 1/3 of them die, 
not from primary cancer, but rather from secondary disease (from 
http://seer.cancer.gov/). Metastatic dissemination is a multi-step process in which 
invasive cells spread from the primary tumour by extravasating and entering the 
circulation (either blood or lymphatic), to then intravasate and colonize distant tissues 
and organs.  In order to become invasive and metastatise, malignant tumours require 
a sufficient blood supply. This is achieved through the remodelling of the host 
vasculature via angiogenesis.   
 
I have shown that acute deletion of endothelial β3-integrin inhibits tumour growth and 
angiogenesis preventatively, but not in already established tumours, while its long 
term deletion is ineffective.  This implies that timing and length of inhibition are critical 
factors to be considered when targeting endothelial β3-integrin expression. In follow-
on studies, I aimed to determine whether endothelial β3-integrin plays a role in the 
process of metastatic spread; in order to assess whether its targeting could prevent 
or delay tumour dissemination or metastatic outgrowth. In fact, targeting the tumour 
vasculature offers many advantages compared to targeting neoplastic cancer cells.  
Such a strategy bypasses the problems of tumour heterogeneity, genomic instability 
and different degrees of metastases common to many cancers. 
 
6.5 Metastasis models: not enough 
 
There are various ways to mimic cancer growth and metastasis in tumour 
transplantation experiments as described in paragraph 6.1. Implantation of human 
cancer cell lines derived from human cancer (xenograft models) is simple, but has 
limitations: the immune responses are impaired in immunocompromised mice and 
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stromal components are not of tumour origin. Syngeneic transplantation bypasses 
the immunologic rejection and allows the investigation of the contribution of the 
immune system to malignant tumour progression and metastasis (Francia et al., 
2011). On the other hand, genetically modified mice which develop metastatic 
disease spontaneously mimic the entire process of tumourigenesis in vivo and, as 
such, they are more reliable as clinically predictive tools for evaluating the efficacy of 
therapeutic agents for the treatment of metastatic disease (Talmadge et al., 2007). 
 
Nevertheless, even encouraging preclinical therapeutic findings employing either 
transplanted or spontaneous tumour metastasis models often fail to reproduce the 
successful outcomes when translated to the clinic (Francia et al., 2011).  There are 
several reasons for this including a failure to establish appropriate and accurate 
models. One example of this discrepancy is the poor predictability of xenograft 
tumour models of whether a treatment is likely to be effective in a metastatic setting 
as a consequence of the differential response of metastasis and primary tumours to 
the therapy. Therefore, it would be beneficial to combine orthotopic or subcutaneous 
tumours model with spontaneous models of advanced metastasis when testing new 
anticancer strategies (Francia et al., 2011). It is thus important to generate mouse 
models that more accurately recapitulate clinical scenarios and this is the reason 
behind the choice to develop spontaneous models through several rounds of 
syngeneic tumour cell transplantation and selection of metastatic cells, such as the 
subcutaneous tumour model of lung metastases CMT19T F1 and the orthotopic 
tumour model of lung and bone metastases B6 LV-1 (developed at Washington 
University). 
 
However, spontaneous metastasis models are challenging to set up and optimize for 
a number of reasons. Tumours can grow asyncronously and metastases can appear 
unevenly, making it difficult to decide when to resect tumours and harvest organs for 
metastatic evaluation. In general, not all mice survive for the entire experiment as 
poor health may require premature sacrifice, meaning that large cohorts of mice are 
required.  Finally, metastatic phenotypes can vary significantly from animal to animal, 
even within the same experimental group. This actually reflects what is seen in the 
clinic: every individual presents differently and our results may simply reflect 
individual variation. The only way to reduce this variable is with further repeats to 
achieve a greater end number, thus making these experiments more labour-intensive 
and expensive. For these reasons, I decided to perform my initial analyses in the 
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constitutive model of endothelial β3-integrin deletion (Tie1Cre transgenic mice): it is 
a simpler model as it does not require tamoxifen treatment. 
 
6.6 Is endothelial β3-integrin anti-metastatic? 
 
My studies have for the first time addressed the potential for targeting endothelial β3-
integrin for the prevention of metastasis: preliminary findings in CMT19 T F1 model 
suggest that, while constitutive deletion of endothelial β3-integrin did not affect 
primary tumour growth, it significantly reduced metastatic spread to lung. αvβ3- 
integrin expression in primary tumours has been found to associate with greater 
metastatic potential (Liu et al., 2012, Desgrosellier et al., 2009, Felding-Habermann 
2003, Sloan et al., 2006), therefore I further investigated the role of β3-integrin in the 
process of metastasis.  
 
Surprisingly, although constitutive deletion of endothelial β3-integrin decreased the 
number of spontaneous metastasis, it did not appear to alter metastatic angiogenesis 
in the lung, as confirmed by no difference in the average size of metastatic foci, 
regardless of endothelial β3-integrin expression.  Interestingly, the difference in the 
number of metastasis between the two genotypes was not observed in an 
experimental metastasis setting. 
 
One explanation may be that fewer tumour cells entered the blood circulation as a 
result of reduced tumour vascular permeability, as reported by Jean et al. (2014), 
whereby inhibition of endothelial FAK was shown to prevent tumour metastasis by 
enhancing barrier function at the primary site. I was able to rule out this hypothesis 
by showing that there was no difference in vivo, in either tumour vascular permeability 
or in the amount of tumour circulating cells.   
 
A second explanation may be that the tumour releases signals, such as pro-
inflammatory cytokines, to prepare the metastatic site prior to spread (Langley and 
Fidler, 2011). It is also becoming increasingly recognised that immune cells can be 
mediators of tumour development and metastasis (De Nardo et al., 2008, Lin and 
Pollard 2007, Joyce and Pollard 2009). Enhanced leukocyte infiltration, causing 
conditions of inflammation, have been suggested to disrupt the normal 
microenvironment preparing the ‘soil’ for metastasising tumour cells (Hu and Polyak, 
2008). 
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To this end, I was able to show that, in absence of endothelial β3-integrin, the number 
of tumour associated macrophages in the lung was reduced before and after 
metastasis had established, thereby suggesting that they may be involved in the 
formation of a pre-metastatic niche. These very interesting, but preliminary, findings 
raise at least 3 questions, yet unaddressed:  
 
- first, how does endothelial β3-integrin regulate the infiltration of macrophages in the 
lung? 
 
The recruitment of leukocytes into peripheral tissues involves interactions with 
endothelium. Leukocytes need to establish transient and dynamic adhesive contacts 
with endothelial cells to transmigrate (Lindbom and Werr, 2002). αvβ3-integrin has 
been shown to function as a heterotypic ligand for CD3, in controlling the arrest and 
extravasation of hematopoietic cells (Lindbom and Werr, 2002).  While its expression 
on leukocytes (monocytes and neutrophils) has been described to be involved in the 
transition between adhesion to the endothelium and diapedesis (Weerasinghe et al., 
1998). Therefore, it would be interesting to investigate whether β3-integrin on 
endothelial cells is involved in the recruitment and/or retention of leucocytes to the 
pre-metastatic lung to promote metastasis outgrowth. 
- second, how do macrophages contribute to the formation of a pre-metastatic niche 
in the lung? 
 
Macrophages infiltrating the tumour contribute to the formation of an inflammatory 
microenviroment which sustains tumour growth and progression and have been 
reported to have a M2 phenotype (Biswas et al., 2006). Macrophages are also 
associated with increased metastatic potential (De Nardo et al., 2009; Joyce and 
Pollack, 2009). They have been shown to upregulate the expression of Cathepsin B 
which leads to increased lung metastasis (Vasiljieva et al., 2006) and they have been 
found to express a truncated isoform of fibronectin which acts as a potent 
chemoattractant for tumour cells (Solinas et al., 2010). Macrophages can also 
promote angiogenesis and exert immunosuppressive activity (Galdiero et al., 2013) 
No difference in vessel density in the metastatic lung would imply at least in theory 
mechanisms other than increased angiogenesis are induced by tumour associated 
macrophage to promote metastatic growth. This mechanistic analysis needs to be 
followed up and investigated further. 
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- Third, are there other cells involved in setting up the pre-metastatic niche? If so, 
who are they and how do they do it? 
 
A wide spectrum of immune cells take part in the tumour environment, such as 
neutrophils and myeloid derived suppressor cells. Interestingly, neutrophils can up-
regulate β2-integrin to interact with ICAM-1 on melanoma cells and promote lung 
metastasis (Huh et al., 2010).  Myeloid derived suppressor cells have been found to 
promote metastasis in the pre-metastatic lung via different mechanisms: up-
regulation of MMP9 which leads to aberrant and leaky vasculature (Yan et al., 2010); 
inhibition of Interferon-γ (IFNγ) which promotes an immune-suppressive environment 
and inflammatory environment (Yan et al., 2010); versican expression, which leads 
to Mesenchymal to Epithelial Transition (MET), thus favouring metastases formation 
(Gao et al., 2012).  These evidences would suggest that other immune cells might be 
involved in setting up the pre-metastatic niche and their contribution would require 
further investigation. 
 
My preliminary data on the role of endothelial β3-integrin in metastatic prevention are 
encouraging and suggest they should be further investigated. These studies will lead 
to a better understanding of the integrin-mediated interactions between endothelial 
cells and tumour microenviroment which mediate metastasis, and will help us 
understand how to manipulate these interactions when designing novel therapeutic 
strategies. 
 
6.7 Mechanisms of pre-metastatic niche formation 
 
Vascular Endothelial cadherin (VEC) is a type I transmembrane protein which 
mediates endothelial cell adhesion and barrier function (Sidibe and Imhof, 2014). This 
protein has a range of phosphorylation sites, each having a unique role in various 
processes. For example, phosphorylation of VEC Y658 has been shown to induce 
vessel permeability via the dissociation of the VEC-β-catenin-p120-catenin-α-catenin 
complex (Potter et al., 2005). More recently, this same residue has been reported to 
be phosphorylated by endothelial FAK to control endothelial barrier function and 
facilitate tumour spread (Jean et al., 2014). Instead, VEC Y731 phosphorylation site 
has been reported to control a different aspect of endothelial barrier function which is 
leukocytes extravasation (Wessel et al., 2014). VEC Y731 has a high baseline 
phosphorylation and in order for extravasation to occur, leukocytes trigger 
dephosphorylation of Y731. 
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The unaltered level of  VEC Y731 phosphorylation I observed in β3-floxed/Tie1Cre 
positive lung endothelial cells would suggest that in absence of endothelial β3-
integrin, VEC Y731 is unable to be dephosphorylated and, as such, the potential for 
leukocyte extravasation is reduced. Therefore, this was consistent with the in vivo 
results of decreased tumour associated macrophages in the metastatic lung of β3-
floxed/Tie1Cre positive mice.  Similarly to endothelial FAK regulating endothelial 
barrier function via VEC Y658 phosphorylation in the primary tumour, I hypothesised 
a model whereby endothelial β3-integrin controls leukocytes extravasation via VEC 
Y731 phosphorylation in the lung.  As such, the lung would become less conducive 
to tumour cell colonisation, therefore reducing metastasis. This would also imply that 
endothelial β3 is not required for tumour cell colonisation at distant site, but it might 
be for macrophage infiltration into the lung during the growth of the primary tumour 
to establish the pre-metastatic niche.   
 
However, this model, envisioned by combining preliminary data and evidence from 
the literature, though promising, is still only a model.  A pre-condition for any further 
investigation is the confirmation that the anti-metastatic effect is endothelial β3-
integrin specific, despite the leakiness of the Tie1 promoter in the bone marrow 
derived cells (20%, Gustafsson et al., 2001). This is essential because bone marrow 
derived cells have also been shown to prepare the pre-metastatic niche (Kaplan et 
al., 2005). More importantly, β3-integrin on bone marrow derived cells is crucial for 
the adhesion and transmigration at sites of neovascularization, such as tumour sites 
(Feng et al., 2008). To exclude that an anti-metastatic effect was due to β3-integrin 
deletion in some bone marrow lineages, it would be necessary to transplant wild-type 
bone marrow into β3-floxed/Tie1Cre positive and see if there is a reversal of the 
phenotype of reduced lung metastasis. Alternatively, spontaneous metastasis 
experiments could be performed in the inducible endothelial transgenic model 
(Pdgfb-iCreERT2), whereby Cre recombinase is not active in the bone marrow 
(Claxton et al., 2008) to assess whether the phenotype of reduced lung metastasis 
could be replicated. 
 
Moreover, to prove this model to be right, it would be crucial to identify the molecular 
players involved in the cross-talk between integrin αvβ-integrin and VEC. Based on 
the recent works from Jean et al. (2014) and Wessel et al. (2014), potential 
candidates may be SHP-2 and FAK/c-Src. SHP-2 is a non-transmembrane protein 
tyrosine phosphatase which associates with SHPS-1 upon its phosphorylation 
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(Tsuda et al., 1998) and it has been shown to mediate dephosphorylation of VEC 
Y731 to allow leucocytes passage across endothelial junctions (Wessel et al., 2014).  
Interestingly, there is evidence suggesting that SHPS-1/SHP-2 complex promote a 
positive feedback loop leading to c-Src/FAK activation during integrin signalling (Oh 
et al.,1998). The precise order in which c-Src and FAK are activated upon integrin 
signalling is still controversial. Regardless, it leads to SHPS-1/SHP-2 complex 
formation and SHP-2 activation. Therefore, it would be tempting to speculate that the 
absence of endothelial β3 integrin causes defective SHP-2 activity, which then results 
in reduced leukocyte extravasation, as a consequence of unaltered level of 
phosphorylated VEC Y731. Consistent with this idea, impaired expression and 
function of FAK would be accomodated in this model, as a result of constitutive 
endothelial β3-integrin deletion.  
 
Further investigation is required for a more thorough understanding of what is 
occurring at the secondary site. Whilst I have not clearly defined the mechanism(s) 
which could explain my metastases findings, I have provided preliminary evidence 
that targeting endothelial β3-integrin could have a potential therapeutic benefit in 
preventing metastatic spread and suggested lines of investigation to move forward 
with these studies.  
 
CONCLUSIONS 
 
This final result chapter contains preliminary data I collected in my last year which I 
have not had the time to follow up. In fact this project will be continued by a new PhD 
student. I thought it was worthwhile to include it as a final part of my work. 
 
In this chapter I have presented initial findings suggesting that: 
 
• Constitutive endothelial β3-integrin deletion reduces the number of  
lung metastasis; 
 
• the reduction in lung metastases which occurs in constitutively β3-
integrin deleted mice correlates with reduced tumour associated 
macrophage infiltration in the lung prior to tumour cell arrival; 
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• further in vivo and in vitro analyses are needed to confirm that it is 
endothelial specific phenotype and to explain it mechanistically. 
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7. SUMMARY AND CONCLUSION 
 
7.1  Novelty and significance 
 
Do these studies help to reconcile the seemingly conflictings findings regarding αvβ3-
integrin functions in tumour angiogenesis?  
 
I believe they do. Genetic data from β3-integrin knockout mice have already helped 
explain some reasons for discrepancies in the literature. Their phenotype of 
enhanced tumor growth and angiogenesis is caused, at least in part, by the 
upregulation of VEGFR2-dependent angiogenic pathways (Reynolds et al., 2002; 
Reynolds et al., 2004).  However, multiple cell types express β3-integrin and 
contribute to tumour angiogenesis, making it difficult to discriminate between  
endothelial cell contributions to the process from from that of other cells (Robinson 
and Hodivala-Dilke, 2011). This is an important question, though, as the original 
observation that spear-headed the development of β3-integrin antagonists, and the 
generation of the knockout mice for that matter, was marked up-regulation of the 
protein in the vasculature. 
 
My studies have specifically addressed this point.  By dissecting its role specifically 
in endothelial cells, I have confirmed β3-integrin plays a proangiogenic role in the 
early steps of angiogenesis. However, as ever, this comes with caveats. I have shown 
that timing is critical. In fact suppressing β3-integrin expression for too long leads to 
“treatment” escape. Moreover, once tumour growth and angiogensis are firmly 
established, suppressing β3-integrin, at least alone, has little effect on the 
progression of the cancer. I would like to speculate that these results recapitulate 
what is often seen in the clinic: patients become resistant to initially successful β3 
integrin blockade and tumours begin to regrow (Desgrosellier and Cheresh, 2010). 
My finding suggests that the antiangiogenic function of αvβ3 inhibition occurs 
transiently and is confined to a specific window during tumour progression. Targeting 
the molecule at later stages will not prove effective (inherent resistance) and, even if 
successful to begin with, over time inhibitory effects are lost (acquired resistance). 
 
Importantly, I was able to identify potentially useful cellular and molecular 
mechanisms accounting for long term adaptation to endothelial β3-integrin “blockade” 
(the most interesting may involve with a FAK feedback loop).  The pathways I have 
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identified may provide useful clues for improving on existing antiangiogenic therapies 
and may, ultimately, help guide future clinical strategies.  
 
In conclusion, my studies help marry up the two sides of the β3-integrin condundrum.  
They cement the concept that the function of β3-integrin in angiogenesis depends on 
the cell expressing it (Robinson and Hodivala-Dilke, 2011) and contribute to further 
understanding the complexity of how endothelial cells can adapt their cellular and 
molecular programmes to circumvent attempts at blocking angiogenesis in 
pathological conditions. 
 
And if so, what is their clinical significance?  
 
My finding that the inducible deletion of endothelial αvβ3-integrin can reduce tumour 
angiogenesis, clearly re-establish the molecule as a valuable antiangiogenic target.  
This is important because, with the recent failure of CILENGITIDE in a phase III 
glioblastoma trial, the field is in danger of giving up on the molecule 
(http://merckgroup.com/en/). However, I believe this might be premature. The models 
I have described provide a powerful tool for the development of novel therapies that, 
in combination with αvβ3-integrin inhibition, could improve therapeutic outcomes in 
clinical settings.  For example, my studies helped identify the potential involvement 
of FAK in promoting escape from  β3-integrin inhibition. One prediction may be that 
combining the antagonism of integrin αvβ3-integrin with FAK inhibition will result  be 
effective in reducing tumour growth and angiogenesis of micrometastases by 
exploiting αvβ3-integrin preventative antiangiogenic effect at secondary site and with 
FAK providing a second barrier to tumour spread (Jean et al., 2014).  Since both 
αvβ3-antagonists and FAK inhibitors are already available and well-tolerated (Eskens 
et al., 2003; Infante et al., 2012), their efficacy when used together could be tested 
(as proof-of-concept) in our spontaneous metastases models. 
 
I showed that different molecular and cellular changes correlate with a constitutive 
deletion of endothelial β3-integrin. What does this mean clinically? It means that the 
therapeutic benefit of these agents (anti-angiogenic drugs along with others) is often 
short lived and resistance develops within a matter of months. Tumours adapt quickly 
under the selective pressure of drug treatment and that explains why the concept of  
drug holiday has recently emerged (Das Thakur et al., 2013). I interpret this as 
following on from a paradigm shift in cancer chemotherapy. In the year 2000 Fidler 
and Ellis said “cancer is a chronic disease and should be treated like other chronic 
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disease” (Scharovsky et al., 2009). This idea has led to a new therapeutic philosophy 
from “the maximun tolerated dose” of standard chemotherapy to the “less is better, 
regularly” of metronomic chemotherapy (Hanahan et al., 2000).   
 
Therefore, preclinical models of resistance, such the Tie1Cre model of constitutive 
deletion of endothelial β3-integrin, will likely provide critical insights in elucidating 
potential mechanisms leading to resistance (as a consequence of chronic treatment), 
and ultimately, to effective treatments.  This might take the form of combinatorial 
targeting or of modulating the timing and dosing of treatments. 
 
7.2 Final conclusions and future works 
 
Overall, my findings have answered some questions and created many more. I 
envision two main lines of investigation spinning off from this project which will likely  
contribute to translational knowledge. These are: 
 
• to directly address the differences between genetic versus pharmacological 
inhibition of β3-integrin, including differenrent class of β3-integrin inhibitors, 
dosing and treatment schemes; 
 
• to address the mechanisms of resistance that build up to compensate for long-
term loss of endothelial β3-integrin,  in order to identify and validate molecular 
targets that might be co-targeted alongside β3 integrin to sustain, or at least 
extend, tumour inhibition. 
 
In my last year, I started to investigate the role of endothelial β3-integrin in the 
process of metastasis and revealed a potential anti-mestastatic effect which I believe, 
deserves further investigation.  Previous work from Taverna et al. (2005) showed that 
the total absence of β3-integrin has very little effect on tumor progression and 
metastasis in a spontaneous model of breast carcinogenesis. However, as I have 
pointed out, this may reflect non-endothelial cell contributions to the process.   
 
My preliminary findings  point to a potential anti-metastatic role for endothelial β3-
integrin. I have uncovered a complex scenario in which pre-metastatic niche and 
inflammation act together to promote tumour progression. Whether this is true or not 
still needs further analyses and confirmation. These findings might provide a rationale 
for synergistically targeting the endothelium and immune cells.  This represents a 
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completely new and exciting project which has been inspiring me for my next step 
and leading me to focus my research interest in the field of immunoangiogenesis. 
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